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After the breakthrough in the treatment of rheumatoid arthritis and
numerous related disorders with biological therapies targeting TNFa at
the Kennedy Institute in London
Millions of patients have tremendously benefitted. However, we cannot
cure these diseases yet and have to search for additional therapeutic
targets.
Since it was shown that synovial fibroblasts (SF) are not only effector cells
responding to inflammatory stimuli, but appear endogenously activated
and potentially involved into spreading the disease [1], we searched for
the epigenetic modifications leading to the activated phenotype of these
cells.
Epigenetics in its scientific definition “is the study of all heritable and
potentially reversible changes in genome function that do not alter the
nucleotide sequence within the DNA”, but might be considered in simpler
terms as the regulation of gene expression.
Epigenetic modifications include:
Acetylation,
Methylation,
Phosphorylation,
Sumoylation,
miRs or microRNAs.
Our laboratory is studying these processes and we have found that RASF
reside in a hyperacetylated synovial tissue and appear hypomethylated
[2]. Hypomethylation leads to the activated phenotype of RASF which is
characterized by the production of matrix-degrading enzymes and of
potent chemokines induced by Toll-like receptor signalling. Current
strategies are designed to methylate these cells to deactivate and
“normalise” them again.
miRs are about 20 nucleotide long smallRNAs acting to destroy specific
mRNA.
I nt h er a c et oi d e n t i f ys p e c i f i cm i R sa sn o v e lt a r g e t sw eh a v ei d e n t i f i e d
for example, that interleukin-6 modulates the expression of the Bone
Morphogenic Protein Receptor Type II through a novel STAT3microRNA
cluster 17/92 pathway, which helps to explain the loss of the BMPR2 in
the vascular cells in pulmonary hypertension [3]. Moreover, miR-203 is
regulating the production of IL-6 [4].
Most interestingly, epigenetic therapy is also on the horizon [5].
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Rheumatology has pioneered in the study of autoantibodies by showing
that they are not only involved in pathogenesis but are also highly useful as
diagnostic biomarkers. The diagnostic biomarker aspect of autoimmunity
has gained increasing importance in cancer and many of the insights gained
in Rheumatology have contributed to understanding the significance of
autoantibodies in cancer.
Features of autoantibodies in rheumatic disorders: In rheumatic
diseases no individual autoantibody-antigen system has sufficient
combination of sensitivity and specificity to serve as a useful diagnostic
biomarker. Instead, several antigen-antibody systems constructed as
profiles of biomarkers are highly effective in distinguishing one disorder
from another. In lupus, anti-double strand DNA and anti-Sm distinguishes
it from scleroderma, where the profile is anti-DNA topoisomerase 1 and
anti-centromere proteins. The autoantigensare cell components involved
in universal and basic gene expression pathways, such as Sm in precursor
mRNA splicing and DNA topoisomerase 1 in DNA replication and
transcription [1].
Features of autoantibodies in cancer: Autoantibodies in cancer target
intracellular molecules referred to as TAAs (tumor-associated antigens). As
in rheumatic disorders, no individual autoantibody-antigen system has
sensitivity and specificity to serve as a stand-alone diagnostic marker [2].
Most tumors show multiple antibody specificities and with panels of TAA-
anti-TAAs (analogous toprofiles) the cumulative sensitivity and specificity
reaches diagnostic significance. Different tumorigenesis pathways are
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driving mechanisms behind the autoantibody response. The immune
responses are directed to products of oncogenes and tumor-suppressor
genes such as p53 and other proteins that regulate and modulate the
functions of p53 [3-5].
Protein phosphatase 2A (PP2A) is an important tumor suppressor
protein. It is a serine/threonine phosphatase and is a trimeric complex.
The B subunit is recruited from several intracellular proteins and the
type of B subunit determines the substrate of its tumor suppressor
activity. One of the B subunits, p90, was identified in our laboratory
with autoantibody from a patient with hepatocellular carcinoma [6]. It
was found to co-immunoprecipitate with other subunits of PP2A [7]
and was shown to function as an inhibitor of the tumor-suppressor
activity of PP2A.
The immune system is capable of sensing dysregulation of tumorigenesis
pathways. The goal of continuing research is in developingTAA-anti-TAAs
for detecting cancer in individual patients and profiles which are
common to specific types of tumors.
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Understanding etiology and molecular pathogenesis of rheumatoid
arthritis is key to the development of precise prevention and curative
therapy for this disease. Recent progress on how genes and environment
interact in causing immune reactions that may induce arthritis in humans
as well as in mice, have provided a conceptual basis for the development
of new prevention and treatment strategies which need to be different for
different subsets of RA. In order to bring this emerging knowledge to the
level where basic and clinical academic science can collaboratewitj
industry for rapid development of the potential new therapies, there is a
need for closer collaboration between basic and clinical scientists from
many centers, and for increased collaboration between industry and
academia in translational medicine.
In Europe, both the EU-funded framework programs and the EU and
industry funder Innovative Medicine Initiative (IMI) funder programs in
rheumatology are geared to accomplishing these goals. This presentation
will be concerned both with the scientific basis of these programs and with
a descriptions of the challenges and potential promises that these new
collaborative programs offer to rheumatology.
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Background: Acute isolated neurological syndromes, such as optic
neuropathy or transverse myelopathy, may cause diagnostic problems
since they can be the first presentations in a number of demyelinating
disorders including multiple sclerosis (MS) and collagen diseases.
However, clinical presentation and lesions evidenced by magnetic
resonance imaging may be similar. Collagen disease coexists in
demyelinating disorders and frequently various collagen disease related
autoantibodies are positive in daily practice.
Hence, the algorithm to overcome these diagnostic and therapeutic
issues should be clarified.
B cell immunity in demyelinating disorders: In primary demyelinating
disease, MS, a renewed interest in the role of humoral immunity in the
pathophysiology has been investigated because oligoclonalIgG band in
the CSF and increased intrathecalIgG synthesis are used as an auxiliary
diagnosis measure. Moreover, in the secondary progressive MS, meningeal
B-cell follicles are associated with early onset of the disease and severe
cortical pathology. B cell but not plasma cell depletion therapy with single
treatment by Rituximab in MS showed reduced inflammatory brain lesions
and clinical relapses.
Oligodendropathy and astrocytopathy in demyelinating disorders:
Neuromyelitisoptica (NMO) was previously considered to be a variant of MS
but is now recognized as an astrocytopathy and secondary demyelinating
event mimicking MS characteristics occurring due to autoantibody mediated
mechanisms. Advancement of molecular biology makes it possible to
differentiate MS by measuring abnormal autoantibody to aquaporin 4 (water
channel). Interestingly, collagen diseases coexist more frequently with NMO
than with MS. B cell depletion therapy with Rituximab has showed the same
benefits, although, plasma exchange therapy is more effective with NMO
than with MS.
TNF therapy and demyelinating event: A report indicates that adverse
events such as the demyelinating lesion in the brain, optic neuritis, and
neuropathy occurred after treatment with anti-TNF alpha therapy in
collagen disease, and TNF antagonizing therapy showed worsening in a
clinical trial with MS. Pathogenesis of these events such as primary or
secondary demyelination are still in enigma.
In this presentation, I will decode the temporal and spatial demyelinating
processes in collagen diseases and show practical approaches and
treatments.
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Epidemiology: Fibromyalgia (FM) is found worldwide, with an estimated
prevalence of 1% to 4% of the general population. In Japan epidemiological
surveillance showed number of the patient up to1.66% in population-based
studies in 2003, following 2.04% by internet surveillance in 2011. 3,500
Japanese patients with our FM data base, frequent age of onset is 35 to
55 years, estimated prevalence of FM, reaching 40% in woman of age 30 to
50 years old. FM occurs in children and adolescents, although only a few
epidemiologic studies.
Pathogenesis: FM was initially one the kind for inflammatory muscle pain.
Following this concept FM was classified so called soft-tissue rheumatism.
Now FM is recognized CNS sensitization following functional pain caused by
neuroendocrine system and stress. The abundant neuroendocrine and pain
regulation descending pathway and sensitization of pain receptor target
molecules such as a2δ ligand, LPA and collapsing response mediator, where
currently protein (CRMP) family have been revealed.
New diagnosis, provisional ACR 2010 criteria: 1990, ACR proposed FM
criteria based on 18 tender point sites on digital palpation with exclusive
differential diagnosis. In 2010, provisional criteria is score based on total
score of severity for pain and somatic symptom (2010 ACR criteria). Based
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“FAS31”. Here, we would like propose the assessment of FM severity
score termed FAS31.
FDA approved of pregabalin in FM by double-blind, multicenter and
randomized study. Both studies enrolled patients with a diagnosis of FM
using the ACR criteria. Each of these studies showed a significant
r e d u c t i o ni np a i nc o m p a r e dw i t hp l a cebo. In addition, improvement
demonstrated based on FIQ. In Japan, this clinical trial has been
developed. Sooner or later, excellent result will be revealed.
In other medication, gabapentin practical efficacy for reduced pain with
FM patient. Several anti-dispersants (SSTIs, SNRIs. TCAs) NSAIDs, muscle
relaxant, anti epileptics and pilocarpine hydrochloride also reduced the
pain and an associated symptom. Based on with multivariant statistical
analysis based on 3,500 patients, we will present several associated
somatic symptoms influencing on drug response for pain and prognosis
with FM.
In conclusion, FM is one the most important scientific field to understand
the pain neurology and rheumatology in near.
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Lysophosphatidic acid (LPA) receptor (LPA1) signaling plays the key role
in initiation of nerve injury-induced neuropathic pain [1-4]. LPA, which
is produced in the spinal cord following the sciatic nerve injury causes
a calpain-mediated demyelination of dorsal root fibers and sprouting
through LPA1 receptor, leading to an induction of synaptic
reorganization underlying allodynia. The LPA1 signaling also initiates
the up-regulation of Cava2δ1 in DRG, leading to an enhancement of
spinal pain transmission underlying hyperalgesia. Similar LPA1-mediated
chronic abnormal pain and underlying mechanisms are observed in
mouse models with Meth-A sarcoma surrounding sciatic nerve (cancer
model) or with chemotherapy (paclitaxel). Central neuropathic pain
following spinal nerve injury is now recently found to include the LPA1-
mediated mechanisms. In contrast, (arthritic) inflammatory pain
following Complete Freund Adjuvant treatment fails to show the
involvement of LPA1 signaling. Thus it seems that many models of
neuropathic pain, but not inflammatory pain model include LPA1-
mediated mechanisms.
Recent studies revealed that another subtype LPA3 receptor plays a crucial
role in neuropathic pain mechanisms in terms of LPA biosynthesis. Nerve
injury and intrathecal administration of LPA increased the levels of
lysophosphatidylcholine (LPC) and LPA in the spinal dorsal horn and dorsal
root with peaks at 1 - 2 h. We obtained the evidence for in vitro LPA
biosynthesis in spinal dorsal horn and dorsal root as well as in vivo one. In
these studies we successfully identified the species of LPC and LPA
molecules by use of Mass Spectrometery. Major species are the molecules
with lipid chain 16:0, 18:0 or 18:1, and their contents were all time-
dependently increased by nerve injury. Interestingly, there was an LPA-
induced amplification of LPA biosynthesis through an activation of LPA3
receptor and microglia. The microglial involvement was found to play key
roles as an initiation of neuropathic pain mechanisms including LPA3-
mediated amplification of LPA biosynthesis.
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The innate immune system is an evolutionally conserved host defense
mechanism against pathogens. Innate immune responses are initiated by
pattern recognition receptors (PRRs), which recognize specific structures
of microorganisms. Among them, Toll-like receptors (TLRs) are capable of
sensing organisms ranging from bacteria to fungi, protozoa and viruses,
and play a major role in innate immunity. Individual TLRs recognize
different microbial components, and give rise to different patterns in
gene expression.
We are now focusing on the role of genes induced in response to TLR
stimulation, particularly the genes that are rapidly induced in a MyD88-
dependent manner within 30 min after LPS stimulation. Among them, we
have recently identified a novel gene named Zc3h12a which has a CCCH-
type zinc finger domain. The knockout mice developed spontaneous
autoimmune diseases accompanied by splenomegaly and lymphadenopathy.
Subsequent studies showed that Zc3h12a is a nuclease involved in
destabilization of IL-6 and IL-12mRNA. We renamed it Regulatory RNase-1
(Regnase-1) based on the function.
We recently found that the IKK complex controls Il6 mRNA stability by
phosphorylating Regnase-1 in response to IL-1R/TLR stimulation.
Phosphorylated Regnase-1 underwent ubiquitination and degradation.
Regnase-1 re-expressed in IL-1R/TLR-activated cells exhibited delayed
kinetics, and Regnase-1 mRNA was found to be negatively regulated by
Regnase-1 itself via a stem-loop region present in the Regnase-1 3’
untranslated region. These data demonstrate that the IKK complex
phosphorylates not only IkBalpha, activating transcription, but also
Regnase-1, releasing the “brake” on Il6 mRNA expression.
O8
Death receptor-induced apoptosis signalling - essential guardian
against autoimmune disease
Andreas Strasser
1*, Lorraine A O’Reilly
1, Philipp Jost
1, Thomas Kaufmann
1,
Stephanie Grabow
1, Elizabeth Kruse
1, Lin Tai
1, Mark Smyth
2, Philippe Bouillet
1
1The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade,
Parkville, Victoria 3050, Australia;
2The Peter MacCallum Cancer Centre, St
Andrews Place, East Melbourne, Victoria 3000, Australia
E-mail: strasser@wehi.edu.au
Arthritis Research & Therapy 2012, 14(Suppl 1):O8
The FasL/Fas system is critical for deletion of autoreactive and antigen-
activated T and B cells. Accordingly, mutations in these proteins result in
lymphadenopathy and autoimmunity in gld and lpr mutant mice, which
lack functional FasL or Fas, respectively. Upon antigenic stimulation of
T cells, FasL is sythesised, directed to and stored in secretory lysosomes
followed by extrusion at the immunological synapse where it is rapidly
downregulated by a metalloprotease, shedding the extracellular portion
(sFasL) to prevent non-specific killing. It is unclear whether the pathology
observed in gld mutant mice is due to the loss of the membrane-bound
or the secreted form of FasL or both.
We have produced a panel of mutant FasL knock-in mice to address this
question. In the first mutant strain the cytoplasmic and trans-membrane
domains of FasL were replaced with the signal peptide from G-CSF.
Activated T cells from these mutant mice can produce cytoplasmic but no
membrane bound FasL and, interestingly, they are defective in FasL-
mediated cytotoxic function and undergo significantly less activation-
induced cell death upon re-stimulation with anti-CD3 antibodies than wt
T cells. The extent of these defects is similar to that seen in FasL mutant gld
T cells. With age these FasL mutant knock-in mice develop lymphadenopathy
and splenomegaly and CD3
+B220
+CD4
-CD8
- T cells accumulate, similarly to
what has been observed in gld and lpr mutant mice. In contrast to gld mice,
the FasL mutant knock-in mice on the C57BL/6 background develop
haemopoietic tumours and reticular cell sarcomas, suggesting that while
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may play a critical role in tissue damage and tumour suppression.
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Molecular definition of cancer specific antigens recognized by T cells
opened an approach to develop cancer specific immunotherapy. Through
a series of key findings in cancer immunology, for development of
effective therapy major effort has been directed to how to induce T cells
with fine specificity, sufficient quantity and high quality in hosts.
We intended to integrate immunobiological strategy of T cells with two
technologies, nanogel technology and retroviral vector technology for
translational research of cancer immunotherapy. Cholesterol-bearing
hydrophobizedpullulan (CHP), physically cross-linked nanogels by self-
assembly, form nanoparticle complex with protein in water.We found that
antigen protein with multiple T cell epitopes, when complexed with CHP,
was efficiently transported to lymph nodes and well captured by antigen
presenting cells such as dendritic cells and macrophages leading to cross
presentation. Hence, CHP-antigen protein complex may become excellent
cancer vaccine to induce both CD8
+ killer T cells and CD4
+ helper T cells of
high quality.
Intrinsic weakness of insufficiency in number of cancer specific T cells in
hosts, prompted us to develop adoptive T cell therapy withlymphocytes
engineered to possess cancer specificity. For this purpose, we developed
novel retroviral vectors to highly express exogenously transduced cancer
specific T cell receptor (TCR), yet suppressing expression of endogenous
polyclonal TCR. This approach allowed us to prepare T cells with finer
specificity of expressed TCR. In addition, use of RetroNectin®, a recombinant
fragment of fibronectin opened a way to ex vivo prepare T cells of sufficient
quantity and good quality for clinical use.
Translational clinical trials of these cancer vaccine and adoptive T cell
therapy are now on-going.
An open innovation to promote fusion of different fields of science and
technology played an essential role in our development of cancer
immunotherapy.
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SKG mouse is a murine model of autoimmune arthritis. A spontaneous
point mutation of the gene encoding an SH2 domain of the ζ-associated
protein of 70 kDa gene (ZAP-70), a key signal transduction molecule in
T cells, causes chronic autoimmune arthritis in SKG mice that resembles
human RA in many aspects. Altered signal transduction from T-cell antigen
receptor through the aberrant ZAP-70 changes the thresholds of T cells to
thymic selection, leading to the positive selection of otherwise negatively
selected autoimmune T cells.
Based on the finding that the skg-mutation of ZAP-70 causes autoimmune
arthritis, we then examined how attenuated TCR signaling affects the
spectrum of autoimmune diseases. In a set of mice with the mutation, the
amount of ZAP-70 protein as well as its tyrosine phosphorylation upon TCR
stimulation decreased from +/+, skg/+, skg/skg,t oskg/− mice in a stepwise
manner. The reduction resulted in graded alterations of thymic positive
and negative selection of self-reactive T cells and Foxp3
+ natural regulatory
T cells (Tregs) and their respective functions. Consequently, skg/− mice
spontaneously developed autoimmune arthritis even in a microbially clean
environment, whereas skg/skg m i c er e q u i r e ds t i m u l a t i o nt h r o u g hi n n a t e
immunity for disease manifestation. After Treg depletion, organ-specific
autoimmune diseases, especially autoimmune gastritis, predominantly
developed in +/+, at a lesser incidence in skg/+,b u tn o ti nskg/skg BALB/c
mice, which suffered from other autoimmune diseases, especially
autoimmune arthritis. In correlation with this change, gastritis-mediating TCR
transgenic T cells were positively selected in +/+, less in skg/+,b u tn o ti n
skg/skg BALB/c mice. Similarly, on the genetic background of diabetes-prone
NOD mice, diabetes spontaneously developed in +/+, at a lesser incidence
in skg/+, but not in skg/skg mice, which instead succumbed to arthritis. Thus,
the graded attenuation of TCR signaling alters the repertoire and the
function of autoimmune T cells and natural Tregs in a progressive manner. It
also changes the dependency of disease development on environmental
stimuli. These findings collectively provide a model of how genetic anomaly
of T cell signaling contributes to the development of autoimmune disease.
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Background: Haemophilic arthropathy (HA), which shares some clinical
and biological injury characteristics with rheumatoid arthritis (RA), is
characterized by chronic proliferative synovitis and cartilage destruction.
Anti-Fas mAb specifically targets the Fas molecule, which is expressed
and activated on the cell surface of inflammatory synovial cells and plays
a key role for induction of apoptosis. Caspases are the final executioners
of apoptosis and their activation requires proteolytic processing of
inactive zymogen into activated fragments.
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capacity of inducing apoptosis analysing caspase 3 activity.
Methods: HA synoviocytes were incubated with IgM 1000 ng/ml (control),
TNFalpha 10 ng/ml, FGF 10 ng/ml, CH11 100 ng/ml (positive control of
apoptosis) with or without anti-Fas mAb at different concentrations (from
0,1 to 1000 ng/ml) for 24 h. RA and healthy synoviocytes were used as
controls. To measure cell proliferation/citotoxicity, the WST-1 assay has
been performed. Caspase 3 activity has been evaluated with ELISA kit and
western blot.
Results: Anti-Fas mAb induced a citotoxic effect in HA (p < 0,001 for any
dose), healthy (p < 0,001 at 100 and 1000 ng/ml) and RA synoviocytes (p <
0,05 for any dose) reaching a maximum effect at 1000 ng/ml. After
stimulation with anti-Fas mAb combined with TNFalpha, there was a
citotoxic effect on healthy (p < 0,001 at 10, 100, 1000 ng/ml anti-Fas mAb),
RA (p < 0,001 for any dose) and HA synoviocytes (p < 0,005 at 1, 10, 100
and 1000 ng/ml anti-Fas mAb). After stimulation with anti-Fas mAb
combined with FGF, there was a citotoxic effect on healthy, RA and HA
synoviocytes (p < 0,001 for any dose). Caspase 3 levels were increased in
HA synoviocytes after anti-Fas mAb treatment in a dose-dependent
manner, even after co-stimulation with TNFalpha (p < 0,001 for
any stimulus). CH11 induced an increase of caspase 3 levels in HA
synoviocytes more than RA synoviocytes. Western blot showed that HA
synoviocytes had higher levels of activated caspase 3 compared to
RA synoviocytes after stimulation with Anti-Fas mAb, CH11 and co-
stimulation with TNFalpha.
Conclusion: Anti-Fas mAb has a dose-dependent citotoxic effect on HA
synoviocytes, even when associated with TNFalpha and FGF. Anti-Fas mAb is
e f f e c t i v ei ni n c r e a s i n gc a s p a s e3l e v e l si nH As y n o v i o c y t e si nad o s e -
dependent manner. HA synoviocytes show higher levels of activated
caspase 3 compared to RA synoviocytes. Our results suggest that anti-Fas
IgM mAb may favour the induction of apoptosis in HA synoviocytes.
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The interaction between the immune and skeletal systems has long been
acknowledged, but molecular mechanisms linking the two systems have
not been demonstrated until recently. Investigation into autoimmune
arthritis as well as the various bone phenotypes found in mice deficient in
immunomodulatory molecules has highlighted the importance of the
dynamic interplay between the two systems and brought about a rapid
evolution of the field of osteoimmunology [1]. In bone loss in autoimmune
arthritis, IL-17-producing helper T (TH17) cells play a major role by inducing
RANKL [2]. Maintenance and mobilization of hematopoietic cells are
regulated by bone cells. In addition to cellular interactions via cytokines,
the immune and skeletal systems share various molecules, including
transcription factors, signaling molecules and membrane receptors. RANKL
stimulates osteoclastogenesis through NFATc1i nc o o p e r a t i o nw i t h
immunoglobulin-like receptors. Here I will discuss emerging topics in
osteoimmunology including the mechanisms underlying bone cell
communication: osteocyte RANKL [3] and inhibition of bone formation by
osteoclast Sema4D [4].
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Disuse osteoporosis, which occurs commonly in prolonged bed rest and
immobilization, is becoming a major problem in modern societies;
however, the molecular mechanisms underlying unloading-driven bone
loss have not been fully elucidated. Bone adjusts its shape and strength
against mechanical stress. Osteocytes are the most abundant cells in
bone and comprise the communication system through the processes
and canaliculi throughout bone. The osteocyte network is considered to
be an ideal mechanosensor and mechanotransduction system. We found
that overexpression of BCL2 in osteoblasts reduces the number of
osteocyte processes, probably due to the function of Bcl2 that modulates
cytoskeletal reorganization, and induces the apoptosis of osteocytes, in
which the transgene expression was reduced, presumably caused by an
insufficient supply of oxygen, nutrients, and survival factors due to the
reduced osteocyte processes. Our BCL2 transgenic mouse with
accumulated dead osteocytes is a useful model to analyze the function of
osteocytes, because a repair process, which replaces dead osteocytes with
new osteocytes by bone resorption and formation, was not evident in the
mice irrespective of the massive accumulation of dead osteocytes
We searched for the molecules responsible for disuse osteoporosis using
BCL2 transgenic mice. Pyruvate dehydrogenase kinase isozymes (Pdk1,
Pdk2, Pdk3, and Pdk4) are negative regulators of pyruvate dehydrogenase
complex (PDC), which converts pyruvate to acetyl-CoA in the
mitochondria, linking glycolysis to the energetic and anabolic functions of
the tricarboxylic acid (TCA) cycle. Pdk4 was upregulated in femurs and
tibiae of wild-type mice but not of BCL2 transgenic mice after tail
suspension. Bone in Pdk4
-/- mice developed normally and was maintained.
At unloading, however, bone mass was reduced due to enhanced
osteoclastogenesis and Rankl expression in wild-type mice but not in
Pdk4
-/- mice. Osteoclast differentiation of Pdk4
-/- bone marrow-derived
monocyte/macrophage lineage cells (BMMs) in the presence of M-CSF and
RANKL was suppressed, and osteoclastogenesis was impaired in the
coculture of wild-type BMMs and Pdk4
-/- osteoblasts, in which Rankl
expression and promoter activity were reduced. Further, introduction of
Pdk4 into Pdk4
-/- BMMs and osteoblasts enhanced osteoclastogenesis and
Rankl expression and activated Rankl promoter. These findings indicate
that upregulation of Pdk4 expression in osteoblasts and bone marrow cells
after unloading is, at least in part, responsible for the enhancement of
osteoclastogenesis and bone resorption after unloading [1].
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Background: Arthritis is characterized by progressive cartilage erosion,
inflammation of adjoining soft tissues and collapse of subchondral bone
due to enhanced osteoclastic resorption. Human joints are complex
structures formed by synovial tissues, articular cartilage and subchondral
bone tissue. Believing on the similarities of normal joints in humans and
monkeys, we have employed a model of collagen-induced arthritis in
Macaca fascicularis (or crab-eating monkey) in an attempt to evaluate the
histological alterations caused by such condition in the extracellular matrix
of the articular cartilage.
Materials and methods: Intermediate phalangeal proximal joints of six
Macaca fascicularis suffering from collagen-induced arthritis were extracted
and fixed with 4% paraformaldehyde solution. Samples were also taken
from disease-free animals as controls. Tissues were embedded in paraffin or
epoxy resin for histochemical and ultrastructural observations. Paraffin
sections were used for alkaline phosphatase (ALP), tartrate-resistant acid
Arthritis Research & Therapy 2012, Volume 14 Suppl 1
http://arthritis-research.com/supplements/14/S1
Page 5 of 54phosphatase (TRAP), cathepsin K, MMP-1, type II collagen, CTX-II (fragmented
type II collagen) and fibronectin staining assessments.
Results: Control monkeys showed faint immunoreactivity against
cathepsin K and MMP-1 in cells covering the articular cartilage and
synovial tissues, indicating physiological levels of collagenous degradation.
In arthritic animals, more intense cathepsin K and MMP-1 staining was
observed in similar locations. ALP-positive osteoblasts and TRAP-reactive
osteoclasts were abundant at the subchondral bone in arthritic samples,
while control ones depicted fewer osteoclasts and weakly-stained ALP-
positive osteoblasts, suggesting stimulated bone turnover in the arthritic
group. Interestingly, a thick cell layer covered the articular cartilage with
arthritis, and cellular debris overlaid this thick cell layer; nonetheless,
articular chondrocytes seemed intact (Figure 1). In arthritic joints, the
synovial tissues displayed cellular debris in abundance. CTX-II was seen in
the superficial layer of the articular cartilage in arthritic samples, but it was
virtually absent in the control group. Fibronectin also accumulated on the
surface of the arthritic cartilage.
Conclusion: Based on the evidence provided, it is possible that matrix
degradation starts not from the adjacent subchondral bone, but from the
most superficial region of the arthritic cartilage.
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Background: Active rheumatoid arthritis (RA) is characterized by
continuous progression of the inflammatory process, eventually affecting
the majority of joints. Thus far, molecular and cellular pathways of disease
progression are largely unknown. One of the key players in this destructive
scenario are synovial fibroblasts (SF) which actively attach to, invade into
and degrade articular cartilage. As RASF are able to migrate in vitro,t h e
current series of experiments were designed to evaluate the potential of
RASF to spread the disease in vivo in the SCID mouse model of RA.
Methods: Healthy human cartilage was co-implanted subcutaneously into
SCID mice together with RASF. At the contralateral flank, simulating an
unaffected joint, cartilage was implanted without cells. To analyze the
route of migration of RASF, the cells were injected subcutaneously,
intraperitoneally or intravenously before or after implantation of cartilage.
In addition, whole RA synovium and normal human cartilage were
implanted separately in order to analyze the effects of matrix and other
cells on the migratory behavior of RASF. To evaluate potential influences of
wound healing, either the primary RASF-containing implant or the
contralateral implant without RASF, respectively, was inserted first,
followed by implantation of the corresponding other implant after 14 days.
After 60 days, implants, organs and blood were removed and analyzed. For
the detection of human cells, immunohisto- and -cytochemistry were
performed with species-specific antibodies.
Results: RASF not only invaded and degraded the co-implanted cartilage,
they also migrated to and invaded into the contralateral cell free
implanted cartilage. Injection of RASF led to a strong destruction of the
implanted cartilage, particularly after subcutaneous and intravenous
application. Interestingly, implantation of whole synovial tissue also
resulted in migration of RASF to the contralateral cartilage in one third of
the animals. With regard to the route of migration, few RASF could be
detected in spleen, heart and lung, mainly located in vessels, most likely
resulting from an active movement to the target cartilage via the
vasculature. With respect to functional aspects, growth factors and
adhesion molecules appear to influence significantly the migratory
behavior of the synovial fibroblasts.
Conclusions: The results support the hypothesis that the clinically
characteristic phenomenon of inflammatory spreading from joint to joint
is mediated, at least in part, by a transmigration of activated RASF,
regulated by growth factors and adhesion molecules.
Acknowledgements: Supported by a grant of the German Research
Foundation (DFG).
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Bone remodeling is a frequently observed phenomenon in musculoskeletal
diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). The level
of imbalance between bone resorption/deposition is responsible for the
morphological changes osteopenia/bone erosion/osteosclerosis observed in
these arthritic conditions.
In RA, increased osteoclastic activity is responsible for the development of
focal osteopenia/erosion and systemic osteoporosis. The increased
osteoclast activity in RA has been demonstrated to be linked to a
dysregulation of pathways including cell-cell interactions, cytokines, and the
receptor activator of nuclear factor B (RANK)/RANK ligand (RANKL) system.
Recent studies have shown that joint erosion in RA is linked to a decrease in
long-term physical function.
Under OA conditions, the subchondral bone is the site of numerous dynamic
morphological changes. These changes are associated with a number of
local abnormal biochemical pathways related to the altered metabolism of
osteoblasts and osteoclasts. At the early stages of the disease process,
increased bone loss and resorption is observed with subchondral bone
associated with local production of catabolic factors including cathepsin K
and MMP-13. Moreover, OA osteoblasts present an abnormal phenotype
resulting in increased production of growth hormones and catabolic factors.
In addition, factors such as osteoprotegerin (OPG) and RANKL have been
Figure 1(abstract O14)
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bone. Their synthesis varies from being reduced in early OA to being
increased in the late stages of the disease. This finding may explain that in
the early stages of OA, bone remodeling favors resorption and in the more
advanced stages of the disease, bone formation is predominant.
Magnetic resonance imaging (MRI) studies in knee OA patients have shown
that the subchondral bone is frequently the site of signal alterations-bone
marrow lesions (BML) - indicative of a great variety of morphological
changes. BML and cartilage loss have been linked in several studies.
Moreover, studies have identified, in OA patients, a number of risk factors
for total knee replacement including BMLs.
The paradigms regarding the role of bone lesions in arthritic diseases raise a
number of important questions. A comprehensive understanding of the
factors that contribute to these changes will provide us with better
knowledge of the pathophysiology of the diseases and the role of these
structural alterations in patient symptoms and prognosis, as well as guiding
the development of new therapeutic strategies.
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The activation threshold of cells in the immune system is often tuned by
cell surface molecules. Among these, Fc receptors expressed on various
hematopoietic cells constitute critical elements for activating or down-
modulating immune responses.
IgGFc receptors (FcgRs) were originally identified as B cell surface
molecules. For more than 40 years, FcgRs have continued to attract the
interest of many basic researchers and clinicians due to their intriguing
IgG binding ability, which provides a critical link between the humoral
and cellular branches of the immune system.
Several activating-type FcgRs, which associate with homodimeric Fc
receptor common g subunits, are crucial for the onset and exacerbation of
inflammatory diseases. In contrast, a unique inhibitory FcgR, FcgRIIB, plays a
critical role in keeping immune cells silent. Murine models for allergic
responses and autoimmune diseases including RA illustrate the
indispensable roles of activating-type FcgRs and the inhibitory FcgRIIB in
the initiation and suppression of inflammation, respectively [1-5].
The ultimate goals of FcgR research are to accomplish our understanding of
this molecular family and to delineate novel therapeutic strategies toward
the conquest of allergic and autoimmune diseases, infectious diseases,
immunodeficiency, transplantation-associated immune disorders, and
malignant tumors. Although many lines of evidence indicate that a part of
the intravenous Ig (IVIg)-mediated anti-inflammatory effects can be
attributable to the blocking of activating-type FcgRs, recent studies have
pointed out an indispensable role of FcgRIIB in therapeutic benefits of IVIg in
several murine models of inflammatory diseases including RA [6]. In this
session, we will give a brief summary of recent knowledge on antibody
biomedicine including IVIgto you, in light of exploiting FcgRs as potential
therapeutic targets for various inflammatory diseases, along with the
comparison withnon-FcgR-mediated mechanisms of IVIg.
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We have generated two RA models, human T-cell leukemia virus type I
(HTLV-I) transgenic mice and IL-1 receptor antagonist (Ra)-deficient (KO)
mice, to elucidate the pathogenic mechanisms of the disease. Both
models spontaneously developed arthritis closely resembling that of RA
in humans. We found that TNF-, but not IL-6-, deficiency suppressed
development of arthritis in IL-1Ra KO mice, while IL-6 but not TNF was
involved in the HTLV-I transgenic mouse model [1]. IL-17 was important
in both models. These observations suggest that pathogenic roles of IL-6
and TNF are different and both TNF, IL-6, and IL-17 are good targets for
therapeutics.
We found that the expression of C-type lectin receptor (CLR) genes was
augmented in the affected joints of these models using DNA microarrays.
Dendritic cell immunoreceptor (DCIR) is one of such CLRs with a
carbohydrate recognition domain in their extracellular carboxy terminus and
an ITIM in its intracellular amino terminus. Because human shared syntenic
locus containing the Dcir gene is linked to several autoimmune diseases
including RA and SLE, we have generated Dcir KO mice to examine the roles
of this gene in the immune system. We found that aged Dcir KO mice
spontaneously developed sialadenitis and enthesitis associated with
elevated serum autoantibodies [2]. DCs were excessively expanded in Dcir
KO mice after aging. Dcir KO mouse-derived bone marrow cells (BMCs)
differentiated into DCs more efficiently than did wild-type BMCs upon
treatment with GM-CSF, owing to enhanced STAT-5 phosphorylation. These
findings indicate that DCIR is crucial for maintaining the homeostasis of the
immune system, suggesting that Dcir is one of novel targets for the
treatment of RA.
We have also found that the expression of Muratin1, which encodes
uncharacterized and secreted protein, is specifically up-regulated in affected
joins of both models. Interestingly, the development of collagen-induced
arthritis was markedly exacerbated in Muratin1 KO mice. I would like to
discuss the roles of Muratin-1 in the development of arthritis.
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Background: Clinical and in vitro studies suggest that subchondral bone
sclerosis due to abnormal osteoblast (Ob) functions, is involved in the
progression and/or onset of osteoarthritis (OA). Human OA subchondral Ob
show a differentiated phenotype, however they fail to mineralize normally.
The canonical Wnt/b-catenin signaling pathway (cWnt) plays a key role in
osteogenesis by promoting the differentiation and mineralization of Ob.
Arthritis Research & Therapy 2012, Volume 14 Suppl 1
http://arthritis-research.com/supplements/14/S1
Page 7 of 54Dickkopfs (DKKs) are potent antagonists whereas R-spondins (Rspo) are
newly described agonists that play key roles in cWnt signalling. However,
the regulation of DKKs and Rspos in OA Ob remains unknown.
Materials and methods: We prepared primary human subchondral Ob
using the sclerotic medial portion of the tibial plateaus of OA patients
undergoing knee arthroplasty, or from tibial plateaus of normal individuals
at autopsy. DKK1, DKK2, SOST and Rspo-1 and -2 expression and production
were evaluated by qRT-PCR and WB analysis. The regulation of their
expression was determined in response to transforming growth factor-ß1
(TGF-ß1) and as a function of the growth of OA Ob. Selective inhibition was
performed using siRNA techniques. cWnt signaling was evaluated by
m e a s u r i n gt a r g e tg e n ee x p r e s s i o nu s i n gt h eT O P f l a s hT c f / l e fl u c i f e r a s e
reporter assay and intracellular ß-catenin levels by WB. Mineralization was
evaluated by Alizarin red staining. TGF-ß1 levels were determined by ELISA.
Results: DKK2 expression and production were elevated in OA Ob
compared to normal whereas DKK1 was similar. Rspo2 expression was
reduced in OA Ob whereas Rspo1 was similar. TGF-ß1mRNA expression and
protein levels were high in OA Ob. TGF-b1 stimulated DKK2 expression and
production in Ob whereas it inhibited Rspo2 expression. cWnt signaling was
reduced in OA compared to normal Ob. This inhibition was due in part to
elevated DKK2 levels and to reduced Rspo-2 levels since correcting DKK2 by
siRNA or the addition of Rspo-2 increased cWnt signaling using the TOPflash
reporter assay. These treatments also increased ß-catenin levels in OA Ob.
Mineralization of OA Ob was reduced compared to normal Ob and was also
corrected in part by inhibiting DKK2 or by Rspo2 addition. Both elevated
DKK2 and reduced Rspo2 levels contributed to abnormal expression of bone
markers by OA Ob.
Conclusions: These studies demonstrate that elevated antagonist or
reduced agonist levels of cWnt signalling interfere in normal Ob function
a n dl e a dt oa b n o r m a lm i n e r a l i z a t i o n. Since these are secreted soluble
proteins, this could lead to potential new avenues of treatment of OA to
correct their abnormal bone phenotype and mineralization.
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Fas ligand (CD 178) and its receptor Fas (CD 95) are members of the TNF
superfamily of ligands and receptors involved in the activation of apoptosis.
Our research group demonstrated that Fas and Fas ligand were expressed
during osteoblast and osteoclast differentiation, and their expression may
be modified by various cytokines. The lack of functional Fas signaling in
murine models leads to altered endochondral ossification, increase of the
bone mass in adult mice, and resistance to ovariectomy-induced bone loss.
We also showed that mice with a Fas gene knockout lose less bone during
antigen-induced arthritis. These changes seem to be, at least in part,
mediated by increased expression of osteoprotegerin (OPG), another
member of the TNF superfamily, which acts as a decoy receptor for receptor
activator for nuclear factor B (RANK) ligand (RANKL). The bone phenotype
of mice lacking Fas signaling may be related to the immunological
disturbance rather than intrinsic bone disorder. To address this question at
molecular level, we performed a set of parabiotic experiments in mice with
non-functional Fas ligand mutation (gld mice). Mice were kept in parabiosis
for 1 to 4 weeks, and for 2 weeks after separation from 4-week parabiosis.
We also analyzed OPG levels in the peripheral blood of patients with
autoimmune lymphoproliferative syndrome (ALPS). Joined circulation
between gld and wild-type mice led to increased expression of bone
protective OPG in the wild-type animal, both at the gene and protein level
at 4 weeks of parabiosis. This effect was sustained even after the separation
of parabiotic mice. At the same time, double-negative T lymphocytes
transferred from gld into wild-type member of a parabiotic pair rapidly
vanished from the periphery of both gld and control mice in parabiosis.
Patients with ALPS had increased OPG mRNA level in peripheral blood
mononuclear cells, as assessed by real-time PCR, in comparison to age- and
sex-matched controls. These findings show that bone and immune changes
are uncoupled during Fas ligand deficiency. Under the assumption that OPG
also acts as a molecular brake in the immune system, downregulation of
OPG in gld mice during parabiosis with wild-type mice could be considered
as a molecular marker of remission. Increased expression of OPG in children
with ALPS leads to the hypothesis that a similar mechanism might be at
play in humans.
O21
Regulation of inflammatory immune responses leading to the
development of bone destructive autoimmune disease rheumatoid
arthritis by IL-27
Takayuki Yoshimoto
1*, Mingli Xu
1,2, Izuru Mizuguchi
1, Yukino Chiba
1,2,
Sadahiro Kamiya
3, Masanori Matsui
4, Shiva Shahrara
5, Junichiro Mizuguchi
2
1Department of Immunoregulation, Institute of Medical Science, Tokyo
Medical University, Tokyo 160-8402, Japan;
2Department of Immunology,
Tokyo Medical University, Tokyo 160-8402, Japan;
3Departments of Clinical
Sciences, Josai International University, Chiba 283-8555, Japan;
4Department
of Microbiology, Saitama Medical University, Saitama 350-0495, Japan;
5Department of Medicine, Northwestern University Feinberg School of
Medicine, Chicago, IL 60611, USA
Arthritis Research & Therapy 2012, 14(Suppl 1):O21
IL-27, a member of the IL-6/IL-12 family of cytokines, induces early helper T
(Th)1 differentiation and generation of cytotoxic T cells and IL-10-producing
type 1 regulatory T cells, while it suppresses the production of inflammatory
cytokines and inhibits Th2 and Th17 differentiation [1,2]. The receptor
activator of NF-kB ligand (RANKL), which is expressed by not only
osteoblasts but also activated T cells, plays an important role in bone-
destructive disease rheumatoid arthritis (RA). Recently, IL-17-producing Th17
cells were identified as the exclusive osteoclastogenic T-cell subset. This is
because Th17 cells express RANKL, and that IL-17 not only induces RANKL
expression on osteoblasts, but also increases the production of various
inflammatory molecules. It was previously reported that IL-27 is detected in
RA synovial membranes and that treatment with IL-27 attenuated
inflammatory responses in collagen-induced arthritis (CIA), one of mouse RA
models.
We have been investigating the role of IL-27 in the regulation of
inflammatory responses leading to the development of bone destructive
autoimmune disease. We first demonstrated that osteoclastogenesis from
bone marrow cells induced by soluble RANKL is inhibited by IL-27 with
reduced multinucleated cell numbers [3]. Then, other group further clarified
that IL-27 directly acts on osteoclast precursor cells and suppresses RANKL-
mediated osteoclastogenesis through STAT1-dependent inhibition of c-Fos,
leading to amelioration of the inflammatory bone destruction. We recently
investigated the mechanistic role of IL-27 in the pathogenesis of CIA and
found that local injection of adenoviral IL-27 transcript into the ankles of CIA
mice attenuates joint inflammation, synovial lining thickness, bone erosion
and leukocyte migration [4]. IL-27 reduced the production of IL-1b and IL-6,
and suppressed Th17 cell differentiation as well as IL-17 downstream target
genes, which leads to decreased IL-17-mediated monocyte recruitment and
angiogenesis possibly through the reduction of neutrophil and monocyte
chemokines. We also elucidated that IL-27 inhibits cell surface expression of
RANKL on naive CD4
+ T cells activated by T cell receptor ligation and
secretion of its soluble RANKL as well [5]. The inhibitory effect was mediated
in part by STAT3 but not by STAT1 or IL-10. In differentiated Th17 cells, IL-27
much less but significantly inhibited the RANKL expression after
re-stimulation.
Taken together, these results suggest that IL-27 regulates inflammatory
immune responses leading to the development of bone destructive
autoimmune disease through multiple mechanisms as described above
(Figure 1), and that IL-27 may be a promising target for therapeutic
intervention to control disease in RA patients.
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Spleen tyrosine kinase (Syk) is a cytoplasmic protein expressed mainly in
immune cells including macrophages and neutrophils and is associated with
receptors containing an immunoreceptor tyrosine-based activation motif
(ITAM), such as Fcg receptors. As Syk-mediated signaling plays an important
role in activation of immune responses, to investigate whether specific
interruption of Syk-mediated signaling can affect the development of
rheumatoid arthritis (RA), we used tamoxifen-induced conditional Syk-KO
mice (iSyk KO) to evaluate the importance of Syk on disease development.
Using a collagen antibody-induced arthritis model (CAIA), iSyk KO mice
showed significantly attenuated disease severity compared to Syk non-
deleted mice (Figure 1). Although iSyk KO mice contained reduced B cell
numbers after deletion of Syk in adulthood, B cells are not required for
arthritis development in CAIA, as demonstrated by using muMT mice which
lack B cells. On the other hand, Syk-deficient macrophages produced less
MCP-1 and IL-6 than Syk-sufficient cells after FcR ligation, which can account
for the absence of a pronounced accumulation of neutrophils and
macrophages in the joints of iSyk KO mice. Our results demonstrate that Syk
in macrophages is likely a key player in antibody-induced arthritis,
mediating the release of pro-inflammatory cytokines and chemokines after
macrophages bind anti-collagen antibody, and indicate that Syk is a
promising target for arthritis therapy.
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Rheumatoid arthritis (RA) is consists of multiple processes such as chronic
inflammation, overgrowth of synovial cells, joint destruction and fibrosis. To
clarify the mechanism of outgrowth of synovial cells, we carried out
immunoscreening using anti-rheumatoid synovial cell antibody, and cloned
‘Synoviolin’ [1]. Synoviolin is endoplasmic reticulum (ER)-resident E3
ubiquitin ligases, and is involved in ER-associated degradation (ERAD).
Synoviolin is highly expressed in synoviocytes of patients with RA.
Overexpression of synoviolin in transgenic mice leads to advanced
arthropathy caused by reduced apoptosis of synoviocytes [1]. We postulate
that the hyperactivation of the ERAD pathway by overexpression of
synoviolin results in prevention of ER-stress-induced apoptosis leading to
synovial hyperplasia [2]. In addition, Synoviolin ubiquitinates and sequesters
the tumor suppressor p53 in the cytoplasm, thereby negatively regulating
Figure 1(abstract O21) IL-27 regulates inflammatory immune responses leading to the development of bone destructive autoimmune disease
RA through multiple mechanisms.
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in response to ER stress, but also a p53-dependent apoptotic pathway.
These studies indicate that Synoviolin is involved in overgrowth of synovial
cells through its anti-apoptotic effects. Further analysis showed that
Synoviolin is also involved in fibrosis among the multiple processes [4].
Therefore, it was suggested that Synoviolin is thought to be a candidate for
pathogenic factor for arthropathy through its involvement of multiple
processes.
As for the treatment of RA, biological agents are approved for clinical use,
and these drugs have dramatically changed the treatment of RA during the
past decade. However, in some cases patients fail to respond to the biologic
treatment or adverse effects develop such as; an increased risk of infections.
It was reported that elevated Synoviolin levels were identified in circulating
monocytes and were associated with nonresponse to infliximab treatment.
Moreover, these agents are associated with high costs and discomfort
arising from subcutaneous or intravenous administration. Thus, there is a
clear need for the development of cheaper, orally administrated therapies
with fewer side effects. Then, we successfully discovered Synoviolin
inhibitors. We are now proceeding with the optimization of small
compounds, and we hope our research will lead to the development of a
new therapy for RA and serve as an example of the therapeutic benefit of
developing E3 ligase inhibitors.
In addition, to clarify the physiological function of Synoviolin in adult, we
recently generate synoviolin conditional knockout mice using tamoxifen
inducible Cre transgenic mice under CAG promoter. In today’s session, I’d
like to introduce the preliminary data of synoviolin conditional knockout
mice.
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Background: The use of cytokine inhibitors has been a major progress in
the treatment of chronic inflammation. However, not all patients respond
and response will be often lost when treatment is stopped. These clinical
aspects indicate that other cytokines might be involved and we focus here
on the role of IL-17. In addition, the chronic nature of joint inflammation
may contribute to reduced response and enhanced chronicity. We had
previously observed that patients not responding well to TNF inhibition had
higher blood expression of synoviolin, an E3 ubiquitin ligase previously
shown to be implicated in synovial hyperplasia in human and mouse
rheumatoid arthritis (RA). Therefore we studied the capacity of IL-17 to
regulate synoviolin in human RA synoviocytes and in chronic reactivated
streptococcal cell wall (SCW)-induced arthritis.
Materials and methods: Chronic reactivated SCW-induced arthritis was
examined in IL-17R deficient and wild-type mice. Synoviolin expression was
analysed by real-time RT-PCR, Western Blot or immunostaining in RA
synoviocytes and tissue, and p53 assessed by Western Blot. Apoptosis was
detected by annexin V/ propidium iodide staining, SS DNA apoptosis ELISA
kit or TUNEL staining and proliferation by PCNA staining. IL-17 receptor A
(IL-17RA), IL-17 receptor C (IL-17-RC) or synoviolin inhibition were achieved
by small interfering RNA (siRNA) or neutralizing antibodies.
Results: IL-17 induced sustained synoviolin expression in RA synoviocytes.
Sodium nitroprusside (SNP)-induced RA synoviocyte apoptosis was
associated with reduced synoviolin expression and was rescued by IL-17
treatment with a corresponding increase in synoviolin expression. IL-17RC or
IL-17RA RNA interference increased SNP-induced apoptosis, and decreased
IL-17-induced synoviolin. IL-17 rescued RA synoviocytes from apoptosis
Figure 1(abstract O22) Arthritis development in iSyk KO mice. Arthritis was induced by i.p. administration of anti-collagen Ab followed by LPS.
Arthritis score was monitored. *; P < 0.001, **; P < 0.01.
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synoviolin expression and protection against apoptosis induced by
synoviolin knowndown. In IL-17R deficient mice, a decrease in arthritis
severity was characterized by increased synovial apoptosis, reduced
proliferation and a marked reduction in synoviolin expression. A distinct
absence of synoviolin expressing germinal centres in IL-17R deficient mice
contrasted with synoviolin positive B cells and Th17 cells in synovial
germinal centre-like structures.
Conclusions: IL-17 induction of synoviolin may contribute in part to RA
chronicity by prolonging the survival of RA synoviocytes and immune
cells in germinal centre reactions. These results extend the role of IL-17
to synovial hyperplasia.
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In osteoarthritis (OA), despite major progress regarding the identification
and roles of catabolic mediators, further knowledge about factors regulating
their expression is needed. In this line of thought, one recently identified
class of molecules, the microRNA (miRNA), has been found to add another
level of regulation to gene expression by down-regulating its target genes.
miRNAs are 20-23 nucleotides (nt)-long single-stranded non-coding RNA
molecules that act as transcriptional repressors by binding to the 3’
untranslated region (UTR) of the target messenger RNA. Recently, miR-140
has emerged as being implicated in OA by modulating genes involved in
the pathogenesis of this disease. The miRNA-140 gene is located between
exons 16 and 17 in one intron of the WW domain containing the E3
ubiquitin protein ligase 2 (WWP2) gene [1]. The miR-140, originally found in
cartilage [2], has recently been linked more specifically to the OA process
[3,4]. The miRNA-140 decreases the expression of some genes known to
play detrimental roles in OA cartilage. Those genes include histone
deacetylase 4 (HDAC4) [2,5], ADAMTS-5 [6,7], Smad3 [8,9], and IGFBP5 [3].
On human chondrocytes, the expression level of miR-140 was found to be
significantly decreased in OA compared to normal [3,4], thus favouring an
increased expression of its target genes and consequently a role in OA
progression. Interestingly, further investigation of the transcriptional
regulation of miR-140 showed that in human OA chondrocytes miR-140 also
has a WWP2-independent regulation. This occurs through the miR-140
intronic regulatory sequence in which the transcription factor NFAT3 acts
directly and NFAT5 indirectly through the growth factor TGF-b1/Smad3.
These data are of importance as they can provide a new basis for the
rationalization of a therapeutic strategy for this disease.
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Osteoclasts, the multinucleated cells that resorb bone, originate from cell
cycle-arrested quiescent osteoclast precursors [1]. Mesenchymal
osteoblastic cells are involved in osteoclast differentiation. Osteoclast
precursors express RANK (a receptor of RANKL), recognize RANKL
expressed by osteoblasts through cell-cell interaction and differentiate into
osteoclasts in the presence of M-CSF. OPG, produced mainly by
osteoblasts, is a soluble decoy receptor for RANKL. Deficiency of OPG in
mice induces osteoporosis caused enhanced bone resorption. Elevated
osteoblastic activity was suppressed by bisphosphonate administration in
OPG-deficient mice. These results suggest that bone formation is
accurately coupled with bone resorption. Collagen sponge disks containing
BMP-2 were implanted into the dorsal muscle pouches in OPG-deficient
mice. TRAP-positive osteoclasts and ALP-positive osteoblasts were
observed in BMP-2-disks preceding the onset of calcification for one week.
OPG and soluble RANK inhibited BMP-2-induced osteoclast formation but
not the appearance of ALP-positive cells in OPG-deficient mice. We then
examined how osteoblasts are involved in osteoclastogenesis other than
RANKL expression, using RANKL-deficient mice. RANKL-deficient mice
showed severe osteopetrosis due to loss of osteoclasts. Injection of RANKL
into RANKL-deficient mice induced many osteoclasts in bone but not soft
tissues [2]. These results suggest that osteoblasts determine the place of
osteoclastogenesis from haemopoietic stem cells in bone. We next
explored roles of osteoclasts in ectopic bone formation induced by BMP
using op/op and c-fos-deficient osteopetrotic mice. The ectopic bones
formed in op/op mice showed extremely rough surfaces, whereas those in
wild-type mice showed smooth ones. Bone mineral density of BMP-
induced ectopic bone in op/op mice was about 2-times higher than that in
wild-type mice. TRAP-positive osteoclasts exhibit in outer of the ectopic
bone in the wild-type mice. In op/op mice, although osteoclasts strongly
exhibit in inside of the BMP-induced ectopic bone, TRAP-positive
osteoclasts did not exhibit in outer of the BMP-induced ectopic bone.
Furthermore, the accentuation of the BMP-induced ectopic bone formation
did not exist in osteopetrotic c-Fos-deficient mice. In c-Fos-deficient mice,
which are completely osteoclasts deficiency, the accentuation of the BMP-
induced ectopic bone formation did not exist. Furthermore, there is no
RANK-positive osteoclast progenitors in bone derived from c-Fos-deficient
mice. These results suggest that RANK-positive osteoclast progenitors are
positively regulate the signal of bone formation. In summary, osteoclastic
bone resorption directly activates osteoblast function and osteoclasts are
involved in normal bone morphogenesis.
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Repair of cartilage injury with hyaline cartilage has been a challenging clinical
problem. Articular cartilage damage sometimes heals with fibrocartilage,
which is different from hyaline cartilage. Fibrocartilage is a type of scar tissue
that expresses types I and II collagen. In contrast, hyaline cartilage does not
express type I collagen. When aiming to induce hyaline chondrogenic cells
directly from dermal fibroblasts, in addition to activation of cartilage-specific
matrix genes, elimination of expression of type I collagen is needed for
generation of hyaline cartilage. Otherwise, the presence of type I collagen
impairs cartilage extracellular matrix architecture, which leads to formation of
fibrocartilage. The generation of induced pluripotent stem cells has provided
a tool for reprogramming dermal fibroblasts to an undifferentiated state by
ectopic expression of reprogramming factors. We found that retroviral
expression of two reprogramming factors (c-Myc and Klf4) and one
chondrogenic factor (SOX9) induces polygonal chondrogenic cells directly
from adult dermal fibroblast cultures. Induced cells expressed marker genes
for chondrocytes but not fibroblasts; the promoters of type I collagen genes
were extensively methylated. Transduction of c-Myc, Klf4, and SOX9
produced two types of cells: chondrogenically reprogrammed cells and
partially reprogrammed intermediate cells. Chondrogenically reprogrammed
cells generated stable homogenous hyaline cartilage-like tissue without
tumor formation when subcutaneously injected into nude mice. Hyaline
cartilage-like tissue expressed type II collagen but not type I collagen. On the
other hand, partially reprogrammed intermediate cells expressed type I
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chondrogenic cells did not undergo pluripotent state during induction from
dermal fibroblast culture, as time-lapse observation did not detect GFP
reporter expression during induction from dermal fibroblasts prepared from
transgenic mice in which GFP is inserted into the Nanog locus. These results
suggest that chondrogenic cells induced by this approach are free from a
risk of teratoma formation which associates with cells prepared through
generation of iPS cells followed by redifferentiation into the target cell type.
The dox-inducible induction system demonstrated that induced cells are able
to respond to chondrogenic medium by expressing endogenous Sox9 and
maintain chondrogenic potential after substantial reduction of transgene
expression. This approach could lead to the preparation of hyaline cartilage
directly from skin, without going through pluripotent stem cells, in future
regenerative medicine.
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Materials and methods: We created a whole-mount in situ hybridization
database, termed EMBRYS http://embrys.jp/embrys/html/MainMenu.html,
containing expression data of 1520 transcription factors and cofactors
expressed in E9.5, E10.5, and E11.5 mouse embryos –a highly dynamic stage
of skeletal myogenesis. This approach implicated 43 genes in regulation of
embryonic myogenesis, including a transcriptional repressor, the zinc-finger
protein RP58 (also known as Zfp238) [1].
Results: Knockout and knockdown approaches confirmed an essential role
for RP58 in skeletal myogenesis. Cell-based high-throughput transfection
screening revealed that RP58 is a direct MyoD target. Microarray analysis
identified two inhibitors of skeletal myogenesis, Id2 and Id3, as targets for
RP58-mediated repression. Consistently, MyoD-dependent activation of the
myogenic program is impaired in RP58 null fibroblasts and downregulation
of Id2 and Id3 rescues MyoD’s ability to promote myogenesis in these cells.
Conclusions: Our combined, multi-system approach reveals a MyoD-
activated regulatory loop relying on RP58-mediated repression of muscle
regulatory factor inhibitors. We applied our systems approaches to other
locomotive tissues research including cartilage and tendon, and revealed
novel molecular network regulating joint cartilage development and
homeostasis via microRNA-140 [2,3] and tendon development by Mkx [4].
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In rheumatoid arthritis (RA), targeting the vasculature may be beneficial
to control the disease. Endothelial cells lining blood vessels are involved
in a variety of functions in inflammation, including recruitment of
leukocytes and cellular adhesion, antigen presentation, coagulation,
cytokine production and angiogenesis. Angiogenesis, the growth of new
vessels, is important for the proliferation of the rheumatoid synovial
tissue pannus where these vessels also serve as a conduit for cells
entering the inflamed synovium from the blood.
We have shown before that the endothelial adhesion molecule E-selectin,
in soluble form, mediates angiogenesis via its endothelial receptor sialyl
Lewis
x on adjacent endothelium [1]. We have used human RA synovial
tissues to produce an antibody detecting related molecules, Lewis
y/H-5-2,
which are mainly known as blood group antigens but are also found on
endothelium in select organs such as skin, lymph node and synovium, but
not most other endothelium. This antigen is rapidly upregulated on
endothelium in vitro in response to stimuli such as tumor necrosis factor-
alpha, that is present in the RA joint. Additionally, this antigen is
upregulated on RA vs. normal synovial endothelial cells, and in soluble
form is upregulated in RA synovial fluid vs. osteoarthritic synovial fluid. In
soluble form, Lewis
y/H-5-2 mediates angiogenesis, cell adhesion via
intercellular adhesion molecule-1, and monocyte recruitment.
Fucosyl transferases (fut1 and fut2) are enzymes that control the synthesis of
Lewis
y/ H - 5 - 2 .W eh a v ee x a m i n e df u t 1d e f i c i e n tm i c et od e t e r m i n ei f
fucosylation is important in angiogenesis and arthritis. Fut1 gene deficient
mouse endothelial cells did not form endothelial sprouts on Matrigel in vitro
to the same extent as wild type mouse endothelial cells. Moreover, the fut1
gene deficient mice were resistant to the development of angiogenesis in
the Matrigel plug and sponge granuloma angiogenesis models in vivo.I n
terms of arthritis development, the Lewis
y/H-5-2 gene deficient mice were
resistant to development of K/BxN arthritis. Moreover, the harvested joints
of these mice had decreased monocyte chemoattractant protein-1/CCL2
and interleukin-1 compared to wild type littermates, indicating that some
inflammatory mediators were downregulated when fut1 was absent. These
experiments suggest that futs may be important in the development of
angiogenesis and inflammatory arthritis and that they may serve as novel
targets in RA therapy.
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Rheumatoid arthritis (RA) affects approximately 0.5% of the world
population, yet the mechanisms underlying the development and
progression of RA remain poorly understood. We are investigating the role
of citrullinated fibrinogen as a pathogenic antigen in RA. Using arthritis
antigen arrays we demonstrate that citrullinated fibrinogen is one of the
earliest targets of the autoantibody response in RA, with autoantibodies
against citrullinated fibrinogen appearing up to 10 years prior to the
development of clinical arthritis. We further demonstrate that approximately
50% of CCP+ RA patients possess circulating immune complexes containing
citrullinated fibrinogen, and that citrullinated fibrinogen containing immune
complexes are deposited in human RA synovial tissues. To determine
whether citrullinated fibrinogen can induce inflammatory arthritis in mice,
we immunized mice with citrullinated fibrinogen and demonstrated that an
inflammatory arthritis results and that both T cells and serum can transfer
arthritis to naïve mice. Fibrinogen is an endogenous ligand for the innate
immune receptor TLR4, and to determine whether citrullination might alter
the ability of fibrinogen to bind TLR4 we performed in vitro macrophage
stimulation assays with native and citrullinated fibrinogen. We found that
citrullinated fibrinogen was ten-fold more potent than native fibrinogen at
stimulating macrophage TNF release. Further, macrophage derived from
mice deficient for TLR4 or MyD88 did not produce TNF in response to
citrullinated fibrinogen. Thus, our results demonstrate a novel mechanism
by which anti-citrullinated protein antibodies (ACPA) specifically targeting
citrullinated fibrinogen may directly stimulate macrophage TNF production,
via co-ligation of TLR4 and Fc-gamma-R. Our findings demonstrate a role for
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response in RA as well as by increasing the potency of fibrinogen as an
endogenous innate immune ligand. These results provide insights into the
mechanisms by which anti-citrulline autoimmunity, and specifically the
citrullination of fibrinogen, may contribute to both the onset and
propagation of inflammation in RA.
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Regulatory T cells (Tregs) are engaged in the maintenance of immunological
self-tolerance and immune homeostasis. IL-10 has an important role in
maintaining the normal immune state. We showed that IL-10-secreting
Tregs can be delineated in normal mice as CD4
+CD25
-Foxp3
- Tc e l l st h a t
express lymphocyte activation gene-3 (LAG-3), an MHC class II-binding CD4
homolog. CD4
+CD25
-LAG3
+ Tregs characteristically express early growth
response gene-2 (Egr-2), a key molecule for anergy induction. Retroviral
gene transfer of Egr-2 converts naïve CD4
+ T cells into IL-10-secreting and
LAG-3-expressing Tregs. Moreover, CD4
+CD25
-LAG3
+ Tregs show B cell-
dependent development. CD4
+CD25
-LAG3
+ Tregs, but not CD4
+CD25
+
Tregs, strongly suppressed the antibody production in B cells co-cultured
with helper T cells. Thus, IL-10-secreting Egr-2
+LAG3
+CD4
+ Tregs are closely
related to B cells and can be exploited for the treat ment of autoimmune
diseases.
Systemic lupus erythematosus (SLE) is a multisystem chronic inflammatory
disease that affects many organs, and the immunological disorders are
accompanied by autoantibody production. Recent case-control association
study revealed that polymorphisms in the Egr-2 influence SLE susceptibility
in humans. Interestingly, adoptive transfer of CD4
+CD25
-LAG3
+ Tregs from
MRL/+ mice suppressed autoantibody production and the progression of
nephritis in MRL/lpr lupus prone mice. In contrast, CD4
+CD25
+ Tregs from
MRL/+ mice exhibited no significant therapeutic effect upon transfer to
MRL/lpr mice. These results indicate that CD4
+CD25
-LAG3
+ Tregs play key
roles in the regulation of humoral immunity by the strong suppressive
activity for B cell antibody production.
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Under steady state conditions, billions of dead and dying cells are
removed by extrusion from epithelial surfaces as well as by phagocytosis.
Cells such as macrophages and dendritic cells have specialized receptors
that directly recognize altered protein or lipids on apoptotic cells or
opsonins that bind to the dying cell. Once engulfed, phagosomes
containing apoptotic cells are rapidly acidified and the contents degraded
by proteases and nucleases in lysozymes. During necrosis, cellular
material is released prior to engulfment and extracellular nucleases as
well as intracellular sensors dictate the inflammatory potential of the
cellular debris. The outcome may be release of TNF-a, IL-1-b or interferon
(IFN)-a depending upon the type of phagocyte, molecular nature of the
cellular particle and the intracellular sensor engaged.
In addition to responses by cells of the innate immune system, we have
recently defined a link between processing of apoptotic cells and their
debris to T cell activation [1]. MFG-E8 is an opsonin (bridging protein)
that binds to phosphatidylserine on apoptotic cells and facilitates their
removal through interaction with integrins on phagocytes. Mice deficient
in MFG-E8 develop lupus like autoimmunity associated with accumulation
of apoptotic cells in vivo. We observed that older MFG-8-/- mice
spontaneously developed a dermatitis associated with CD8 T cell
infiltration and striking activation of effector memory CD8 T cells. T cell
responses to both exogenous and endogenous apoptotic cell associated
antigens were enhanced in MFG-E8 deficient mice and transfer of
ovalbumin (OVA) reactive OT-I CD8 T cells caused accelerated diabetes in
MFG-E8-/- RIP-mOVA mice and skin disease in kmOVA transgenic mice.
The enhanced CD8 T cell response was attributed to increased cross-
presentation by dendritic cells (DCs) associated with increased detection
of antigen peptide MHCI complexes. Investigation of intracellular
trafficking revealed that, whereas intact apoptotic cells ingested by wild
type DC rapidly fused with lysosomes, in the absence of MFG-E8, smaller
apoptotic cell fragments persisted in endosomal compartments and failed
to fuse with lysosomes.
These observations suggest that in addition to altering the rate of
clearance of apoptotic cells, MFG-E8 deficiency promotes immune
responses to self antigens by altered intracellular processing leading to
enhanced antigen presentation. Thus, handling of dead and dying cells
impacts both innate and adaptive immune responses to self antigens.
Reference
1. Peng Y-F, Elkon KB: Autoimmunity in MFG-E8-deficient mice is associated
with altered trafficking and enhanced cross-presentation of apoptotic
cell antigens. J Clin Invest 2011, 121:2221-2241.
O33
From discovery of RANKL to clinical application of anti-human RANKL
antibody
Hisataka Yasuda
1*, Yuriko Furuya
2, Kohji Uchida
2
1Bioindustry Division, Oriental Yeast Co Ltd, Tokyo, Japan;
2Nagahama
Institute for Biochemical Science, Oriental Yeast Co Ltd, Shiga, Japan
Arthritis Research & Therapy 2012, 14(Suppl 1):O33
Osteoporosis is a common bone disease characterized by reduced bone
and increased risk of fracture. In postmenopausal women osteoporosis
results from bone loss attributable to estrogen deficiency. Receptor
activator of nuclear factor-B ligand (RANKL) is a pivotal osteoclast
differentiation factor [1]. Discovery of RANKL has opened a new era in the
understanding of mechanisms in osteoclast differentiation over the last
decade. The discovery also results in the development of a fully human
anti-RANKL neutralizing monoclonal antibody (called denosumab) and
denosumab has been approved for the treatment of osteoporosis in
Europe and the US.
H e r eIr e p o r tan o v e lr a p i db o n el o s sm o d e lw i t hG S T - R A N K La st h ef i r s t
topic [2]. Pharmacologic studies of candidates for the treatment of
osteoporosis with this model can be done in short periods such as 3 days
and a couple of weeks although it took several months in the conventional
methods with ovariectomized(OVX)-rats. This model also is useful for the
rapid analyses in the functions of osteoclasts in vivo. The RANKL-induced
bone loss model is the simplest, fastest, and easiest of all osteoporosis
models and could be a gold standard in the evaluation of novel drug
candidates for osteoporosis as well as OVX.
Osteopetrosis is generally caused by failure of osteoclast-mediated
resorption of skeleton. There are a numerous mouse models of
osteopetrosis without osteoclasts, including c-fos deficient mice, op/op
mice, RANKL-deficient mice and RANK-deficient mice. As the second topic I
report a mouse model of osteopetrosis induced by a denosumab-like anti-
mouse neutralizing monoclonal RANKL antibody [3]. One injection of the
antibody increased bone mass markedly with remarkable decrease in
osteoclast surface and number after two weeks. In addition, osteoblast
surface, mineral apposition rate, and bone formation rate were also
reduced markedly. These results are consistent with the recent report
treating human RANKL-knock in mice with denosumab [4]. These inducible
models of osteoporosis and osteopetrosis using normal mice exhibit
exactly mirror images in terms of change in bone mass and are quite
useful to accelerate research on osteoclast biology as well as bone
metabolism in vivo.
In conclusion, the discovery of OPG/RANKL/RANK system guided us to
reveal the mechanism regulating osteoclast differentiation and activation.
The past decade has witnessed significant progress in the development
of the RANKL antibody as a pharmaceutical agent. This is a story from a
discovery of RANKL to clinical application of anti-human RANKL antibody.
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Microparticles are small membrane-bound vesicles that are released from
activated and dying cells by a blebbing process. These particles circulate in
the blood and display potent pro-inflammatory and pro-thrombotic
activities. In addition, particles are an important source of extracellular
DNA and RNA and may participate in the transfer of informational nucleic
acids. Because microparticles contain DNA as well as other nuclear
antigens, we have investigated their ability to bind to anti-DNA and other
anti-nuclesome antibodies that characterize the prototypic autoimmune
disease systemic lupus erythematosus (SLE). For this purpose, we
generated microparticles from HL-60, Jurkat and THP-1 cells induced to
undergo apoptosis in vitro. Using FACS analysis to assess antibody binding,
we showed that particles can bind some but not all monoclonal anti-DNA
and anti-nucleosome antibodies from MRL-lpr/lpr and NZB/NZWF1 lupus
mice. For the monoclonal anti-DNA, DNase treatment reduced binding.
Like the monoclonal antibodies, patient plasma also bound to the particles
although this activity was not directly correlated with levels of anti-DNA
antibodies as measured by an ELISA. To determine whether particles
c i r c u l a t i n gi nt h eb l o o do fp a t i e n t sc a nr e p r e s e n ti m m u n ec o m p l e x e s ,
FACS analysis was performed on particles isolated from patient plasma.
These studies indicated that, while the total levels of microparticles in the
blood of patients with SLE did not differ significantly from those of normal
controls, the number of IgG-positive particles was significantly elevated
using a R-phycoerythrin-labeled anti-human IgG (g-chain specific) reagent.
In this study, the number of IgG-positive particles was correlated with
levels of anti-DNA. In similar studies with plasma from MRL-lpr/lpr and
NZB/NZWF1 mice, we showed that the total levels of particles were
increased compared to those of BALB/c control mice and that the number
of particles that stained with an anti-IgG reagent was also increased.
Furthermore, plasma of mice could bind to particles generated in vitro
from apoptotic cells. Together, these findings indicate that microparticles
can express antigenically active DNA in an accessible form, either because
of a surface location or particle permeability. Furthermore, they
demonstrate that microparticles can form immune complexes and that at
least some of the immune complexes in the blood in SLE contain particles.
Current studies are characterizing the immune properties of these
complexes and their potential role in pathogenicity.
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TNF-a is a key pathogenic factor in inflammatory arthritis. Rapid and
transient signaling and functional responses of cells to TNF-a,s u c ha s
activation of NF-gB and MAPKs, are well known. These signaling mechanisms
are widely assumed to be functional in cells chronically exposed to TNF-a
and to mediate the pathogenic effects of TNF-a in chronic inflammation. We
investigated the responses of primary macrophages to TNF-a over the
course of several days and compared patterns of signaling and gene
expression to RA synovial macrophages. The acute inflammatory response
to TNF-a subsided after several hours and was followed by an IFN response
characterized by sustained expression of STAT1 and downstream target
genes. TNF-a-mediated induction of an IFN response was mediated by IFN-b
and was sensitive to inhibition by Jak inhibitors. Concomitantly TNF-a
induced a state of macrophage resistance to the homeostatic cytokines
IL-10 and IL-27. Microarray analysis demonstrated that sustained TNF-a
signaling induced expression of novel genes not appreciated to be
‘TNF-inducible’, but are highly expressed in RA synovial macrophages.
Induction of an IFN response and abrogation of homeostatic cytokine
signaling was also observed in RA synovial macrophages and likely
contributes to the pathogenic actions of TNF-a during arthritis.
Subsequently and surprisingly, TNF-a induced a tolerant state in
macrophages, with diminished cytokine production on lipopolysaccharide
(LPS) challenge and protection from LPS-induced lethality. TNF-a-induced
cross-tolerization was mediated by coordinate action of two inhibitory
mechanisms, suppression of LPS-induced signaling and chromatin
remodeling. Mechanistically, TNF-a-induced cross-tolerance was
distinguished from TLR-induced tolerance by strong dependence on the
nuclear kinase GSK3, which suppressed chromatin accessibility and
promoted rapid termination of NF-gB signaling by augmenting negative
feedback by A20 and IgBa. These results reveal an unexpected
homeostatic function of TNF-a and provide a GSK3-mediated mechanism
for preventing prolonged and excessive inflammation. This homeostatic
mechanism may be compromised during RA synovitis, possibly by
hypomorphic alleles of TNFAIP3 (encodes A20) or by cytokines that
suppress A20 expression or antagonize its function. These data suggest
that augmenting homeostatic functions and signals and thereby
rebalancing the pro- versus anti-inflammatory profile of TNF-a may
represent an efficacious alternative therapeutic approach to suppress
chronic inflammation.
Overall, the data reveal novel signals and functions of TNF-a and that are
likely operative during chronic inflammation and RA synovitis. Targeted
inhibition of these non-traditional functional components of the TNF-a
response may be efficacious in alleviating chronic inflammation while
preserving acute TNF-a responses and host defense against infections.
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Background: Synovial fibroblasts are key players in the pathogenesis of
Rheumatoid Arthritis (RA) and potentially attractive treatment targets.
Upon activation within the joint’s inflammatory milieu, they gain a
transformed phenotype and produce pro-inflammatory cytokines (mainly
IL-6) and tissue destructive enzymes [1].
Materials and methods: Synovial fibroblasts were isolated via enzymatic
processing from synovial tissues obtained from patients with RA or
Osteoarthritis (OA). Synovial fibroblasts (passages 2-4) were stimulated
with TNF-a ( 1 0n g / m l )o n l yo nd a y1 .T h ee x p r e s s i o no fT N F - a-target
genes was measured by qPCR in time course experiments (1, 3, 6, 24, 48,
72, 96 and 120 hours after TNF-a stimulation).
Human macrophages (Mj) generated in vitro (blood derived CD14+ cells
stimulated for 48 h with M-CSF) were used in similar time course
experiments as controls.
Results: In Mj it was observed a rapid (within 1-3 hours) induction of
TNF-a-target genes (including TNF-a, IL-1b, IL-6 and IL-8)t h a tw a s
restrained back to the baseline within a few hours (3-24 hours depending
on the gene). In stark contrast, synovial fibroblasts displayed a remarkably
more sustained response to TNF-a. IL-6 mRNA expression was induced
within a few hours by TNF-a, and induction increased continuously for
72-96 h despite the absence of any further exogenous TNF-a stimulation.
The levels of IL-6 mRNA induced by TNF-a in synovial fibroblasts were
substantially higher compared to human Mj, suggesting that within the
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source of IL-6. By adding the supernatants from 96 h TNF-a-stimulated
fibroblast cultures on unstimulated synovial fibroblasts, a similar robust
induction of IL-6 mRNA was observed, suggesting that there is a TNF-a-
induced soluble factor that mediates the sustained response. A similar
pattern of sustained expression was observed for other TNF-a-target
genes including IL-1b, IL-8 and MMPs. Interestingly, there was no
difference between OA- and RA-derived synovial fibroblasts in their
response to TNF-a.
Conclusions: In contrast to human Mj, synovial fibroblasts display a
sustained inflammatory and tissue destructive response to TNF-a.O u r
observations suggest that synovial fibroblasts may lack the homeostatic
mechanisms that control and terminate the effects of TNF-a on human
Mj [2]. To support this hypothesis, further investigation is needed at the
level of proximal and distal TNF-a signaling events and at the level of
epigenetic regulation of TNF-a-target genes in synovial fibroblasts.
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Interleukin-6 (IL-6) is a multifunctional cytokine that regulates immune
response, inflammation, and hematopoiesis. Although IL-6 plays several
important physiological roles, deregulated overproduction of IL-6 causes
various clinical symptoms and laboratory abnormalities. In the locomotor
disorders such as rheumatoid arthritis (RA) and juvenile idiopathic arthritis
(JIA), IL-6 overproduction has been shown to be involved in inflammatory
manifestations as well as joint destruction. Thus the blocking IL-6
signaling may be a therapeutic approach in those diseases. Various
therapeutic antibodies targeting IL-6 have been developed, and
tocilizumab (TCZ), an anti-IL-6 receptor antibody, precedes the others in
clinical use.
TCZ, even in monotherapy, has been demonstrated to induce DAS28
remission frequently in patients with RA and suppress the radiographic
progression of joint damage. TCZ more significantly reduced radiological
progression in patients with risk factors for rapid progression (i.e. high
urinary C-terminal crosslinking telopeptide, high urinary pyridinoline/
deoxypyridinoline ratio, low body mass index, and presence of joint space
narrowing at baseline) than those without the risk factors. Furthermore,
early decreases in serum type IIA procollagen amino terminal propeptide,
CRP, and/or matrix metalloproteinase 3 (MMP-3) within 12 weeks can
predict for the preventive effects of TCZ on one year progression of joint
destruction in RA.
Although long-term treatment with TCZ is well tolerated, it goes without
saying that it is beneficial not only for the patients but also for medical
economy. To test the possibility of drug free remission introduced by
TCZ, Drug free REmission after cessation of Actemra Monotherapy
(DREAM) study was conducted. A total of 187 patients, who had received
TCZ in the previous clinical trials (the mean treatment duration was 4.3
years), were enrolled, and discontinued TCZ. Remission, defined as DAS28
less than 2.6, was maintained in 10% of the patients without any drug
over 52 weeks. Furthermore, low serum IL-6 (<35 pg/mL) and
normalization of MMP-3 levels at cessation of TCZ were identified as
independent predictive markers for the longer duration of drug free
remission. In addition, retreatment with TCZ in the patients, who
responded to initial TCZ monotherapy, and experienced loss of efficacy
after cessation of TCZ, was well tolerated and showed excellent efficacy
equivalent to that observed at the initial treatment with TCZ.
In the near future, tailor made therapy for individual patients will be
developed on the basis of genome wide association study results, gene
expression profile in peripheral blood cells and/or various biomarkers.
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Rheumatoid arthritis (RA) is a representative autoimmune disease
characterized by chronic and destructive inflammatory synovitis. The
multiple cytokinesand cell surface molecules play a pivotal role in
the pathogenesis of RA and binding of these molecules to their ligands on
the cell surfaceinduce various signal intracellular transduction including
p h o s p h o r y l a t i o no fk i n a s ep r o t e i n s .T h et y r o s i n ek i n a s ei st h ef i r s t
intracellular signals to be phosphorylated and 14 tyrosine kinases are
known to be involved in RA. Among them, members of Janus kinase (Jak)
familyare essential for the signaling pathways of various cytokines and are
implicated in the pathogenesis of RA. An orally available Jak3 inhibitor
tofacitinib is currently in clinical trials for RA with satisfactory effects and
acceptable safety [1,2]. A phase 2 double-blinded study wascarried out to
investigate the efficacy and safety of tofacitinib in Japanese patients with
active RA andinadequate responseto methotrexate (MTX). A total of 140
patients were randomized to tofacitinib 1, 3, 5, 10 mg, or placebotwice
daily and ACR20 response rates at week 12, a primary endpoint, was
significant for all tofacitinib treatment groups [3]. Thus, tofacitinib in
combination with MTX was efficacious and had a manageable safety
profile and tofacitinib 5 and 10 mg twice a day appear suitable for further
evaluation to optimize their potential for the treatment of RA. Although
the mode of action of tofacitinib has remain unclear, we clarified thatthe
inhibitory effects of tofacitinib could be mediated through the suppression
of IL-17 and IFN-g production and proliferation of CD4
+ T cells, presumably
Th1 and Th17 cells by in vitro experiments. We next conducted a
treatment study in the SCID-HuRAg mice, an RA animal model utilizing
SCID mice implanted with synovium and cartilage from patients with RA
and tofacitinib was administered via an osmotic mini-pump. Tofacitinib
decreased serum levels of human IL-6 and IL-8 in the mice and reduced
invasion of the synovial tissue into the implanted cartilage as well as
accumulation of immune cells in the synovium.Taken together, orally
available low molecular weight products such as tofacitinibtargeting
intracellular signaling molecules, would provide enormous power and
flexibility in the treatment of RA.
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Cell-based therapy for regenerative medicine is a major field of biomedical
research including its use in the treatment of degenerative joint disease. The
goal of regenerative medicine is to develop methods to repair, replace, and
regenerate diseased, injured, or non-functional tissues. Towards this goal,
stem or progenitor cells have been considered a highly desirable candidate
cell type, because of their expandability and potential to be induced toward
specific cell differentiation lineages. A key requirement in musculoskeletal
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needs to be a three-dimensional structure. This may be accomplished
through the use of engineered constructs derived by cell seeding into
natural or synthetic biomaterial scaffolds. While direct cell injection is the
most convenient means of cell delivery, a scaffold-based approach is
capable of producing three-dimensional engineered tissues with mechanical
properties compatible with those of various musculoskeletal tissues. Of the
40-50 million Americans with osteoarthritis (OA), an estimated 10-12% suffer
from post-traumatic OA. We have developed an impact model for the
development of post-traumatic OA. Data on the characteristics of this model
in vitro and in vivo will be presented. Focal lesions developed in vivo
resulting from these traumatic impacts will be repaired using stem cell-laden
hydrogel or nanofiber constructs. Concurrently, cell-hydrogel and cell-
nanofibrous constructs are currently being developed for the engineering of
cartilaginous tissues, and information on the fabrication and biological
attributes of these various tissue-engineered composites will be presented.
In conclusion, tissue engineering and regenerative medicine presents an
exciting, emerging inter-disciplinary research field that is a natural platform
for life scientists, engineers, and clinicians working together to develop
therapeutic solutions for diseased or injured tissue and organs.
Support: Commonwealth of Pennsylvania Department of Health and the
United States Department of Defense.
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Antisense homology box (AHB): In 1984, Blalock proposed the possible
role of antisense peptides for molecular interaction among proteins
(BBRC, 121: 203, 1984).
We speculated that interactions between sense- and antisense-peptides
should play a role in formation of the tertiary structure of proteins. We
developed a novel computer program named ANTIS to find antisense
peptide sequences between proteins to be compared (Nature Med.
1:894,1995). ANTIS revealed the presence of an appreciable number of
sense and antisense peptide pairs within any protein molecule and those
portions were designated as antisense homology boxes (AHB).
Complementary peptide: Each peptide should have specific structure
determined by its amino acid sequence which may react with its antisense
peptide. To generate candidates of complementary peptide (C-pep)
reactive to a target amino acid sequence based upon the sense-antisense
amino acid relationship. We invented an evolutionary computer program
(MIMETIC) that generatesC-pep sequences that have a potential to interact
with a target peptide (Microbiol. Imm.46:211, 2002).
C5a inhibitory peptides: C5a anaphylatoxin is considered to be an
effective target for treatment of hyperinflammation since C5a stimulates
generation of tumor necrosis factor alpha (TNFa and other inflammatory
cytokines. Amino acids 37 to 53 of C5a (RAARISLGPRCIKAFTE) is an
antisense peptide to AHBpeptides of the C5a receptor (C5aR), and this has
been designated PL37. This region of C5a is presumed to be a potential
site for C5aR stimulation. Using the computer program MIMETIC, we
generated 19 C-peps to PL37. One of the 7 inhibitory C-peps to PL37
which interfered with C5a function was termed PepA(ASGAPAPGPAGP-
LRPMF). To improve stability, we modified PepA by acetylation of its
N-terminal alanine generating acetylated PepA (AcPepA).
AcPepA rescued Cynomolgusmonkyes at lethal shock induced by bacterial
LPS (4 mg/kg).The excellent therapeutic effect of AcPepA is due to
restriction of high mobility group box 1 (HMGB1) surge induced by the
effect of C5a on C5L2, which is the second C5a receptor, since the
released HMGB1 has the capacity to stimulate TLR4 as an endogeneous
ligand resulting in further activation of inflammatory cells to release
inflammatory cytokines forming positive feedback circuit of inflammation.
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Biological agents targeting a specific molecule provide an effective means
for therapeutic management of rheumatoid arthritis (RA) due to their
specificity and powerful functional capabilities, which has resulted in a
paradigm shift in the treatment strategy of this disease. The dramatic
improvement of the sign and symptoms of a patient with RA first came
from the report with chimeric anti-TNF alpha monoclonal, infliximab in
1993. The observation was confirmed in the double-blind randomized
controlled study comparing this biological agent and placebo in 1994.
The first approved biologics for RA was TNF Receptor 1-Ig fusion protein,
etanercept in the United States in 1998. Until now, nine biological agents
are approved in RA worldwide. Revolutionary change of RA management
with biological therapies obtained in western countries and Japan has
been reviewed [1].
Atreatment strategy that uses tightly controlled dosesof administered
biologics, targeting clinical remission or low disease activity, and followed
by discontinuation of the biologics may be advantageous from botha
health and economical point of view. This strategy is now being
examinedin several clinical studies and trials in Japan for several biologics,
including infliximab, etanercept, tocilizumab, and abatacept [1].
It is ideal to personalize medical treatment for individual RA patients by
predicting efficacy and safety of a given biologic. In order to identify
predictive factors, enormous amounts of efforts have put forth. Although
several clinical variables have been associated with efficacy and safety,
they are often unrealistic in clinical practice. We found that the baseline
circulating TNF levels [2] and Fc gamma 3B polymorphism [3] are
important predicting factors for response to infliximab in RA patients, and
discuss the role of these markers in real world. Further clinical studies
using biomarkers and molecular expression pattern [4,5] should provide a
clue to find the appropriate predicting markers or even new therapeutic
targets. In the near future, the information accumulated from these studies
may allow selecting the best biological agents in individual patient.
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Biologic therapies not only offer the prospect of improved patient
outcomes in a variety of autoimmune diseases, but also the opportunity to
explore the specific target’s role in the underlying mechanisms of disease.
Over recent years we have studied the role of regulatory T cells (Treg) in
patients with rheumatoid arthritis before and after anti-TNF therapy. We
have shown that Treg from patients with rheumatoid arthritis have
defective suppressor function. This Treg defect is linked with abnormalities
in the expression and function of CTLA-4. Anti-TNF antibody therapy did
not reverse CTLA-4 dysfunction but instead induced the differentiation of a
distinct and potent Treg population. These induced Treg were able to
inhibit IL-17 production, in contrast to Treg from healthy individuals,
patients with active RA or RA patients treated with etanercept, a modified
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therapeutic benefit of switching between different anti-TNF agents and
the differing incidence of tuberculosis between adalimumab and
etanercept.
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Recent studies have demonstrated that hedgehog pathway is activated in
chronic myeloid leukemia (CML) stem cells via up-regulation of
Smoothened (Smo), a seven transmembrane domain receptor protein.
LDE225 is a small molecule Smo antagonist which has entered Phase I
clinical evaluation in patients with solid tumors. We performed a
comprehensive drug combination experiment using a broader range of
concentrations for LDE225 and nilotinib. Compared with single agents,
the combination of LDE225 and nilotinib was more effective at reducing
the outgrowth of resistant cell clones. No outgrowth was observed in the
presence of 2 μM nilotinib plus 20 μM LDE225. Also co-treatment with
LDE225 and nilotinib resulted in significantly more inhibition of growth
than treatment with either agent alone in BaF3 cells expressing wt-BCR-
ABL and BCR-ABL mutants (M244V, G250E, Q252H, Y253F, E255K, T315A,
T315I, F317L, F317V, M351T, H396P). The observed data from the
isobologram indicated the synergistic effect of simultaneous exposure to
LDE225 and nilotinib even in BaF3 cells expressing T315I. To assess the in
vivo efficacy of LDE225 and nilotinib ,a t h y m i cn u d em i c ew e r ei n j e c t e d
s.c. with BaF3 cells expressing random mutagenesis for BCR-ABL
mutation. 7 days after injection (average tumor volume, 100 mm
3), the
mice were randomised into four groups (5 mice per group), with each
group receiving either vehicle, LDE225 (20 mg/kg; p.o. once every day),
nilotinib (30 mg/kg; p.o. once every day), LDE225 (20 mg/kg; p.o. once
every day) + nilotinib (30 mg/kg; p.o. once every day). The LDE225 and
nilotinib combination more effectively inhibited tumor growth in mice
compared to either vehicle- or nilotinib- or LDE225-treated mice.
Histopathologic analysis of tumor tissue from LDE225 plus nilotinib-
treated mice demonstrated an increased number of apoptotic cells
detected by TUNEL staining. To investigate combined effects of LDE225
and nilotinib on primary Ph-positive acute lymphocytic leukemia (ALL)
cells, NOD/SCID mice were injected i.v. with bone marrow mononuclear
cells from a Ph positive ALL patient. Treatment with LDE225 and nilotinib
demonstrated a marked segregation of apoptotic cells in both the central
bone-marrow cavity and the endosteal surface. These results suggest
that the combination with a Smo inhibitor and ABL TKIs may help to
eliminate the Ph positive ALL cells. Taken together, the present study
shows that the combination of LDE225 and nilotinib exhibits a desirable
therapeutic index that can reduce the in vivo growth of mutant forms of
BCR-ABL-expressing cells.
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The ubiquitin ligase Cbl-b plays a major role in skeletal muscle atrophy
induced by unloading [1]. The mechanism of Cbl-b-induced muscle
atrophy is unique in that it does not appear to involve the degradation of
structural components of the muscle ,b u tr a t h e ri ti m p a i r sm u s c u l a r
trophic signals in response to unloading conditions. Recent studies on the
molecular mechanisms of muscle atrophy have focused on the role of IGF-
1/PI3K/Akt-1 signaling cascade as a vital pathway in the regulation of the
balance between hypertrophy and atrophy [2,3]. These studies indicate
that under muscle wasting conditions, such as disuse, diabetes and fasting,
decreased IGF-1/PI3K/Akt-1 signaling augments the expression of atrogin-
1, resulting in muscle atrophy. However, these studies did not address the
mechanisms of unloading-induced impairment of growth factor signaling.
In the present study, we found that under both in vitro and in vivo
experimental conditions, Cbl-b ubiquitinated and induced specific
degradation of IRS-1, a key intermed i a t eo fs k e l e t a lm u s c l eg r o w t h
regulated by IGF-1/insulin and growth hormone, resulting in inactivation of
Akt-1. Inactivation of Akt-1 led to upregulation of atrogin-1 through
dephosphorylation (activation) of FOXO3, as well as reduced mitogen
response, in skeletal muscle. Thus, activation of Cbl-b may be an important
mechanism underlying the failure of atrophic muscle to respond to growth
factor-based treatments such as IGF-1 (Figure 1).
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Background: Semaphorins were originally identified as axon guidance
factors involved in the development of the neuronal system. However,
accumulating evidence indicates that several members of semaphorins, so-
called ‘immune semaphorins’, are crucially involved in various phases of
immune responses (Figure 1) [1-3]. In addition, semaphorins and their
receptors have been shown to be crucial for the pathogenesis of
immunological disorders such as atopic dermatitis, multiple sclerosis,
systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis,
These semaphorins regulate immune cell interactions during physiological
and pathological immune responses. However, conventional static analysis
could not determine definitively whether they regulate immune cell
movement.
Materials and methods: Plexin-A1-/- mice were previously established
[4]. Combinational studies, including imaging technique for visualizing
single-cell dynamics and conventional immunological assays were
performed.
Results and discussion: We find that plexin-A1-mediated semaphorin
signals are crucially involved in the transmigration of DCs across the
lymphatics to exit the periphery to induce antigen-specific T-cell priming
using plexin-A1-/- mice. In addition, adoptive transfer experiments identify
that Sema3A produced in the lymphatics functions as a ligand for the
plexin-A1/NP-1 receptor complex expressed in DCs. Interestingly, plexin-A1
is localized at the trailing edge but not the leading edge of DCs during
migration. Sema3A induces phosphorylation of the myosin light chain to
promote actomyosin contraction, resulting in increased DC velocity in the
constricted area (Figure 2). Collectively, these findings not only demonstrate
the involvement of semaphorins in immune cell trafficking but also indicate
that semaphorins are therapeutic targets to treat immunological disorders.
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Figure 2(abstract O45) Sema3A produced by the lymphatic induces actomyosin contraction during transmigration.
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In canonical NF-B signaling pathway, a ubiquitin ligase called SCF (Skp1,
Cul1, F-box protein) complex is essential for I-B degradation. The activity
of the SCF complex is positively regulated by a post-translational
modification of Cul1 subunit with a ubiquitin-like protein NEDD8. Like
ubiquitin, NEDD8 possesses evolutionary conserved Lys residues on its
surface, and forms poly-NEDD8 chain in vivo and in vitro [1,2]. Despite the
importance of the NEDD8 modification in all eukaryotic cells, little is
known about the function of poly-NEDD8 chain. To elucidate the function
of the poly-NEDD8 chain in vivo,w es c r e e n e dpoly-NEDD8 chain binding
proteins (PNBPs) using a yeast two-hybrid system. Of the identified PNBPs,
PNBP1 was identical to a gene present in non-HLA celiac disease and
rheumatoid arthritis risk loci [3].
PNBP1 interacted with NEDD8, NEDD8-conjugating enzyme Ubc12 and Cul1.
PNBP1 strongly associated with wild-type Cul1, but not its NEDDylation
defective Cul1(K720R) mutant, suggesting that the interaction is mediated in
part through NEDD8. Furthermore, PNBP1 promoted NEDDylation of Cul1 in
an in vitro reconstitution assay. These activities were dependent on RING-
finger domain of PNBP1. Finally, knockdown of PNBP1 led to reduction of
the NF-B activation, suggesting that PNBP1 is an important modulator of
the NF-B signaling pathway.
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Background: Neural stem cells (NSCs) possess the ability to self-renew and
to differentiate into the three major cell types found in the central nervous
system (CNS). Recent studies have shown that epigenetic gene regulation
events such as DNA methylation and histone modification play important
roles in regulating NSC fate specification. In this context, we have previously
shown that the histone deacetylase inhibitor valproic acid (VPA) enhances
neuronal differentiation of NSCs. Perhaps because these patterns of NSC
differentiation are exquisitely controlled during normal embryonic
development, restoration of damaged neural networks in the injured adult
CNS is severely limited. Here, using a mouse model of spinal cord injury(SCI),
we examined the effectiveness of NSC transplantation and differentiation
control by VPA administration.
Materials and methods: NSCs were transplanted into the SCI epicenter
7 days after injury. Non-transplanted control and transplanted mice were
then intraperitoneally administered VPA or saline daily, for 7 days, whereafter
we monitored their hindlimb motor function using the open field locomotor
scale for 6 weeks. We next analyzed the migration, morphology, neuronal
marker expression and viability of these cells after co-administration with
VPA. We examined extensively the roles of the neurons responsible for
reconstruction of broken neuronal networks using two neuronal tracers,
immunoelectron microscopy, and two cell-ablation methods.
Results: We show that transplanting NSCs and administering VPA enhances
the functional recovery of their hindlimbs. Neuronal differentiation of
transplanted NSCs was promoted in VPA-treated mice. Anterograde
corticospinal tract tracing revealed that transplant-derived neurons partially
reconstructed the broken neuronal circuits, most likely in a ‘relay’ manner.
Ablation of the transplanted cells abolished the recovery of hindlimb motor
function, indicating that transplanted cells contributed directly to the
improvement of motor function.
Conclusions: These data raise the possibility that epigenetic regulation
in transplanted neural stem cells can be exploited to provide treatment
for SCI.
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Fukushimura Brain Bank (FBB) was established under the auspices of
Fukushimura Hospital, a legally incorporated medical institution. It is
managed completely within the private sector.
“Fukushi” is a Japanese word that means welfare and “mura” is a village. We
have several buildings for the aged and disabled, and about 800 elderly
people reside within the complex.
The Fukushimura Hospital was established in 1982 and is managed by the
Sawarabi MedicalCooperative. It currently has 487 beds. Our patients mainly
have dementia and cerebrovascular problems. The hospital plays a pivotal
role within the village and acts as the central facility.
FBB was established in 1990. We have a long history of collecting samples,
not only from patients but also from residents of our care houses and
nursing homes within the Fukushimura complex. This allows us as medical
doctors and researchers to obtain clinical information or blood samples,
sometimes even before the onset of illness. In our institute, all clinical and
pathological dataare held in the office of individual data management.
In collecting FBB samples, we always keep in mind future biochemical and
molecular analyses and collaborations. The brains are separated into two
hemispheres. One hemisphere is fixed in formalin for neuropathological
analysis and the other is precisely subdivided into coronary sections and
small blocks which are saved in Eppendorf tubes. After samples are
photographed, they are frozen on dry ice (slices) and in liquid nitrogen
(tubes). Finally, all material is stored at -80 degrees in 9 refrigerators for later
use in research.
Although our bank has gone unrecognized in the past, our farsighted efforts
have been gaining considerable attention in recent years in Japan. We now
have over 20 collaborators and supply more than 30 research institutes with
our samples. In addition, our research institute was approved in 2004 by the
Japanese Ministry of Education, Culture, Sports, Science and Technology, as
one of the non-governmental institutes which is permitted to apply for
governmental grants and we became a member of the Comprehensive
Brain Science Network in 2010. FBB at the Choju Medical Institute,
Fukushimura Hospitalis a unique facility and one of the most active brain
banks in the world.
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Page 20 of 54Background: IL-1 receptor antagonist deficient (Il1rn-/-) mice
spontaneously develop arthritis. We previously demonstrated that IL-17
plays a crucial role in the development of arthritis in Il1rn-/- mice.
Furthermore we showed that IL-1 Ra-deficiency in T cells is important for
the development of arthritis. It is not known, however, which IL-17-
producing cells are involved in the pathogenesis of arthritis in this model.
Results: To identify the source of IL-17 in Il1rn-/- mice, we analyzed IL-17-
producing cells. We found that IL-17 production from both CD4+ T cells and
©™T cells was increased in the draining lymph nodes. To clarify the roles of
CD4+ T cells and
©™T cells in the development of arthritis,
©™T cells or CD4+
T cells were depleted in Il1rn-/- mice using antibodies. The development of
disease was suppressed in both cases, suggesting both Th17 cells and IL-17-
producing
©™T cells were involved in the pathogenesis. Then, the
pathogenic role of IL-17-producing
©™T cells in the absence of Th17 cells
was examined.
We generated mice with IL-17 producing
©™T cells, but without Th17 cells,
by adoptively transferring Il17-/-Il1rn-/–T cells into nude mice in which IL-17-
producing
©™T cells are present. We found that these mice still developed
arthritis and that only
©™T cells produced IL-17. Finally, to corroborate that
the development of arthritis in this transfer system is dependent on IL-17,
we adoptively transferred Il17-/-Il1rn-/--T cells into Il17-/-nu/nu mice. The
development of arthritis was significantly suppressed in Il17-/-Il1rn-/--T cell-
transferred Il17-/-nu/nu mice compared with Il-17+/+nu/nu mice transferred
with Il17-/-Il1rn-/--T cells, suggesting that
©™T -cell-derived IL-17 is important
for the develop arthritis.
Conclusion: These results indicate that
©™T cell-derived IL-17 plays an
important role in the pathogenesis of arthritis in Il1rn-/- mice.
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Background: Thalassemia is defined as a complete absence of one or more
of the four globins in the red blood cells due to the deletion of or
nonfunctioning of one or more genes.
Osteoporosis is a universal medical problem, affecting both genders.
Materials and methods: 74 thalassemic patients 36 male and 38 female
below the age of 25 years.
The study was a clinical cross-sectional for both genders with thalassemia
major, Investigation done included a chest × ray, serum iron, total iron
binding capacity (TIBC), transferrin saturation, serum calcium, serum
phosphorus, serum alkaline phosphatase, blood urea, serum creatinine,
and a DXA bone scan.
Statistical analysis:-P-value–S.P.S.S.–chi-square.
Results: We found that the bony disorder in thalassemic patients
increased with age (bone pain, carpopedal spasm, osteoporosis), and with
low serum iron and low T.I.B.C. and with increased transferrin saturation.
The compliance of patients with treatment was rated as in 24 good, in 36
fair and in 14 bad.
The prevalence of osteoporosis in thalassemic Iraqi patients DXA scans
was found to be 67.5% while osteopenia was found in 9.4% and normal
BMD in 22.9%.
Discussion: During the last decade, the presence of osteopenia and
osteoporosis in well-treated thalassaemics has been described in different
studies with high prevalence up to 50%.
Several factors are implicated in reduction of bone mass in thalassaemia
major. Delayed sexual maturation, growth hormone (GH) and insulin
growth factor-(IGF)-1 deficiency, parathyroid gland dysfunction, diabetes,
hypothyroidism, ineffective haemopoiesis with progressive marrow
expansion, direct iron toxicity on osteoblasts, as well as liver disease have
been indicated as possible etiological factors for thalassaemia-induced
osteoporosis. Furthermore, iron chelating has correlated with growth
failure and bone abnormalities, and high desferrioxamine dosage has
been associated with cartilage alterations.
Conclusions: Osteoporosis in thalassemic Iraqi patient was too high and
even more in those patients with bad compliance regard attendance to
the Thalassemia centre.
Recommendations: We need to inform the thalassemic patients about
the risk of osteoporosis and the need for their awareness regard such
complication and the importance of their compliance with therapy.
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Background: Gout is characterized by intra-articular deposition of
monosodium urate monohydrate (MSU) crystals. The role of neutrophil
influx in acute gouty arthritis is well established, while the contribution of
monocytes (MNs) and their secreted inflammatory mediators is not. Here
we demonstrate the role of MSU in MN migration.
Materials and methods: To examine the role of MSU crystals in normal
human peripheral blood (PB) MN migration, we performed MN chemotaxis
in a modified Boyden chamber in vitro using either MSU crystals or gouty
synovial fluids (SFs) as stimuli. To examine mechanisms of MN migration, we
performed MN chemotaxis with MSU in the presence or absence of
chemical signaling inhibitors. We determined the in vivo role of MSU crystals
or gouty SFs in homing of dye-tagged MNs using normal human synovial
tissue (ST)-severe combined immunodeficient (SCID) mouse chimeras. To
investigate the contribution of MSU to production of leukocyte
chemoattractants macrophage migration inhibitory factor (MIF) and
epithelial neutrophil activating factor-78 (ENA-78/CXCL5), and the signaling
molecules involved in secretion of these cytokines, we stimulated MNs with
MSU crystals with or without chemical signaling inhibitors, and performed
ELISAs on conditioned medium. We also assayed for MIF in gouty SF by
ELISA.
Results: We found a significant two fold increase in in vitro MN migration
in response to MSU crystals, while gouty SFs increased MN migration five
fold compared to negative control (p < 0.05). MSU crystal induced MN
migration was significantly decreased by inhibitors of p38 MAPK, Src, and
NFB, suggesting that crystal induced MN migration occurs via these
pathways. After engrafting SCID mice for 4 weeks, we injected dye-tagged
human PB MNs via tail vein. Simultaneously, we injected MSU crystals or
gouty SFs into ST grafts. After 48 hours, we harvested the STs and found
an increase in MN homing to the grafts injected with MSU crystals or SFs
(p < 0.05), indicating that either of these stimuli could recruit MNs in vivo.
Human MNs stimulated with MSU for 24 hours released significantly higher
quantities of the potent leukocyte chemoattractants MIF and ENA-78/
CXCL5. MIF was six fold higher in gouty SFs compared to osteoarthritic
fluids, suggesting the importance of MIF in gouty arthritis. MIF or ENA-78/
CXCL5 secretion depended on the p38 MAPK pathway.
Conclusions: This data suggests an intriguing role for MSU crystals and
gouty SFs in MN migration and provides evidence that MNs and their
secreted products may be potential therapeutic targets for treating gout.
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Stress-induced pain, as in Fibromyalgia (FM), is considered to be caused by
intense events involving physical and psychological injury and is reinforced
by successive stress. Previously, we have established a novel mice model of
FM, using intermittent cold stress (ICS) exposure. Mice given ICS caused
abnormal pain, including mechanical allodynia and hyperalgesia to
nociceptive thermal and chemical stimuli, which lasted for more than
2 weeks. In contrast, those given cons t a n tc o l ds t r e s s( C C S )d i dn o t .T h e
abnormal pain was generalized, female-predominant and specific for A-delta
and A-beta, but not C-fiber-stimuli in the electrical stimulation-induced
nociceptive test. The mechanical allodynia induced by ICS was effectively
suppressed by intraperitoneal or intracerebroventricular injection of
gabapentin. The potency and duration of anti-allodynia effects were much
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nerve injury. Taken together, these findings indicate that mice given ICS
manifest most of characteristics observed in fibromyalgia patients in terms
of pharmacology and pain physiology.
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The purpose of research is study of offenses of appearance of anemia
among rheumatoid arthritis (RA) patients, revealing of their etiologic
reasons, as well as the estimation of character of used anti anemia means
of medicine on the basis of retrospective analysis of history of disease.
Coming out of above stated histories of illness of RA patients were
analyzed to presence of established as accompanying disease of anemia.
Results of this analysis are represented on picture as it seen on the
presented data, 33,3% of patients with RA anemia is verified as
accompanying pathology. Therefore at 1/3 patients with P anemia takes
place. The study of etiologic causes of anemia at these patients shows
that in 76,6% cases anemia bears ferrous deficit character, 20%- anemia
of chronic diseases and only in 3,4% cases - auto immune anemia.
Therefore, the majority of patients of RA anemia bears ferrous deficit
character.
The high frequency of appearance of ferrous deficit anemia among RA
patients, probably is explained by that in conditions of this disease
changes of pH happen among gastro duodenal area. Besides, wide use of
non steroidal anti inflammatory medicine (NAIM) at RA also may effect to
pH of stomach. And in cases of destroyed reaction of ambience change
of ferrous assimilation. That fact of ferrous deficit anemia may has
independent character at analyzed RA patients is excluded. But on their
history of illness it is impossible to determine this fact.
Study of offenses of appearance of anemia at RA patients depending on age
categories is evidencing on that 83,4% of patients with anemia comes to
patients from 31 to 60 years old, and among patients of 31 to 40 years old
appears 25% patients, from 41 to 50 years old - 26,7% and from 51 to
60 years old - 31,7%, accordingly.
Results of these analysis showed that if at patients with debut RA anemia
appears at 1,5% cases, than among RA patients with prolongation of
anamnesis from 1 to 5 years old, from 5 to 10 years old appears in
33,3%, 28,7% and in 34,8% cases accordingly. Therefore as far as
increasing of prolongation of current of RA, specific gravity of patients
with anemia increases.
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Osteoclasts mediate the degradation of bone during RA and are derived
from macrophages. The yersinia outer protein M (YopM) is an effector
protein of Yersinia s p e c i e st h a ti sa b l et oe n t e rh o s tc e l l sb ym e m b r a n e
penetration. In the cell YopM mediates down-regulation of inflammatory
responses. We investigated whether YopM has the potential to act as a
“selfdelivering” immune therapeutic agent by reducing the inflammation
and joint destruction linked to RA.
Using confocal laser scanning we analysed the penetration of recombinant
YopM into bone marrow macrophages (BMMs). Furthermore we studied the
e f f e c t so fY o p Mo no s t e o c l a s t o g e n e s i su s i n gin vitro osteoclast formation
assay. To unravel the signaling pathways of YopM, we tested for
phosphorylation of MAP-kinases (ERK, AKT and p-38) and activation of NF-KB
signaling by Western Blot analysis. With respect to a potential in vivo
application of YopM, we injected YopM intra articular and intravenous in
mice and monitored the distribution by fluorescence reflection imaging
(FRI). We treated hTNFtg mice, as animal model for RA, with YopM and
recorded clinical parameters (weight, grip strength and paw swelling).
Finally we analysed the destruction of bone and cartilage histologically
compared to untreated hTNFtg mice and wildtype mice.
As seen in confocal scanning microscopy, YopM penetrated the cell
membrane of BMMs and accumulated near the nucleus. Studying the
signaling pathways affected by YopM, we found that YopM reduced the
TNFa induced activation of NF-kB via reducing the phosphorylation of IkBa.
TNFa mediated phosphorylation of MAP kinases were not altered by YopM.
Most interestingly, we found a strong reduction of osteoclast formation by
YopM. Incubation of BMMs with YopM led to a 90% reduction in osteoclasts
precursors and osteoclasts. YopM-Cy5 injected into the hind paws of hTNFtg
mice was detectable in the joint without a systemic distribution for 48 hours
and elimination mediated through renal clearance.
Analysing the clinical parameters of RA in hTNFtg mice, we observed a delay
of onset of paw swelling in mice treated with YopM. At histological analysis
of the hind paws, we found reduced bone destruction and decreased
osteoclast formation, as well as less inflammation in YopM treated hTNFtg
mice in comparison to untreated hTNFtg mice.
These results suggest that YopM has the potential to reduce inflammation
and bone destruction in vivo. For this reason YopM may constitute a
novel therapeutic agent for the treatment of RA.
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Autoreactive T cells are a central element in many systemic autoimmune
diseases. The generation of these pathogenic T cells is instructed by antigen
presenting cells. However, signalling pathways in APC that drive
autoimmunity are not completely understood. Here we show that that
conditional deletion of PTEN in myeloid cells are almost completely
protected from the development of two prototypic model autoimmune
diseases, collagen induced arthritis (CIA) and experimental autoimmune
encephalomyelitis (EAE). Myeloid specific deletion of PTEN lead to a
significant reduction of cytokines pivotal for the induction of systemic
autoimmunity such as IL-23 and IL-6 in vitro and in vivo. In addition, PTEN
deficient dendritic cells showed reduced activation of p38 MAP-kinase and
increased inhibitory phosphorylation of GSK3b in vitro. Dendritic cell and
macrophage phenotypic maturation and migration to lymph nodes as well
as collagen specific T and B cell activation was comparable in wt and
myeloid specific PTEN
-/-. However, analysing the impact of myeloid specific
PTEN deficiency on T cell polarization, we found a significant reduction of a
Th17 type of immune response characterized by reduced production of
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higher numbers of regulatory T cells myeloid specific PTEN
-/-. In contrast,
myeloid specific PTEN deficiency did not affect serum transfer arthritis,
which is independent of the adaptive immune system and solely depends
on innate effector functions. These data demonstrate that the presence of
PTEN in myeloid cells is required for the development of systemic
autoimmunity. Deletion of PTEN in myeloid cells inhibits the development of
CIA and EAE by preventing the generation of a pathogenic Th17 type of
immune response.
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Background: Acute Serum Amyloid A (A-SAA) is an acute phase protein
strongly expressed in rheumatoid arthritis (RA) synovial tissue (ST) critically
involved in regulating cell migration and angiogenesis. These processes are
dependent on downstream interactions between extracellular matrix and
cytoskeletal components. Additionally the Notch signalling pathway has
been show to regulate endothelial cell (EC) morphogenesis and is critically
involved in vessel formation, branching and morphogenesis. The aim of this
study was to examine if A-SAA-induced angiogenesis, cell migration and
invasion are mediated by the NOTCH signalling pathways.
Materials and methods: Immunohistology was used to examine Notch1,
DLL-4 and HRT-1 in RA synovial tissue (RAST). avb3a n db1-integrins,
filamentous actin (F-actin) and focal adhesion expression in RAST and
rheumatoid arthritis synovial fibroblast cells (RASFC) was assessed by
i m m u n o f l u o r e s c e n c e .N O T C H 1I C ,i t sl i g a n d sD L L - 4 ,J A G G E D1a n d
downstream signaling components HRT1, HRT2 were quantified by Real-
time PCR. NOTCH1 IC protein was assessed by western blot. A-SAA-induced
angiogenesis cell migration and invasion were assessed by Matrigel tube
formation, scratch and invasion assay. A-SAA modulation of filamentous
actin (F-actin) and focal adhesions (vinculin) was examined by dual
immunofluorescence. Finally, A-SAA-induced angiogenesis, invasion, altered
cell shape and migration were performed in the presence or absence of
siRNA against NOTCH 1.
Results: Notch1 and its ligands DLL-4 and HRT-1 were expressed in RAST
both in the lining layer and perivascular regions. Additionally avb3, b1-
integrin and F-actin predominantly localised to vascular endothelium and
lining cells in RAST, compared with osteoarthritis and normal control
synovial tissue. A-SAA significantly upregulated levels of Notch1 mRNA
and protein in ECs. Differential effects were observed on Notch ligands
HRT-1 and Jagged 1 mRNA in response to A-SAA stimulation. In contrast,
A - S A Ai n h i b i t e dD L L - 4m R N A( p<0 . 0 5 ) ,c o n s i s t e n tw i t han e g a t i v e
feedback loop controlling interactions between NOTCH1 IC and DLL-4 in
the regulation of EC tip vs. stalk cells development. A-SAA induced
disassembly of endothelial cell F-actin cytoskeleton and loss of focal
adhesions as demonstrated by a reduction in vinculin staining. Finally,
A-SAA-induced angiogenesis, cell migration and invasion were inhibited
in the presence of NOTCH 1 siRNA (p < 0.05).
Conclusion: A-SAA induces the NOTCH signalling pathway and
cytoskeletal rearrangement which allows temporal and spatial
reorganization of cells during cell migratory events and EC morphology.
Together these results suggest a critical role for A-SAA in driving cell
shape, migration and invasion in the inflamed joint.
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Background: Cigarette smoking has been shown as major environmental
risk factor for rheumatoid arthritis (RA). Epidemiological studies indicate an
association of cigarette smoking with development of RA [1,2], although
molecular mechanisms remain unknown. The aim of this study is to
analyze the influence of cigarette smoke on the gene expression regulated
by histone deacetylases (HDACs) in RA synovial fibroblasts (RASF).
Methods: RASF obtained from patients undergoing joint replacement
surgery were stimulated with freshly prepared cigarette smoke extract
(CSE) for 24 hours. Expression of HDACs was measured at the mRNA level
by Real-time TaqMan and SYBR green PCR and at the protein level by
immunoblot analysis. Global histone 3 (H3) acetylation was analyzed by
immunoblot.
Results: Stimulation of RASF (n = 8-10) with CSE significantly enhanced
t h ee x p r e s s i o no fH D A C 1( x - f o l d :2 . 0±0 . 4 ;p=0 . 0 4 ) ,H D A C 2( 1 . 9±0 . 3 ;
p = 0.02) and HDAC3 (2.4 ± 0.4; p = 0.01) at the mRNA level while the
expression of HDAC 4-11 remained unchanged. On the protein level,
expression of HDAC1 and HDAC3 were not altered, whereas the
expression of HDAC2 protein was decreased in CSE stimulated RASF. No
measurable changes in global acetylation of H3 were induced by CSE in
RASF (n = 6).
Conclusion: CSE specifically downregulates the expression of HDAC2 in
RASF. Differential regulation of HDAC2 at the mRNA and protein level
points to post-transcriptional degradation mechanisms induced by
smoking. Even though global H3 acetylation was not changed by CSE,
decreased HDAC2 levels might be associated with hyper-acetylation and
thus increased expression of specific HDAC2 regulated genes.
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Background: Peroxisome proliferator-activated receptor gamma (PPARg)
is a ligand activated transcription factor and member the nuclear
hormone receptor superfamily. Several lines of evidence indicate that
PPARg have protective effects in osteoarthritis (OA). Indeed, PPARg has
been shown to down-regulate several inflammatory and catabolic
responses in articular joint cells and to be protective in animal models of
OA. We have previously shown that IL-1 down-regulated PPARg
expression in OA chondrocytes. In the present study we will investigate
the mechanisms underlying this effect of IL-1.
Materials and methods: Chondrocytes were stimulated with IL-1, and
the level of PPARg and Egr-1 protein and mRNA were evaluated using
Western blotting and real-time reverse-transcription polymerase chain
reaction, respectively. The PPARg promoter activity was analyzed in
transient transfection experiments. Egr-1 recruitment to the PPARg
promoter was evaluated using chromatin immunoprecipitation (ChIP)
assays.
Results: We demonstrated that the suppressive effect of IL-1 on PPARg
expression requires de novo protein synthesis and was concomitant with
the induction of the transcription factor Egr-1. ChIP analyses revealed that
IL-1 induced Egr-1 recruitment at the PPARg promoter. IL-1 inhibited
the activity of PPARg promoter and overexpression of Egr-1 potentiated
the inhibitory effect of IL-1, suggesting that Egr-1 may mediate the
suppressive effect of IL-1.
Conclusions: These results indicate that Egr-1 contributes to IL-1-
mediated down-regulation of PPARg expression in OA chondrocytes and
suggest that this pathway could be a potential target for pharmacologic
intervention in the treatment of OA and possibly other arthritic diseases.
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Background: Systemic sclerosis (SSc) associated interstitial lung disease
(ILD) is the leading cause of morbidity and mortality in SSc patients.
Aim of the study: To detect and determine the prevalence of ILD in
patients with SSc in Sulaimani Governorate.
Patients and methods: A sample of thirty patients with SSc (whom
fulfilled the American Rheumatism Association preliminary criteria for the
diagnosis of SSc), were collected from Sulaimani internal Medicine
teaching hospital from July 2009 to July 2010.
All patients were evaluated in a cross sectional study for the evidence
of ILD, almost all patients were submitted to chest radiographs (CXR),
pulmonary function tests (PFT) and oxygen saturation by pulse
oximetry (Spo2) and high-resolution computed tomography (HRCT)
scan.
Results: Patients ages ranged from 23-68 years with mean (45.57)
years, with female predominance 27(90%) compare to 3(10%) male.
Majority of patients had limited type of systemic sclerosis 21(70%), and 15
(50%) cases had restirictive ventilatory defect. Out of the thirty patients in
the study 16(53.3%) patients had evidence of ILD on HRCT.
Conclusion: 1. ILD is common among patients with SSc (dcSSc type).
2. PFT & HRCT are sensitive tools for diagnosis ILD among patients
with SSc.
Table 2(abstract P13) Distribution of HRCT scans abnormalities
Variables Frequency Percent
CT chest
Normal 14 46.7
Abnormal 16 53.3
Fibrosis
No 19 63.3
Yes 11 36.7
Traction bronchiactetic changes
No 19 63.3
Yes 11 36.7
Ground glass
No 22 73.3
Yes 8 26.7
Honey comb
No 26 86.7
Yes 4 13.3
Table 1(abstract P13) Results of pulse oximetry both during rest and exertion, chest x-ray finding,
pulmonary function test
Frequency Percent
O2 Saturation (rest)
Above 92 20 66.7
Below 92 10 33.3
O2 Saturation (exertion)
Above 92 13 43.3
Below 92 17 56.7
CXR
Normal 19 63.3
Basal reticular shadowing 11 36.7
Pulmonary function test
Normal 15 50.0
Restrictive 15 50.0
Obstructive 0 00.0
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Background and objective: New concepts of therapy highlight an early
use of effective treatment to prevent further joint damage in RA. Altered
expression of epigenetic marks like miRs offers us the possibility to
develop new diagnostic tools and novel therapeutic targets.
We found miR-146, -155 and -203 to be upregulated in rheumatoid
arthritis (RA) synovial fibroblasts (SF) compared to osteoarthritis (OA) SF
[1,2]. Based on the comprehensive analysis of the expression of 260 miRs
we found miR-196a to be one of the most downregulated miRs in RASF.
In peripheral blood mononuclear cells, miR-132 and -223 are upregulated
in established RA compared with healthy controls (HC) [3,4].
Our aim was to analyze miRs as potential systemic markers in early stages
of the disease and to find new miRs locally at the site of inflammation
that play a role in the pathogenesis of RA.
Methods: MiRs from sera of patients with treatment naïve early RA (ERA),
with treated established RA and HC were isolated by phenol-chloroform
extraction. TaqMan Low Density Array was used to analyze the expression
of 260 miRs in RASF and OASF. MiR-196a expression was further analyzed
in additional RASF and OASF, RA and OA synovial tissues. TaqMan
RealTime-PCR was used for quantification of miRs and functional
experiments (MTT, scratch assay, AnnexinV FACS) were performed
following transfection with pre-miR or miR-196a inhibitor.
Results: In sera of patients with ERA, the expression of miR-146a was lower
than in both HC (p < 0.05) and established RA sera (p < 0.001) while miR-
155, 132, -203 and -223 showed no differences.
In RASF, the expression of miR-196a is significantly lower than in OASF
(p < 0.0001) as well as in RA synovial tissues compared with OA (p =
0.01). RASF transfection with pre-miR/miR-196a inhibitor resulted in
down/upregulation of predicted targets HOXC8 and ANXA1. Pre-miR-
196a suppressed cell proliferation (27.5%) and migration (41.5%) and
induced apoptosis (54.1%) while miR-196a inhibitor enhanced both
proliferation (81.9%) and migration (231%) and reduced apoptosis
(52.3%) in RASF.
Conclusion: In contrast to established RA synovial fibroblasts where an
increased expression of miR-146a was reported, our data showed that in
early arthritis sera miR-146a is significantly downregulated and might
characterize an early clinical stage of the disease. The low expression of
miR-196a in both RA synovial tissue and in isolated SF contributes to the
aggressive and invasive phenotype of RASF by modifying proliferation,
migration and apoptosis with an impact on the pathogenesis of RA.
Acknowledgements: This work was supported by IAR-EPALINGES, FP7
Masterswitch, MH CR- grant project No.10065-4 and ARTICULUM
fellowship.
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Background: Immune cell-derived microparticles (MPs) are present at
increased amounts in synovial fluid of rheumatoid arthritis (RA) patients
[1] and can activate disease-relevant signalling pathways in RA synovial
fibroblasts (SF) [2,3]. Increased resistance to apoptosis is one of the main
characteristics of aggressive phenotype of RASF [4,5] and MPs have been
shown to mediate both pro- and anti- apoptotic effects in different
target cells [6,7]. The aim of the present study was to investigate the
functional role of immune cell-derived MPs in modulating the apoptosis
of SF in RA.
Methods: MPs were isolated by the differential centrifugation from cell
culture supernatants of U937 cells, untreated or stimulated with TNFa or
poly(I:C) for 16 h. Flow cytometry was used to measure the counts and
surface expression of CD4 and Fas on MP. Proinflammatory response of
RASF induced by MPs was determined by measuring IL-6 protein levels
by ELISA. Proliferation of OASF (n = 3) and RASF (n = 4) stimulated with
MPs for 24 h was investigated by MTT Cell Proliferation Assay. Functional
role of MPs (after 24 h treatment) in spontaneous apoptosis and
apoptosis mediated by Fas Ligand (FasL) or TNFa-Related Apoptosis
Inducing Ligand (TRAIL) was measured by flow cytometry using Annexin
V/propidium iodide staining of RASF and OASF.
Results: Poly(I:C)-induced MPs but not MPs from unstimulated U937
cells increased the production of IL-6 in RASF (mean ± SE: 1873 ± 325
Figure 1(abstract P13) Subsets of Systemic sclerosis.
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Page 25 of 54pg/mL, p = 0.002, n = 9 and 476 ± 182 pg/mL, n = 6, respectively)
when compared to unstimulated RASF (304 ± 61 pg/mL, n = 9).
No changes in proliferation or spontaneous rate of apoptosis were
observed in RASF or OASF stimulated with MPs. Treatment of RASF
( n=5 )a n dO A S F( n=5 )w i t hF a s Lo rt r e a t m e n to fR A S F( n=7 )w i t h
TRAIL for 24 h significantly increased apoptosis of SF (p = 0.010; p =
0.036 and p = 0.016, respectively). Poly(I:C)-induced MPs inhibit FasL-
induced apoptosis of RASF (% decrease ± SE: 40.2 ± 7.0%; p = 0.001; n
=5 )a n dO A S F( 4 1 . 1±9 . 5 % ;p=0 . 0 3 6 ,n=5 )a n dd e c r e a s e dT R A I L -
induced apoptosis of RASF (29.9 ± 6.8%, p = 0.093). In contrast, TNFa-
induced MPs had no effect on Fas-induced apoptosis in SF (n = 3). MPs
from untreated U937 cells did not influence FasL- or TRAIL-induced
apoptosis of RASF (n = 5) and OASF (n = 4). Fas was not expressed on
the surface of MPs, indicating that Poly(I:C)-induced MP did not act as a
decoy to decrease the effective concentration of FasL in cell culture
supernatants.
Conclusions: Immune cells and SF can communicate via MPs. The
impairment of the death receptor-induced apoptosis pathway mediated
by immune cell-derived MPs may contribute to synovial hyperplasia and
joint destruction in RA.
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Background: In systemic lupus erythematosus (SLE), type I interferon
and plasmacytoid DCs (pDCs) are supposed to play important roles.
However, there are few evidences for pDCs activation in SLE. Murine
pDCs are reported to produce soluble LAG3 (sLAG3) upon activation and
pDCs are responsible for most of sLAG3 in mice serum [1]. Therefore,
serum sLAG3 concentration was examined in SLE and other autoimmune
diseases.
Materials and methods: This study enrolled 45 SLE patients who met
ACR criteiria. Disease activity was rated using a SLE disease activity index
(SLEDAI). sLAG3 concentrations were measured by a quantitative
sandwich enzyme immunoassay [2].
Results: The ratio of sLAG3 concentration in SLE to control was 3.10+/-
1.05, PM/DM to control was 1.04+/-0.08, and RA to control was 0.77+/-
0.14. In addition, sLAG3 concentrations showed a significant correlation
with SLEDAI. Interestingly, elevation of sLAG3 was observed even in
patients with SLEDAI = 0. These results suggested that sLAG3 could be a
specific and novel marker for SLE.
Conclusions: sLAG3 can be a novel marker for SLE. sLAG3 in sera of SLE
patient may reflect the activation of pDCs. Because sLAG3 shows
adjuvant effect when combined with active immunization [3], sLAG3 may
contribute to the exacerbation of lupus. The association between
elevated sLAG3, type I interferon signature and activation of pDCs should
be investigated further.
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Background: Rheumatoid arthritis (RA) is one of the most common
articular diseases with a prevalence of 1% worldwide [1,2]. The clinical
features of RA include chronic inflammation of systemic joints associated
with synovial hyperplasia followed by impairment of quality of life [3,4].
Recently, we have shown that Synoviolin/Hrd1, an E3 ubiquitin ligase, is a
novel causative factor for arthropathy [5]. However, the mechanism that
regulates synovial cell outgrowth is not fully understood.
Materials and methods: Human embryonic kidney (HEK)-293 cells, HEK-
293T cells, NIH3T3 cells and synovial cells were cultured in DMEM medium.
Transient transfection assays were performed in HEK-293 cells and HEK-
293T cells. HEK-293 cells transfected with NF-B-Luc were treated with 100
ng/ml of phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), or 10
ng/ml of TNF-a for 24 h, and luciferase activities were measured. siRNAs
with 21 nucleotides for human GCIP were chemically synthesized.
Transfection with siRNAs and cell survival assay were carried out.
Figure 1(abstract P16) sLAG3 concentrations in SLE and other
autoimmune diseases measured by ELISA.
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Page 26 of 54Results: Grap2 cyclin D interacting protein (GCIP), Id like HLH protein,
was down-regulated in the rheumatoid synovial cells. Introduction of
GCIP into mouse fibroblast NIH3T3 cells resulted in growth suppression,
whereas knockdown with siRNAs in synovial cells enhanced cell growth.
GCIP associated with CBP and repressed transcription of CREB-target
genes such as cyclin D1 by inhibition of interaction between CBP and
RNA polymerase II complexes. Binding assays revealed that GCIP bound
to CBP via acidic region, not HLH domain, and this interaction was
regulated by phosphorylation of GCIP in a cell cycle-dependent manner.
Therefore, GCIP has inhibitory effect on cell proliferation via interference
with CBP-mediated transcription.
Conclusions: We propose the novel inhibitory mechanisms of Id protein
family; the coactivator CBP is a functional target. Furthermore, down-
regulation of GCIP may be a key factor in rheumatoid synovial cell
outgrowth.
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Nucleotide sensing-TLRs (Toll-like receptors) recognize pathogen derived-
nucleic acids and trigger immune response [1]. Because of the highly
conserved structure of nucleic acids ,t h e s eT L R sh a v er i s kt or e c o g n i z e
host derived-nucleic acids and induce autoimmune disease, therefore it is
important to clarify the mechanisms and control the response.
We found that the responses of TLR7 and TLR9 are balanced reciprocally,
and Unc93 homolog B1 (Unc93B1) is a key molecule for this balancing
system [2]. Unc93B1 is known as an essential molecule for TLR3, TLR7,
and TLR9 responses, and the function depends on its C-terminal region
[3]. The balancing function of Unc93B1 is located on 34th aspartic acids
from N-terminal, and alanine mutant (D34A) Unc93B1 up-regulates TLR7
response and down-regulates TLR9 response (Figure 1) [2].
It is reported that TLR7 or TLR9 response contributes to some kinds of
autoimmune disease and TLR7 overexpressed mice develop SLE like
autoimmune disease [4-8]. To investigate the significance of reciprocal
TLR7/TLR9 balance in vivo, we generated Unc93b1
D34A/D34A mice and
observed the phenotypes.
As results, Unc93b1
D34A/D34A mice were born according to Mendelian rule
but started to die spontaneously at 10 weeks old and over half of
Unc93b1
D34A/D34A mice died within 1 year (Figure 2A) [9]. Unc93b1
D34A/
D34A mice developed various phenotypes, for example, splenomegaly,
hepatitis, glomerulonephritis, thrombocytopenia, myeloproliferative
disorder (Figure 2B-2E). Especially, lethal acute hepatitis was observed in
moribund mice and infiltrated myeloid cells in liver were expanded in
spleen. These phenotypes are vanished by TLR7 deficient Unc93B1
D34A/
D34A mice, thus TLR7 hyper-response caused by TLR7/TLR9 balance
disruption is factor of phenotypes in Unc93b1
D34A/D34A mice (Figure 2).
Not only innate immune system, acquired immune system is also affected
by D34A mutation. Expanded memory T cells, up-regulation of ICOS and
CD69 on T cells were observed by TLR7 dependent manner and some
classes of serum immunoglobulin level is increased in Unc93b1
D34A/D34A
mice. In addition, Th1 and Th17 cells were expanded and activated in
Unc93b1
D34A/D34A mice. The activation of T cells were TLR7 dependent, and
Figure 1(abstract P18) The D34A mutation of Unc93B1 up-regulates TLR7 response and down-regulates TLR9 response. (A and B). Empty vector
was transfected to bone marrow derived stem cells (BMSCs) from wild tipe mice (gray bars). Empty vector (yellow bars), wild type Unc93B1 expressing
vector (blue bars), or D34A Unc93B1 expressing vector (red bars) were transfected to BMSCs from 3d mice. Transfected BMSCs were cultured with
puromycin and GM-CSF to differentiate to dendritic cells (DCs). After differentiation, DCs were harvested and stimulated by TLR7 ligands (A, loxoribine,
μg/ml) or TLR9 ligands (B, CpG-B, nM). Culture supernatant was corrected and subjected to ELISA for measurement of IL-12p40 (ng/ml).
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Page 27 of 54mature B cell depleted Ighm
-/-Unc93b1
D34A/D34A mice did not induce T cell
activation and moderated phenotypes (Figure 3D and 3E). It suggests that B
cells are activated by TLR7 hyper-response, and the B cells activate T cells to
generate phenotypes of Unc93b1
D34A/D34A mice.However, thrombocytopenia
was not completely recovered in Ighm
-/-Unc93b1
D34A/D34A mice but
completely recovered in Rag2
-/-Unc93b1
D34A/D34A mice. Interaction between
cell types and phenotypes should be confirmed as a future plan.
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Figure 2(abstract P18) Unc93b1
D34A/D34A mice develop systemic lethal inflammation spontaneously. (A) Survival curves of Unc93b1
WT/WT,
Unc93b1
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D34A/D34ATlr7
-/- mice (blue, red, or green line, respectively). (B and C) Macroscopic images of spleen (B) and liver (C).
(D) Microscopic analyses of liver. Histological samples were stained by Hematoxyline and Eosine (H&E) or silver impregnation. (E) Platelet counts in
peripheral blood from indicated genotypes of mice. Bars in the graph indicate averages.
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Fas is a member of the TNF receptor family and crucial for induction of
apoptosis. MRL- lpr/lpr mice, which carry a mutation of Fas, spontaneously
develop systemic autoimmune disease including arthropathy, indicating that
Fas plays an important role in elimination of self-reactive immunocytes by
apoptosis. In addition to autoimmune diseases, we found a novel
phenotype of FasKO mice exclusively in Balb/c genetic background that is
allergic blepharitis. Allergic blepharitis is revealed in Balb/c FasKO mice from
15 week-old and about 85% of the mice suffered from allergic blepharitis at
35 week-old. Serum concentrations of both IgG1 and IgE Abs were about
100-times higher in 20-week old FasKO mice than in WT mice; however,
there was no significant difference between WT and FasKO mice in the
ability of B cells to produce IgG1 and IgE Abs in the presence of IL-4 and
anti-CD40 Ab inducing co-stimulatory signals. Additionally, the production of
IL-4 by T cells was same. These results suggested that other type of cells
Figure 3(abstract P18) T cells and B cells are activated in Unc93b1
D34A/D34A mice. (A or D) Flow cytometry analysis for memory T cells (A upper, or
D) or Th1/Th17 cells (A lower). (B) Expression of ICOS was measured by cell surface staining of CD4+ T cells. Mean fluorescent intensity (MFI) was
calculated and indicated by dots. Black bars in the graph indicate average of MFI. (C) Flow cytometry analysis for matrginal zone B cells. (E) Survival
curves of Unc93b1
D34A/D34A (Red) or Unc93b1
D34A/D34AIghm
-/- (Green) mice.
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identify the cells enhancing IgG1 and IgE Abs production, we cultured B cells
in vitro in the presence of IL-4 and anti-CD40 Ab together with various types
of cells from Balb/c FasKO mice. In the result, we found FasKO non-T non-B
cells upregulated the production of both IgG1 and IgE from B cells.
Moreover, the number of these cells was specifically increased in Balb/c
FasKO mice.All the results indicate that these cells enhance production of
IgG1 and IgE from B cells in the presence of IL-4 and anti-CD40 Ab, and
excessive accumulation of these cells may cause allergy via hyper-
production of IgE.
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Background: Receptor activator of nuclear factor-Bl i g a n d( R A N K L ) ,a
member of tumor necrosis factor (TNF)-a, is produced by osteoblasts (Obs)
and stimulates its receptor RANK on osteoclast (Oc) progenitors to
differentiate them to osteoclasts. WP9QY peptide designed to mimics TNF
receptor’s contact site to TNF-a was known to abrogate osteoclastogenesis
in vitro by blocking RANKL-RANK signaling. WP9QY ameliorated collagen-
induced arthritis and osteoporosis in mouse models. Here we report that
the peptide surprisingly exhibited bone anabolic effect in vitro and in vivo.
Materials and methods: WP9QY was administered subcutaneously to mice
three times per day for 5 days at a dose of 10 mg/kg in normal mice,
followed by peripheral quantitative computed tomography (pQCT) and
histomorphometrical analyses. To clarify the mechanism by which the
peptide exerted the bone anabolic effect, we examined the effects of the
peptide on osteoblast (Ob) differentiation/mineralization with mouse MC3T3-
E1 (E1) cells and human mesenchymal stem (MSC) cells, and those on
osteoclast (Oc) differentiation with RAW264 cells in the presence of sRANKL.
Results: WP9QY augmented bone mineral density (BMD) significantly in
cortical bone not in trabecular bone. Histomorphometrical analysis showed
that the peptide had little effect on osteoclasts in distal femoral
metaphysis, but markedly increased bone formation rate in femoral
diaphysis. The peptide markedly increased alkaline phosphatase (ALP, a
marker for Ob) activity in E1 and MSC cell cultures and decreased tartrate-
resistant acid phosphatase (TRAP, a marker for Oc) activity in RAW264 cell
culture in a dose-dependent manner, respectively. In addition, the peptide
stimulated mineralization evaluated by alizarin red staining in E1 and MSC
cell cultures. The anabolic effect of WP9QY peptide was enhanced
markedly by addition of BMP2.
Increases in mRNA expression of IGF1, collagen type I, and osteocalcin
were observed in E1 cells treated with the peptide for 12 and 96 h in
GeneChip analysis. Addition of p38 MAP kinase inhibitor reduced ALP
activity in E1 cells treated with the peptide, suggesting a signal through
p38 was involved in the mechanisms.
Conclusions: Taken together, the peptide abrogated osteoclastogenesis
by blocking RANKL-RANK signaling and stimulated Ob differentiation/
mineralization with unknown mechanism in vitro. However, in our
experimental conditions the peptide exhibited bone anabolic effect
dominantly in vivo. Since the peptide is known to bind RANKL, we
hypothesize that the peptide shows the bone anabolic activity with
reverse signaling through RANKL on Obs.
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T-regs and Th17 cells are the new generation of CD4+T-cells which play
crucial role in autoimmunity. Both of subsets can influence each other
and probably have common precursor. A key question for understanding
the mechanism of autoimmunity is to recognize how T-regs and Th17
cells turn from self-protection to autoreactivity. Based on literature data
and own observations, we have constructed a conception of age-
dependent thymic T-cells maturation “peripherialisation” as cause of
errors in Th17-T-reg cells interrelations. The connection of T-regs with
thymus is determined currently. Connection of Th17 cells with thymus
remains to be determined properly. Main, there may be naturally
occurring Tregs of thymic origin that are resistant to cell death and serve
as “reserve pool” for autoimmunity protective suppressors. This
mechanism could be affected by external factors producing profound
lymphopenia [1]. Previously we found that RA patients with numerous
rheumatoid nodules (RN) and lymphopenia had statistically reliable
decrease of CD3+T-cells level. We found definite negative correlation
between CD3+PBL amount and RN number (p = 0,029). In all RA patients
with and without RN we didn’t found the decrease of CD4 receptor.
Hereby we expected to find unusual CD3-4+ and CD3-8+ cells in RA.
Otherwise the percentage of CD3+4+ and CD3+8+ cells was normal in
general. But in 4 RA patients after magnetic separation of CD3+T-cells we
detected reliable amount of CD3-4+ lymphocytes (25-28%) These cells
were not detected before separation. One of possible explanation of this
phenomenon is CD3 molecule modulation after the contact with anti-CD3
antibodies conjugated with magnetic particles. So the presence of T-cells
with unusual phenotype in peripheral blood of RA patients doesn’tg i v e
absolute evidence of T-cells maturation disorders. According to our
viewpoint “recent thymic emigrants” (RTE) fraction presence among
Figure 1(abstract P19) Balb/c FasKO mice develope allergic blepharitis.
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regs function. Otherwise the absence of RTE among them leads to
immunopathology. CD31 receptor and T cell receptor rearrangement
excision circles (TREC) are now markers of RTE. We investigated the
number of CD4+CD31+T-cells in RA patients. The preliminary results
permit us to suggest the diminution of RTE in RA (less then 1%/ml) We
also found the diminution of TREC amount in PBL of 22 rheumatoid
arthritis patients, (Median 0,035539 units). FOXP3, RORg,R O R a and CD31
expression in RA will permit to establish role of RTE in autoimmunity.
Acknowledgements: The work is done in framework of project 11-04-
01670 sponsored by Russian Foundation of Basic Research.
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Background: The dendritic cell immunoreceptor (DCIR) is an important
member of C-type lectin superfamily, which has been shown evidence for
susceptibility to arthritis in multiple animal models. The human DCIR
polymorphisms have been shown a nominal association with rheumatoid
arthritis (RA) susceptibility, mainly with anti-cyclic citrullinated peptides
(anti-CCP) antibody -negative RA in Swedish population. We aimed to
investigate the possible association of DCIR with RA susceptibility in
Chinese Han population.
Methods: A total of 1193 patients with RA and 1278 healthy controls
were genotyped for single-nucleotide polymorphism (SNP) rs2377422 and
rs10840759. Association analyses were performed on the whole data set
and on RA subsets based on the status of anti-CCP antibody in RA
patients. The interaction between rs2377422 and HLA-DRB1 shared
epitope (SE) was also analyzed for RA susceptibility. Finally, we carried
out association analysis of rs2377422 with DCIR mRNA expression in RA
patients.
Results: The DCIR rs2377422 was found significantly associated with RA
(allele analysis: OR 1.17, 95%CI 1.04-1.31, p=3.67 × 10
-3; genotype analysis
(recessive model C/C vs. T/T + T/C): OR 1.37, 95%CI 1.08-1.73, p=9.04 ×
10
-3). Following stratification for anti-CCP status, a suggestive association
of rs2377422 with anti-CCP-positive RA was observed (p=0.058, OR 1.34,
95%CI 0.99-1.82). In contrast, the CC genotype of rs2377422 was found
specifically to confer susceptible risk for anti-CCP-negative RA (OR 1.92,
95%CI 1.27-2.90, p=1.99 × 10
-3), despite loss of power in the analysis. The
relative risk of RA was 3.0 (95%CI 1.33-6.91, p=6.48 × 10
-3) in individuals
carrying rs2377422 TT genotype with SE alleles, and 9.06 (95%CI 3.33-
25.61, p=2.08 × 10
-6) in individuals carrying rs2377422 CC genotype with
SE genes. The interaction between rs2377422 and SE alleles was
significant, as measured by the attributable proportion (AP) due to
interaction (0.60). DCIR gene transcription quantification analysis further
proved the dominant effect of rs2480256 CC genotype on DCIR
expression levels in RA patients (C/C vs. T/T + T/C: 0.55 ± 0.09 vs. 0.24 ±
0.02, p=1.67 × 10
-3).
Conclusions: Our study provides evidence for association between DCIR
rs2377422 and RA, particularly with anti-CCP-negative RA in non-
Caucasian populations.
P23
Association between serum level of Vitamin D with autoantibodies
expression, disease activity (SLEDAI) and bone mineral density (BMD) in
patients with Systemic Lupus Erythematosus (SLE)
Handono Kalim
1*, Singgih Wahono
1, Putra Suryana BP
1, Lenny Puspitasari
1,
Fajar Hadi Wijayanto
1, Kusworini Handono
2
1Rheumato-Immunology Division, Department of Internal Medicine,
Brawijaya University, Malang, Indonesia;
2Department of Clinical Pathology
Faculty of Medicine, Brawijaya University, Malang, Indonesia
Arthritis Research & Therapy 2012, 14(Suppl 1):P23
Backround: Vitamin D defficiency has been reported to have negative
association with clinical manifestation and disease activity of SLE [1,2]. Vit
D has an important role in the pathogenesis of SLE [3] and it is necessary
to give vit D supplementation to the patients [4]. The objective of our
study was to determine the association between serum vitamin D level
with auto antibodies expression, disease activity and bone mineral
density in SLE patients.
Patients and methods: 55 female patients with SLE were recruited from
Clinic of Rheumato-Immunology, Saiful Anwar Hospital, Malang, Indonesia.
Mean age of the patients 31.12 years (12-64 yo) with duration of illness
18,4 months (2-54 mo). Serum vitamin (25 (OH)D3 level was assayed using
ELISA method (Cusabio, normal value>30 ng/mL). Anti ds-DNA and Anti
Cardiolipin antibodies were assayed using ELISA method (Diagnostic
Automation, Inc, USA). Disease activity assessed by SLE disease activity
index (SLEDAI) and BMD was assessed by bone densitometry using DEXA.
Association between variables (serum vitamin D and autoantibodies level,
BMD and SLEDAI) were analyzed using Spearman correlation.
Result: The mean of serum 25(OH)D3 level was 22.80 ± 16,23 ng/mL.14
patients (25.5%) had vitamin D deficiency (<10 ng/mL), 34 patients
(61.8%) had vitamin D insufficiency (10-30 ng/mL), and 7 patients (14.7%)
had normal vitamin D levels. There were significant difference level of
anti-dsDNA antibodies (112.46 vs 267.13 U/ml; p < 0.05) and IgM ACA
(16.40 vs 29.7 IU/ml; p < 0,05) in patients with vitamin D insufficiency
and vitamin D defisiency. Serum level of 25(OH)D3 were negatively
related with level of anti-dsDNA and IgM ACA (r: - 0, and r: - 0,72
respectively). The mean of SLEDAI was 15,0 +1 0 . 4 6 .S e r u mv i t a m i nD
levels were inversely correlated with SLEDAI (R=-0.319, p<0.05). Normal
BMD at lumbal spine found in 21 (38.2%) patients. 26 patients (47.3%)
were osteopenia, and 8 (14.5%) patients were osteoporosis. At femoral
neck, 25 (45.5%) patients had normal BMD, 23(41.8%) patients were
osteopenia, 7 (12.7%) patients were osteoporosis. There were no
significant correlation between vitamin D level and BMD at lumbal spine
(p = 0,531) and at femoral neck (p = 0,175).
Conclusion: A large proportion ofSLE patients had low vitamin D levels.
There were positive association between vit D level and autoantibodies
expression in SLE and negative association between serum vitamin D
levels with SLEDAI. No association was found between serum vit D level
and BMD.
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Uncoupling protein 3 (UCP3) is primarily expressed in the inner membrane
of skeletal muscle mitochondria. It has been proposed that UCP3 reduces
production of reactive oxygen species (ROS) and oxidative damage.
However, the mechanisms by which UCP3 attenuates ROS production are
not well understood. Here we report that UCP3 interacts with the non-
processed form of thioredoxin 2 (Trx2), a redox protein that is localized in
mitochondria, but not processed Trx2, which is involved in cellular
responses to ROS. The hydrophilic sequences within the N-terminal tail of
UCP3, which faces the intermembrane space, are necessary for binding to
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Page 31 of 54Trx2. In addition, Trx2 directly associated with UCP3 through a
mitochondrial targeting signaling sequence, was processed in the
intermembrane space, and thereby allowing redox reactions. A bimolecular
fluorescence complementation analysis demonstrated that the interaction
of these proteins occurs in the mitochondrial intermembrane space.
Furthermore, increased UCP3 expression significantly attenuated ROS
production in isolated mitochondrial without effects on membrane
potential, however this effect is lost by Trx2 knock down. These results
suggest that UCP3 binds to Trx2 in the mitochondrial intermembrane
space and attenuates ROS production.
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Background: TNFa is synthesized as a membrane-bound precursor and
proteolytically released from cells. Soluble TNFa is the primary mediator of
pathologies such as rheumatoid arthritis, Crohn’s disease, and endotoxin
shock. Although several different enzymes have been implicated in this
proteolytic activity, recent studies lean toward the TNFa converting
enzyme (TACE/ADAM17) as the most relevant TNFasheddasein vivo.In the
present study, we asked whether the inactivation TACE could yield a
protection from lipopolysaccharide(LPS)-induced septic shockin mice.
Materials and methods: To abrogate TNFa shedding activity in vivo, we
generated conditional TACE-deficient mice using Cre-loxP system [1]. We
mated these mice with Mx1-Cretg mice and LysM-Cretg mice to inactivate
TACE in BM cells and macrophage/monocyte lineage cells, respectively.
Endotoxin shock was induced by i.p. injection of 5 μg of LPS and 20 mg of
D-galactosamine. All injected mice were closely monitored every hour for
the first 16 h and every 3-6 h thereafter.
Results/conclusions: We found that temporal disruption of TACE under
the control of Mx1 transgene prevented lethality from endotoxin shock.
Furthermore, inactivation of TACE in macrophage/monocyte lineage cells
also rendered significant protection against LPS-induced septic shock.
Consistent with these findings, serum TNFa levels in the TACE mutant
mice were much lower than those in control mice. The present study thus
shows that 1) TACE is indeed a principal enzyme responsible for the
release of soluble TNFa in vivo, and that 2) inactivation of TACE in
macrophage/monocyte lineage cells is sufficient to yield strong protection
against LPS-induced endotoxin shock. Taken together, the present data
indicate inhibition of TACE activity as a potential therapeutic target for
TNFa-related disorders.
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Background: A community-based survey on the prevalence of
hyperuricemia and associated factors was carried out in 1996 and 2001.
Materials and methods: In the target community in1996, 2037 dwellers
(age≥15 years old) were interviewed with relevant questionnaires from
house to house. According to even house number, 807 blood samples
(age≥ 40 years old) were taken for serum uric acid (SUA) levels measured
with the uricase-peroxidase enzymatic method. In 2001, 830 residents
≥ 40 years of age were taken for SUA levels measured with the same
enzymatic method. Cholesterol, triglyceride, blood urea nitrogen,
glycosylated hemoglobin, ESR, rheumatoid factor etc were measured as
possible risk factors to enter the multiple logistic regression analysis on
hyperuricemia.
Results: T h ep r e v a l e n c eo fh y p e r u r i c e m i aw a s1 5 . 1 %( 5 1c a s e s / 3 3 8 ,
SUA>7 mg/dl) in men, 8.7% in women (41 cases/469, SUA>6 mg/dl) and
seven gout male patients were found in 1996. The prevalence of
hyperuricemia was 19.5% (52 cases/266, SUA>7 mg/dl) in men, 12.6% (71
cases/564, SUA>6 mg/dl) in women in 2001.The prevalence of gout in
2037 dwellers in Huangpu District was 0.77% in men and 0.34% in both
sexes in 1996 [1].
Conclusions: The mean SUA level in each age group in 2001 was higher
than that of in 1996 (see Table 1). The prevalence of hyperuricemia was
increased rapidly (Male: 15.1% in 1996 to 19.5% in 2001; Female: 8.7% in
1996 to 12.6% in 2001 p < 0.05). Azotemia (≥23 vs. <23 mg/dl),
hypertriglyceridemia (≥200 vs. <150 mg/dl, 150–200 vs. <150 mg/dl) were
the associated risk factors by multiple logistic regression analyzing the
independent effect of each variable on hyperuricemia.
Reference
1. Chen S, Du H, Wang Y, Xu L: The epidemiology study of hyperuricemia
and gout in a community population of Huangpu District in Shanghai.
Chin Med J (Engl) 1998, 111(3):228-30.
P27
Adrenal function in rheumatoid arthritis: acorrelation with disease
activity
Richard Imrich
1,2*, Miroslav Vlcek
1,2, Jana Kerlik
1, Michael Vogeser
3,
Fabian Kirchhoff
3, Adela Penesova
1,2, Zofia Radikova
1, Jozef Lukac
4,
Jozef Rovensky
4
1Laboratory of Human Endocrinology, Institute of Experimental
Endocrinology, Slovak Academy of Sciences, Bratislava, 833 06, Slovakia;
2Center for Molecular Medicine, Slovak Academy of Sciences, Bratislava, 831
01, Slovakia;
3Institute of Clinical Chemistry, Hospital of the University of
Munich, Munich, 81377, Germany;
4National Institute of Rheumatic Diseases,
Piestany, 921 12, Slovakia
Arthritis Research & Therapy 2012, 14(Suppl 1):P27
Background: Hypothalamic-pituitary-adrenocortical dysfunction contributes
to a complex pathogenesis of rheumatoid arthritis (RA). Decreased
production of adrenal androgens and subtle changes in cortisol production
has been observed in RA, particularly in femalepatients with premenopausal
onset of the disease. Our study was aimed to investigate (1) adrenocortical
function in relation to disease and inflammatory activity and to analyze
cortisol bioavailability in RA females.
Materials and methods: Adrenal steroids including free plasma cortisol
responses to the low-dose ACTH stimulation test (1 µg Synactheni.v.) were
investigated in 23 premenopausal RA and in 15 age- and BMI-matched
healthy females. Twelve (N = 12) out of 23 RA patients were on low-dose
glucocorticoids (<8.5 mg/day of prednisone or equivalent). When patients
were divided into low (disease activity score 28; DAS28≤ 3.2) and moderate
to high disease activity (DAS28>3.2) subgroups, glucocorticoid-treated
patients comprised 53% and 50% of patients in each of the subgroups.
Plasma C-reactive protein, interleukin (IL)-1b, IL-4, IL-6, IL-8, IL-10, IL-17,
interferon gamma and tumor necrosis factor alpha concentrations were
measured at the baseline.
Results: RA patients had high C-reactive protein, IL-6, IL-8 and tumor
necrosis factor alpha. Patients with DAS28>3.2 had lower (p < 0.05) total
Table 1(abstract P26) Comparison of SUA levels in
different age group over 5 years
Year/Age 40-49 50-59 60+
Male 2001 **5.85 ± 1.02 (56) *6.04 ± 1.14 (74) 6.20 ± 1.32 (136)
1996 5.38 ± 1.06 (100) 5.53 ± 1.30 (50) 5.90 ± 1.45 (188)
Female 2001 4.19 ± 0.88 (164) 4.72 ± 1.07 (146) **5.14 ± 1.17 (254)
1996 4.13 ± 0.94 (118) 4.49 ± 1.05 (84) 4.74 ± 1.07 (267)
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androstenedione responses in the ACTH test compared to healthy controls.
Patients with DAS28>3.2 had lower (p < 0.05) dehydroepiandrosterone
response in the ACTH test compared to patients with DAS28≤ 3.2. C-reactive
protein (CRP), DAS28, and interleukin (IL)-6 negatively correlated with
androstenedione response to Synacthen. Responses of all measured adrenal
steroids were lower (p < 0.05) in patients on low-dose glucocorticoids
compared to healthy controls. RA patients not treated with glucocorticoids
had lower total cortisol response (p = 0.038) compared to controls, however,
these patients did not differ in free plasma cortisol in the ACTH test.
Conclusions: The present data indicate an association of increased
disease activity with a decrease in adrenal androgen-producing
zonareticularisin RA. A modest suppression of stimulated cortisol in
glucocorticoid-untreated RA patients is not associated with decreased
cortisol bioavailability.
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Objective: F i b r o b l a s t - l i k es y n o v i o c y t e s( F L S )a r ea m o n gt h ep r i n c i p a l
effector cells in the pathogenesis of rheumatoid arthritis (RA).This study
shows the variety of stimulating effects of a proliferation-inducing ligand
(APRIL), and its specific effect on the FLS in the affected RA synovium
(RA-FLS).
Results: A significantly higher level of soluble APRIL was detected in RA
serum compared with in normal serum. Among the three receptors of APRIL
tested, RA-FLS expressed only the B cell maturation antigen (BCMA),
whereas the FLS in the affected osteoarthritis synovium (OA-FLS) expressed
none of the receptors. Moreover, RA-FLS expressed transcription factor PU.1
and B cell specific-transcriptional co-activator OBF.1, which were normally
expressed during myeloid and B-lymphoid cell development. The expression
levels of PU.1 and OBF-1 were correlated with those of BCMA in RA-FLS.
APRIL stimulated RA-FLS but not OA-FLS to produce interleukin (IL)-6, tumor
necrosis factor (TNF)-a,I L - 1 b and APRIL itself. APRIL also enhanced the
receptor activator of nuclear factor kappa B ligand (RANKL) expression in
RA-FLS. Moreover, APRIL enhanced the cell-cycle progression of RA-FLS.
Neutralization of APRIL by BCMA-Fc fusion protein attenuated all these
stimulating effects of APRIL on RA-FLS.
Conclusions: RA-FLS express BCMA, and are stimulated by APRIL. These
results provide evidence that APRIL is one of the main regulators in the
pathogenesis of RA.Epigenetic regulation of BCMA transcription in RA-FLS
might contribute to the underlying mechanisms of this condition.
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Background: Increased advanced glycation end (AGE) products have been
reported to be an important cause of increased osteoblast apoptosis in
osteoporosis [1,2]. Methylglyoxal (MG) is a reactive dicarbonyl compound
endogenously produced mainly from glycolytic intermediates. The
involvement of specific reactive oxygen spesies (
￿OH/ H2O2 /
￿O2
-)i n
increased apoptosis (caspase-3 expression) caused by methyl glyoxal
exposure in osteoblast still speculative [3,4]. The aim of our study is to assess
the role of specific reactive oxygen species signalling on the effect of MG as
an AGE on increased caspase-3 expression in pre-osteoblast.
Materials and methods: Pre-osteoblast MC3T3E1 cell line was obtained
from American Type Culture Cell. Caspase-3 expression in the cells were
assayed in basal condition and after the cells exposed with methyl glyoxal
on dose 5 μM for 6 hours incubation. Diethylthiocarbamoic acid,
mercaptosuccinate, or deferoxamine was added in the culture media to
block specific reactive oxygen species signalling for the development of
osteoblast apoptosis. The caspase 3 expression were assesses from each
different groups of preosteoblast culture: preosteoblast exposed to nothing,
preosteoblast exposed to methyl glyoxal, preosteoblast exposed to
diethylthiocarbamoic (SOD blocker), exposed to mercaptosuccinate
(glutathion peroxidase blocker) and exposed to deferoxamine (Fe
++ blocker);
and osteoblast exposed to methyl glyoxal and diethylthiocarbamoic, or
mercaptosuccinate, or deferoxamine. The result were analyzed using
Kruskall Wallis test with p < 00.5 significant.
Results: Our study showed that MG significantly increased caspase3
expression (apoptosis) of osteoblast. Expression of caspase3 in osteoblast
were significantly highest when the cells exposed to SOD blocker compare
with when the cells exposed to GSH and Fe
++ blocker whether the cells
exposed to MG. Hydroxyl radical increase caspase-3 expression higher than
another reactive oxygen species (
￿OH > H2O2 >
￿O2
-)i np r e - o s t e o b l a s t
MC3T3E1 without exposed methyl glyoxal. The result showed that
superoxide radical more dominant in increasing caspase-3 expression than
another reactive oxygen species (
￿O2
- >
￿OH > H2O2)i np r e - o s t e o b l a s t
MC3T3E1 with MG exposure. There is no significant differences regarding
the effecfts of GSH and Fe
++block on osteoblast caspase3 expression.
Conclusion: The increased osteoblast apoptosis caused by AGE (MG) is
mediated by specific reactive oxygen signalling, SOD activation.
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Objective: To evaluate the discrepancy between patient and physician in
assessment of global severity in early rheumatoid arthritis (RA) and to
explore factors affecting the discrepancy at 1-year since the diagnosis of RA.
Methods: One hundred nine patients with RA with median disease duration
of 4 months were enrolled in this study. The global assessment was
performed using 100 mm-visual analog scale (VAS). The difference between
patient’s and physician’s assessment wascalculated by subtracting
physician’sV A Sf r o mp a t i e n t ’s VAS, and the difference more than 20 mm
was defined as discordant.RA patients were stratified by concordance and
discordance of VAS scoring at 1-year after the diagnosis. To clarify the
factors affecting the discrepancy, clinical characteristics, disease activity
using Disease Activity Score (DAS28) 3-variables, functional status by Health
Assessment Questionnaire (HAQ) were compared between patients with
concordance and discordance.
Results: The discordance between patient’s and physician’s VAS at 1-year
was found in 41 patients (37%), consisting of 5 patients whose VAS was
better than physicians and 36 patients whose VAS was worse than
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significantly higher in patients with discordance group where patients
rated themselves worse than physicians than in patients with
concordance (p < 0.05). HAQ score was correlated with the degree of the
difference (R = 0.49, p < 0.05).
Conclusions: Higher disease activity and higher HAQ score was
associated the discordance between patient’s and physician’s VAS in early
RA patients, indicating the possibility of physicians underestimating the
patient’s global disease severity at 1-year since diagnosis.
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Background: Long bones develop through a strict coordinated process of
endochondral ossification within the growth plate resulting in the
replacement of cartilage by bone and defect in this coordinated process
m a yr e s u l ti ns k e l e t a la b n o r m a l i t i e ssuch as dwarfism, kyposis and also
age-related defects such as osteoarthritis (OA). PPARg, a transcription
factor, plays a key role in lipid homeostasis but its in vivo role in cartilage/
bone development is unknown. Therefore, we determined the specific in
vivo role of PPARg in endochondral bone ossification, cartilage/bone
development and in OA using cartilage-specific PPARg knockout (KO) mice.
Materials and methods: Cartilage-specific PPARg KO mice were generated
using LoxP/Cre system. Histomorphometric/immunohistochemical analysis
was performed to account for ossification patterns, chondrocyte
proliferation, differentiation, hypertrophy, skeletal organization, bone
density, calcium deposition and mouse OA phenotypic changes during
aging using OARSI scoring. Real-Time PCR and western blotting was
performed to determine the expression of key markers involved in
endochondral ossification and cartilage degradation.
Results: Histomorphometric analyses of embryonic and adult mutant mice
demonstrate reduced long bone growth, calcium deposition, bone density,
vascularity as well as delayed primary and secondary ossification. Mutant
growth plates are disorganized with reduced cellularity, proliferation,
differentiation, hypertrophy and loss of columnar organization. Isolated
chondrocytes and cartilage explants from E16.5 and 3 weeks old mutant
mice further show decreased expression of ECM production products,
aggrecan and collagen II, and increased expression of catabolic enzyme,
MMP-13. Furthermore, aged mutant mice exhibit accelerated OA-like
phenotypes associated with enhanced cartilage degradation, synovial
inflammation, and increased expression of MMP-13, and MMP-generated
aggrecan and collagen II neoepitopes. Subsequently, we show that loss of
PPARg and subsequent downstream alterations in phosphatase and tensin
h o m o l o go nc h r o m o s o m et e n( P T E N ) /Akt pathway contribute towards
increased expression of OA catabolic and inflammatory markers, thus
enabling the articular cartilage of PPARg-deficient mice to be more
susceptible to degradation during aging.
Conclusions: For the first time, we demonstrate that loss of PPARg in the
cartilage results in endochondral bone defects and subsequently
accelerated OA in mice. PPARg is essential for normal development of
cartilage and bone.
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Along with a huge amount of works about the importance of a metabolic
syndrome in development of cardiovascular diseases, within last decade in
the literature there was a series of reports on a pathogenetic role of this
syndrome in formation and more serious current of some other diseases of
an internal. In process of doctrine development about a metabolic
syndrome [1], there was new data about existence at gout of various signs
insulin resistance [2]. At the same time, there are insufficiently studied
questions on a role of various categories of a hyperglycemia (a
hyperglycemia on an empty stomach and a postloading hyperglycemia) in
a pathogenesis and gout and hyperuricemia clinic.
Method of the inquiry: 120 males with gout at age 30-69 were
examined to investigate the connection between different categories of
hyperglycemia and level of uric acid in patients with gout. Gout was
revealed on the basis of criteria of American Rheumatic Association.
Glucose tolerance condition was revealed by carrying out standard test of
glucose tolerance (TGT) with revealing of glycemia on an empty stomach,
and also in one and two hours after taking 75 gr glucose by the
examined patients.
The results: According to the revealed findings average levels of
uric acid in patients with gout with normal glucose tolerance had
531,56 ± 0,38 mcmol/l. With damaged glucose tolerance on an empty
stomach and in two hours after glucose loading, levels of uric acid were
more higher(658,18 ± 0,27 mcmol/l and 656,22 ± 0,34 mcmol/l
correspondingly). At the same time on damaged glucose tolerance in an
hour after glucose loading average level of uric acid was 501,16 ± 0,33
mcmol/l. We should draw attention that the difference of average levels
of uric acid among people with disorders glucose tolerance on an
empty stomach and in two hours after glucose loading was more differ
from level of uric acid among people with glucose tolerance disorder in
an hour after glucose loading (p*<0,05).
Conclusion: According to these results we can come to the conclusion
that the level of hyperglycemia has connection with existence in
patients with hyperglycemia on an empty stomach and two hours after
glucose loading. At the same time the problem about connection of
uric acid level with hyperglycemia in an hour after glucose loading
should be examined farther. Perhaps, that rising of glycemia level in an
hour after glucose loading is a compensator mechanism in patients
with gout.
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Background: B cell depletion therapy is effective in the treatment of
various autoimmune diseases. However, this therapy is shown to be
associated with increased risk of adverse effects such as opportunistic
infections. Therefore, in this study, we developed and analyzed the
Table 1(abstract P32) Average findings of uric acid in
blood in patients with different categories of
hyperglycemia
Categories of hyperglycemia n M ± m
Normal tolerance 13 531,56 0,38
Hyperglycemia on an empty stomach 11 658,18 * 0,27
Hyperglycemia after 1 hour 20 501,16 0,33
Hyperglycemia after 2 hours 76 656,22 * 0,34
* Note: in the table is shown the reliability of differences concerning an
indicator in hyperglycemia group in 1 hour after loading a glucose.
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in collagen-induced arthritis model.
Methods: Since the antigenic targets of pathogenic antibodies are
identified in collagen-induced arthritis (CIA) model, we developed toxin-
conjugated peptide tetramers, which contained pathogenic epitope of
mouse type II Collagen (CII). The male DBA/1J mice were immunized with
bovine CII and injected with toxin-conjugated peptide tetramers on day
10 and day 20 after CIIimmunization.We analyzed the effect of toxin-
conjugated peptide tetramers on the production of autoantibodies and
clinical course of arthritis.
Results: The incidence of arthritis was significantly lower (P < 0.05) in the
tetramer-treated group than in the control group. The mean serum
antibody levels for CII did not differ significantly, but there were
significant differences in the anti-peptide antibodies over time.
Conclusions: Peptide tetramer is effective in the selective depletion of
antigen-specific B cells and decreased the incidence of arthritis in CIA
model. Therefore, depletion of antigen-specific B cells using this
strategy might be a new therapeutic intervention of autoimmune
diseases.
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Self tolerization in peripheral is critical to prevent autoimmune diseases
including arthritis and here we focus on the role of PD-1 in tolerance
induction against the antigen associated with apoptotic cellsdelivered
intravenously(i.v.). We accessed delayed type hypersensitivity (DTH)
reaction against hapten (TNP) as antigen specific immune response, in
which the injection of TNP-apoptotic cells i.v.suppressedDTH in wild type
mice but we found not in PD-1 KO mice (Figure 1). Adaptive transfer of
CD8 T cells into PD-1 KO mouse from wild type mice tolerated with TNP-
apoptotic cells suppresses DTH. This result shows PD-1 functions on CD8
T cells for immune suppression.Additionally we neutralized the PD-1 with
antibody to determine the phase when PD-1 functions for immune
tolerance by apoptotic cells, and identified PD-1functionsparticularly at
the initial phase of antigen specific immune response. We are further
studying the mechanism of suppressive role of PD-1+ CD8 T cells that
should be activated with apoptotic cells.
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Background: Juvenile idiopathic arthritis (JIA) is a rheumatic pediatric
disease characterized by synovial inflammation in one or more joints [1].
Inflammation results in hyperplastic changes of the synovium, destruction
of articular cartilage and subchondral osteoresorption. Murine models of
arthritis revealed impaired osteogenic/chondrogenic differentiation of
synovial mesenchymal progenitors via inflammation-induced activation of
NF-B [2].
We aimed to explore frequency, plating efficiency and osteoblastogenic
potential of synovial mesenchymal progenitors and correlate them with
intensity of local and systemic inflammation in patients with JIA.
Materials and methods: Synovial fluid cells were collected from 19
patients with oligoarticular JIA (oJIA) and 8 patients with poliarticular JIA
(pJIA), plated in density 1.5 × 10
6/mL in 24-well plates, and cultured in
aMEM + 10% FCS. Osteoblastogenesis was stimulated by the addition of
50 μg/ml ascorbic acid and 5 mmol b-glycerophosphate. To exclude
inflammatory and hematopoietic cells, adherent cells were passaged
three times, and osteoblastogenesis again induced in fourth passage (P4).
Osteoblastogenesis was assessed by intensity of alkaline phospatase (AP)
histochemical staining. In addition, osteoblast (Runx2, AP, OPG, RANKL)
and cytokine/chemokine (IL-1, IL-4, CCL2, CCL4 and MIP1a)g e n e
expression were assessed in P4 osteoblastogenic cultures.
Results: Plating efficiency of synovial mesenchymal progenitors was
d e c r e a s e di np a t i e n t sw i t hp J I Ai nc o m p a r i s o nt op a t i e n t sw i t ho J I A .
Passage was successful only in 3 (37.5%) pJIA patients, and 18 (94.7%)
oJIA patients. Plated at equal density, P4 synovial adherent cells from
pJIA patients formed less fibroblastic colonies. Osteoblastogenesis was
higher in children with oJIA than in children with pJIA, both from
primary synovial cells (median 1119.08; IQR 476.57-1470.26 vs. 141.58;
IQR 14.47-237.50, arbitrary units, p < 0.005, Mann-Whitney test), and P4
cells (median 1162.00; IQR 102.00 to 5484.50 vs. 12.00; IQR 6.00-307.37,
arbitrary units, p < 0.05). Osteoblastogenesis from primary synoviocytes
negatively correlated with erythrocyte sedimentation rate (r= -0.4139,
p = 0.03), and synovial concentration of IL-17 (r= -0.4174, p = 0.04).
Expression of osteoprotegerin and CCL2 was decreased in P4
osteoblastogenic cultures from pJIA in comparison with oJIA patients
(p < 0.05).
Conclusions: Severe forms of JIA are characterized by decreased
proliferation, osteogenic differentiation and immunoregulatory potential
of synovial mesenchymal cells, correlating with inflammatory activity.
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Figure 1(abstract P34) PD-1 is essential for tolerance induced by
apoptotic cells. TNP-apoptotic cells were injected intravenously into
PD-1 hetero- or homo- deficient mice. The mice were immunized with
TNP (Filled bar) or preconditioned with apoptotic cells before
immunization with TNP (open bar).
Arthritis Research & Therapy 2012, Volume 14 Suppl 1
http://arthritis-research.com/supplements/14/S1
Page 35 of 54Tokai University School of Medicine, Isehara, Kanagawa, Japan;
3Department
of Pediatric Hematology and Oncology Research, National Research Institute
for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan;
4Department of Systems BioMedicine, Tokyo Medical and Dental University,
Bunkyo-ku, Tokyo 113-8510, Japan;
5Core Research for Evolutional Science
and Technology, Japan Science and Technology Corporation, Saitama
332-0012, Japan
E-mail: riho@hope.tokai-u.jp
Arthritis Research & Therapy 2012, 14(Suppl 1):P36
microRNAs (miRNAs), which are class of post-transcriptional regulators
such as short 19 to 23-nucleotide non-coding RNAs, complementarily
bind seed sequences in the 3’-untranslational region of multiple target
mRNAs, resulting in their suppression of translation or degradation [1]. In
the former case, since the mRNA expression of the targets does not any
change, transcriptomics approach, such as expression array, cannot
identify the targets.
Recent studies shed light on the fine-tuning mechanism of miRNAs in
myriad biological processes including development [2], tumorigenesis [3]
and inflammation [4]. We have identified enhancement of mir-146a
expression in rheumatoid arthritis synoviocyte and macrophages [5],
whilst suppression of them in osteoarthritis [6]. Another group also have
identified the enhancement of mir-146a and mir-155 in response to
bacterial pathogen such as lipopolysaccaride [7]. Recently, mice lacking of
mir-155 are resistant to collagen-induced arthritis (CIA) [8], whilst
administration of mir-146a complexed with aterocollagen into joint
attenuates pathological condition of CIA [9]. These results indicate that
mir-146a and mir-155 plays an important role for developing arthritis and
inflammation. However, the targets of both two miRNAs and their
molecular mechanisms are not still fully identified.
In this study, in order to identify the targets of them in translational level, we
established gain of function models using adenovirus- and CMV promoter-
mediated overexpression in several culture models and performed liquid
chromatography-tandem mass spectrometry-based shotgun proteomics in
these models.
Acknowledgements: The authors sincerely thank Dr. Yanagiya R for
helpful advice on preparation of adenovirus, and Dr. Inoue A for the gift
of CMV vector for mir-146a.
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Age-dependent changes in immune system such as thymus gland
involution, T-cells amount decrease, are typical both for autoimmune
diseases (Rheumatoid arthritis - RA), and progressive atherosclerosis
characterized as “accelerated ageing”. But till now processes of T-cell
maturation were studied only by indirect methods. The introduction of
T-cell receptor excision circle (TREC) PCR-assay seemed to enable direct
detection of recent thymic emigrants in peripheral blood and therefore
the quantification of thymic output [1]. High TREC levels were detected
during childhood, and were decreasing with age, but TREC-expressing
cells are not completely lost in the elderly. At the first stage of our
investigation we studied TREC level in 3 groups of healthy donors: 16
people. 16 - 30 years old (group 1, TREC Median 0,156299 Units),
8 persons 30 - 45 years old (group 2, TREC Median 0,08782 Units) and 9
people over 45 years (group 3 TREC Median 0,051858 Units). Thereby we
confirmed age-related decline of thymic output in healthy donors.
In RA patients we found age-dependent statistical definite difference of
TREC expression. In the 1-st group (n-12, age range 40,4+2,8 y) TREC
amount was following: Median 0,00766 I/U lower level 0,00045, upper level
0,01961. In the 2-nd group (n = 16, age range 57,5+1,32) TREC were
diminished (Median 0,00065, lower level 0,000002, upper level 0,00095).
Detected high TREC amount in some young RA patients is not entirely
consistent with the data of literature.TREC level in patients with chronic
forms of coronary heart disease (age 55 - 70 years old) was lower but
comparable with donors group 3 (TREC Median 0,0200 Units).
Unexpectedly high level of TREC comparable with donors group 2 we
detected in patients with Acute Myocardial Infarction (AMI) (10 patients,
age range 48 - 71 y) (TREC Median 0,089845 Units). According to our
viewpoint, the content of TREC in peripheral blood lymphocytes depends
both on thymic output and “peripheral” factors, such as survival time of
“naive” T cells in periphery. Recent data give evidence that the up-
regulation of Th1 cell-functions and interferon-g hyperproduction existed
in patients with AMI after the onset of symptoms. This may participate in
the immune-mediated ventricular remodeling after AMI. The slowing of
“naive"-T-cells turnover and Th1/Th2 imbalance could be the reason of
TREC increase in AMI patients.
The work is done in framework of project 11-04-01670 sponsored by
Russian Foundation of Basic Research. Project director Dr. Goloviznin M.V.
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Background: Antigen induced arthritis (AIA) is an experimental model of
rheumatoid arthritis induced by methylated bovine serum albumin
(mBSA) [1]. Hyperplastic synovia in AIA contains fibroblast-like
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chondroblasts or adipocytes [2]. Since Fas is shown to inhibit osteoblast
differentiation [3], we were interested whether such inhibitory effect may
contribute to the pathogenesis of AIA.
Materials and methods: AIA was induced in mice with a Fas gene
knockout (Fas -/-). Three weeks after pre-immunization with mBSA in
complete Freund’s adjuvant, wild-type (C57BL/6, wt) and Fas -/- mice
were injected with mBSA into each knee, whereas controls were injected
with equal volume of phosphate buffered saline (PBS). Three weeks after
injection we assessed joint diameters, histology, μCT scans, and
differentiation of bone marrow- and synovia-derived osteoblasts.
Results: Knee diameters were increased in mBSA-injected wt mice
compared to PBS-injected controls (3.21 ± 0.2 vs. 2.98 ± 0.1, p < 0.05,
t-test), and this increase was not significant in Fas -/- mice (2.97 ± 0.2 vs.
2.87 ± 0.1). Histology revealed presence of synovial hyperplasia in both
mBSA-injected groups, but mBSA-injected wt mice had decreased
trabecular bone volume in distal femoral metaphyses (BV/TV) compared
to controls (1.08 ± 0.57 vs. 2.55 ± 0.43; p < 0.05, t-test). There was no
significant difference between mBSA-injected and control group in Fas -/-
mice (2.34 ± 0.62 vs. 2.61 ± 0.65). μCT analysis showed that mBSA-
injected wt mice had decreased BV/TV (2.99 ± 0.19 v. 1.96 ± 0.19; p <
0.001, t-test) and trabecular number (TbN) (1.03 ± 0.03 vs. 0.64 ± 0.02), as
well as increased trabecular separation (TbSep) (256,89 ± 1395,12 vs.
312.40 ± 1323.91), compared to controls. mBSA injected Fas -/- mice had
decreased TbN compared to controls (0.815 ± 0.01 vs. 0.64 ± 0.04; p <
0.05, t-test), with no significant difference in other trabecular parameters.
Osteoblast differentiation was inc r e a s e di nb o t hw ta n dF a s- / -m B S A -
injected mice.
Conclusions: Our study demonstrated that Fas deficiency attenuated the
development of clinical signs and bone loss in AIA. The mechanisms of
this phenomenon need to be clarified.
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Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic synovitis that progresses to destruction of cartilage
and bone. Bone marrow (BM) cells have been shown to contribute to this
pathogenesis. In this study, we compared differentially expressed molecules
in BM cells from RA and osteoarthritis (OA) patients and analyzed abnormal
regulatory networks to identify the role of BM cells in RA.
Materials and methods: Gene expression profiles (GEPs) in BM-derived
mononuclear cells from 9 RA and 10 OA patients were obtained by DNA
microarray. Up- and down-regulated genes were identified by comparing
the GEPs from the two patient groups. Bioinformatics was performed by
Expression Analysis Systemic Explorer (EASE) 2.0 based on gene ontology,
followed by network pathway analysis with Ingenuity Pathways Analysis
(IPA) 7.5.
Results: The BM mononuclear cells showed 764 up-regulated and 1,910
down-regulated genes in RA patients relative to the OA group. EASE
revealed that the gene category response to external stimulus, which
included the gene category immune response, was overrepresented by the
up-regulated genes. So too were the gene categories signal transduction
and phosphate metabolism. Down-regulated genes were dominantly
classified in three gene categories: cell proliferation, which included mitotic
cell cycle, DNA replication and chromosome cycle, and DNA metabolism.
Most genes in these categories overlapped with each other. IPA analysis
showed that the up-regulated genes in immune response were highly
relevant to the antigen presentation pathway and to interferon signaling.
The major histocompatibility complex (MHC) class I molecules, HLA-E, HLA-F,
and HLA-G, tapasin (TAP) and TAP binding protein, both of which are
involved in peptide antigen binding and presentation via MHC class I
molecules, are depicted in the immune response molecule networks.
Interferon gamma and interleukin 8 were overexpressed and found to play
central roles in these networks.
Conclusions: Abnormal regulatory networks in the immune response and
cell cycle categories were identified in BM mononuclear cells from RA
patients, indicating that the BM is pathologically involved in RA.
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Background: To estimate the prevalence of latent tuberculosis (TB)
infection according to the interferon-gamma release assay (IGRA,
QuantiFERON®-TB Gold In-Tube, QFT) in patients with rheumatoid arthritis
(RA), and assess the risk factors for incidence of active TB after TNF alpha
blocking agents treatment.
Methods: A multicenter, prospective, and observational study was started
in April, 2011 for patients with RA in Taiwan University Hospital, Taipei
Veterans General Hospital, and Chang Gung Memorial Hospital in Keelung.
Patients who take anti-TNFa regiments or not (defined as naïve or never
take agent) were both enrolled in the study. The clinical history, DAS-28
score, chest film finding, sputum survey for active TB, and QFT screening
results were collected.
Results: A total of 147 patients were enrolled in the study, in which five of
them (3.4%) had history of anti-TB treatment and none had active TB at
the beginning of the investigation. There were 75 patients undergoing
anti-TNFa treatment before the study (42 patients (56%) took etanercepts
and the other 33 (46%) ones took adalimumabs) and 72 patients had not
(Table 1).
Based on QFT test, the frequency of latent TB infection (LTBI) were 12.5%
(9/72) for naïve patients, and 10.7% (8/75) for biologics users (p > 0.05).
Risk analysis showed no difference between different QFT results in study
patients (Table 2).
The interval between starting etanercepts or adalimumabs treatment and
screening for QFT test were 22.5 and 14.4 months (p > 0.05), respectively.
Subgroup analysis showed possible risk factors for LTBI in patients who had
history of adalimumabs or etanercept treatment were the history of anti-TB
treatment and negative for BCG scar, respectively (p < 0.05). Other factors
including DAS-28 score, presence of rheumatoid factor, white cell count, and
previous immunosuppressant dosage (ie, prednisolone and methotrexate)
were not related to the LTBI status (Table 3).
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negative QFT result after adalimumab therapy (p<0.05). In current study,
none of patients with positive or indeterminate QFT result received
preventive INH treatment and none of them had evidence of non-
tuberculosis mycobacterium infection.
Conclusion: The overall frequency of LTBI in patients with RA was 11.6%
in this study. Although history of anti-TB treatment and negative BCG
scar were risk factors for LTBI, other factors still need to be considered
due to limited sample size in current study. Further regular follow up
should be done.
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Background: Loss of TGF-b signaling in mice leads to promoted
hypertrophic conversion of articular chondrocytes, which process is
suggested to be linked to progression of osteoarthritis (OA). However, the
molecular mechanisms by which TGF-b signaling inhibits chondrocyte
maturation remain unclear. We screened for mediators downstream of
TGF-b signaling to inhibit chondrocyte hypertrophy.
Materials and methods: We induced choncrocyte differentiation of
ATDC5 cells with BMP-2. A TGF-b type I receptor inhibitor compound
SB431542 was applied to inhibit endogenous TGF-b signaling. Expression
of differentiation markers was evaluated by real-time RT-PCR and
immunoblot. The function of SnoN was studied by stable overexpression
and siRNA-knockdown approaches. Organ culture system using mouse
embryo metatarsal bone was employed to study the roles of TGF-b
signaling and SnoN in chondrocyte maturation.
Results: BMP-induced expression of Col10a1 gene, a specific marker for
hypertrophic chondrocytes, was further up-regulated dramatically, upon
treatment with SB431542. In metatarsal bone organ culture, zone of calcified
matured chondrocytes was expanded upon SB431542 application.
Expression of Id1 gene, the direct target of BMP Smads, was enhanced by
SB431542, although the phosphorylation (activated status) of BMP-Smads-1/
5/8 was not influenced by SB431542 application. Therefore, BMP signaling
seemed to be blocked by TGF-b signaling at the level beneath the
phosphorylation process of BMP-Smads. We evaluated expression profile of
BMP signal-inhibitors, and found that SnoN was the only gene which
expression was induced upon TGF-b treatment, while was inhibited by
SB431542 application. Indeed, knockdown of SnoN resulted in enhanced
hypertrophic maturation of ATDC5 cells, and overexpression of SnoN
suppressed it. To evaluate in vivo contribution of SnoN in cartilage cell
hypertrophy, we studied expression of SnoN protein by immunohisto-
chemistry. In mouse growth plate, SnoN was present only in prehy-
pertrophic chondrocytes, but excluded from hypertrophic zone. In human
OA specimens, SnoN was positive around ectopic hypertrophic chond-
rocytes of moderate OA cartilages, whereas SnoN was not detected in
severe-graded OA cartilages. These data support the idea that SnoN inhibits
hypertrophic conversion of chondrocytes in vivo,a sw e l la sin vitro.
Conclusions: Our results suggest that SnoN suppresses hypertrophic
transition of chondrocytes, as a mediator of TGF-b signaling, to prevent
the progression of OA.
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Osteoclast differentiation is critically dependent on cellular calcium (Ca
2+)
signaling. Intracellular Ca
2+ concentration ([Ca
2+]i) is regulated by two flux
pathways; Ca
2+ oscillations evoked by the release of Ca
2+ from the
endoplasmic reticulum, and/or Ca
2+ entry from the extracellular fluid. The
latter is carried out by the plasmamembrane localized Ca
2+ permeable
channel such as “transient receptor potentials (Trps)”. Trpv4-deficient mice
show an increased bone mass due to impaired osteoclast maturation,
because Trpv4 mediates Ca
2+ influx at the late stage of osteoclast
differentiation and hereby regulates Ca
2+ signaling [1]. Furthermore,
substitutions of amino acids R616Q/V620I of Trpv4 have been discovered as
gain of function mutations resulting in increased Ca
2+ transport [2]. Since
the region of these substitutions at the trans-membrane pore domain is
perfectly conserved between species, we created a mutant of the mouse
Trpv4 (Trpv4
R616Q/V620I) and characterized it on Ca
2+ signaling especially in
the occurrences of oscillations at the initial step of osteoclast differentiation.
Intact Trpv4 and Trpv4
R616Q/V620I were equally transduced by retroviral
infection into bone marrow derived hematopoietic cells isolated from WT
mice, and mock-transfection was used as control. The resorptive activity
was significantly increased in Trpv4
R616Q/V620I-expressing osteoclasts when
treated with RANKL for 7 days, associating increased NFATc1 and
calcitonin receptor mRNA expression. Noteworthy, the expression of these
differentiation markers was already elevated in Trpv4
R616Q/V620I cells
before RANKL treatment, suggesting that the activation of Trpv4
advances osteoclast differentiation through Ca
2+-NFATc1 pathway.
Accordingly, basal [Ca
2+]i, analyzed in progenitor cells treated with RANKL
for 24 hr, increased 2 fold in intact Trpv4 (p < 0.05) and 3 fold in
Trpv4
R616Q/V620I (p < 0.01) compared to controls. Although spontaneous
Ca
2+ oscillations were absent in control progenitor cells, Trpv4
R616Q/V620I
progenitor cells already displayed irregular oscillatory pattern.
In summary, our findings provide evidences that the activation of Ca
2+
permeable channel supports Ca
2+ oscillations in progenitor cells and
therefore promotes the potential of osteoclast differentiation.
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Rheumatoid arthritis (RA) causes sever joint damage and significant
disability of daily living. The symptoms of RA patients are mainly from
chronic inflammation and continuous joint destruction, however, the
mechanisms underlying how inflammation and joint destruction in RA
develop and are sustained chronically remain largely unclear. In this study,
we show that signal transducer and activator of transcription 3 (STAT3)
plays a critical role in both chronic inflammation and joint destruction in
RA. We found that inflammatory cytokines, such as IL-1b,T N F a and IL-6,
activated STAT3 either directly or indirectly and induced expression of
inflammatory cytokines, further activating STAT3. STAT3 activation also
induced expression of receptor activator of nuclear factor kappa B ligand
(RANKL), an essential cytokine for osteoclast differentiation. STAT3
knockout or pharmacological inhibition resulted in significant reduction of
the expression of both inflammatory cytokines and RANKL in vitro. STAT3
inhibition was also effective in treating an RA model, collagen induced
arthritis (CIA), in vivo through significant reduction in expression of
inflammatory cytokines and RANKL, inhibiting both inflammation and joint
destruction. Thus our data provide new insight into pathogenesis of RA
and provide evidence that inflammatory cytokines induce a cytokine
amplification loop via STAT3 that promotes sustained inflammation and
joint destruction.
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Background: Previous studies demonstrated a regulatory role of interleukin
1 (IL-1) in inflammatory cartilage damage and bone destruction in human
tumor necrosis factor transgenic (hTNFtg) mice, an animal model for
Rheumatoid Arthritis (RA). Moreover, blocking of IL-6 has been shown to
reduce local bone erosions in this model. Therefore we wanted to
investigate the effect of a combined depletion of IL-1 and IL-6 on the
development and severity of inflammatory, erosive arthritis.
Methods: We first crossed IL1a and ß deficient (IL1-/-) mice with IL6-/-
mice to generate IL1-/-IL6-/- double knockout mice. We next intercrossed
these animals with arthritogenic hTNFtg mice to receive IL1-/-IL6-/-
hTNFtg mice. We weekly assessed clinical signs of arthritis in hTNFtg,
IL1-/-hTNFtg mice, IL6-/-hTNFtg mice and IL1-/-IL6-/-hTNFtg mice starting
from week 4 after birth until week 16. We stained decalcified paw
sections from all 4 genotypes with hematoxylin&eosin to determine the
amount of inflammatory synovial pannus formation, with tartrate-
resistant acid phosphatase (TRAP) to evaluate the number of synovial
osteoclasts and the occurrence of subchondral bone erosions, with
toluidine-blue to assess articular cartilage damage. Quantitative analysis
of histopathological changes were performed using the Osteomeasure
Software System.
Results: We found a significant reduction in the clinical signs of arthritis,
indicated by an increase of paw swelling and a decrease in grip strength,
in IL1-/-IL6-/-hTNFtg mice when compared to their hTNFtg littermates. In
line with these findings we observed a significant decrease in synovial
inflammation in IL1-/-IL6-/-hTNFtg mice when compared to hTNFtg
animals. Moreover, the number of synovial TRAP+ osteoclasts was
markedly diminished in IL1-/-IL6-/-hTNFtg mice and reduced osteoclast
formation, was accompanied by significantly less subchondral bone
erosions. Additionally, we found a conserved articular cartilage structure
showing almost no cartilage degradation in IL1-/-IL6-/-hTNFtg mice
compared to their hTNFtg littermates. In IL1-/-IL6-/-hTNFtg mice clinical,
as well as, histological signs of disease, including joint inflammation,
bone destruction and cartilage damage were also significantly diminished
when compared to IL6-/-hTNFtg mice. However, by comparing IL1-/-IL6-/-
hTNFtg mice with IL1-/- hTNFtg mice we found a similar reduction on
synovial inflammation, as well as subchondral bone erosions and articular
cartilage destruction.
Conclusion: The phenotype of IL1-/-IL6-/-hTNFtg mice does not differ
from IL1-/-hTNFtg animals indicating no synergistic effects when IL-1 and
IL-6 is simultaneously blocked in TNF-mediated arthritis.
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Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease and
characterized by synovial hyperplasia. We previously cloned an E3
ubiquitin ligase, Synoviolin, as a regulatory factor of cell proliferation [1].
It suggested that endoplasmic reticulum (ER) associated degradation
system (ERAD) via Synoviolin has important roles for overgrowth of
synoviocytes [2,3]. Meanwhile, it is known that autoantibodies to
citrullinated proteins are specific for RA and good markers for RA.
Peptidyl-Arginine Deiminases 4 (PADI4) is identified as the RA-susceptible
gene [3]. However functions of citrulinated proteins are unclear. In this
study, we hypothesize that the accumulation of citrullinated proteins in
RA synoviocytes could associate for ER stress and explore the crosstalk of
ubiquitination and citrullination.
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Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease
affecting cartilage andb o n e .R e c e n t l y ,m u c ha ttention on the role of
neutrophils in the pathology of RA has been paid. However, the capability
of RA neutrophils from periphery and bone marrow (BM) to produce
cytokines like IL-17 and IFN-g has not been well understood. Our aim is to
analyze neutrophil distribution in BM, blood and synovium and to
elucidate IL-17, IL-4 and IFN-g production and surface expression of RANKL
on peripheral and synovial neutrophils during the progression of zymosan-
induced arthritis (ZIA).
Materials and methods: In the present study BALB/c and SCID mice were
injected intra-articularly with zymosan. Cells from BM, periphery and
synovium were collected at day 7 and day 30 of ZIA and the frequencies of
Ly6G
+CD11b
+ neutrophils and surface expression of RANKL and CD69 on
them were evaluated by flow cytometry. In some experiments peripheral
neutrophils were isolated at day 7 of ZIA, re-stimulated in vitro with
zymosan in the presence or the absence of IL-17, then fixed, permeabilized
and used for flow cytometry analyses of IL-17, IL-4 and IFN-g intracellular
levels and of surface RANKL expression. Apoptosis of cultured neutrophils
was detected by annexin/propidium iodide kit. The ability of peripheral
neutrophils to affect RANKL or IL-17-induced osteoclast differention of
bone marrow precursors in vitro was evaluated after TRAP staining of cell
co-cultures.
Results: The development of inflammatory process in SCID mice after
zymosan injection was related to increased frequencies of Ly6G
+CD11b
+
neutrophils in periphery and synovium along with elevated IL-17
production in plasma and serum. We observed that arthritic neutrophils
collected at day 7 of disease have higher IL-17, IL-4 and IFN-g intracellular
levels than healthy cells. Exogenous IL-17 increased the cytokine and
RANKL expression on healthy and arthritic neutrophils in vitro. While
neutrophils were able to inhibit RANKL-induced osteoclast differentiation,
they increased the number of TRAP positive mature osteoclasts in the
presence of IL-17.
Conclusions: We suggest that Ly6G
+CD11b
+ peripheral neutrophils that are
positive for IL-17, IL-4, IFN-g and RANKL can migrate to the synovium where
they can affect inflammatory and destructive processes. Our study displays
new aspect of the role of neutrophils in the pathology of RA and provides
diverse ground for the development of novel therapeutic strategies.
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According to the multiple studies women suffer from rheumatoid arthritis
(RA) three times more often than men. The women seem to be ill at the age
of more active working activity that results in early disability. The great
attention is paid to the hereditary factors, particularly, to HLA-system, in the
RA development. In this connection the question about early diagnosis and
primary prevention of rheumatoid arthritis remain to be important.
Consequently, we studied distribution of HLA I class antigens (A, B, C) in
86 Uzbek women with RA. HLA were identified with 2 step standard
microlymphocytotoxicity test using antileucocyte HLA-antisera (St-Petersburg,
Russia) and rabbit complement. Control group consist of 301 healthy random
Uzbeks. In current study 39 antigens were expressed. Higher frequency was
found for A25 (15.1% vs. 0.7% in control), A28 (22.1% vs. 4.9%, respectively)
with p < 0.001. Antigen A19 (3.5% vs. 11.9% in control, p < 0.01).
In HLA-A locus (17.4% vs. 4.9% in control); B18 were met in 9.3% vs. 3.7%
in control, (p > 0.05); B22 (10.5% vs. 1.3% in control, p > 0.05); B27
(15.1% vs. 8.9% in control, p > 0.05).
Cw4 (12.8% vs. 36.2% in control, p > 0.05) met reliably more rare in
HLA-A locus.
The highest indicator of risk was established for A25 (RR = 26.6), then for
B 2 2( R R=8 . 7 ) ,B 1 6( R R=4 . 0 ) ,B 2 7( R R=2 . 8 ) ,B 1 8a n dA 1 0( R R=2 . 7 ) .
Results showed that antigens A25 and A28 (p < 0.001), have major effect,
while the B16, B18, B22, B27 - additive contribution to the predisposition
to the RA among Uzbek women.
Analysis of results in different clinical RA forms revealed association of slowly
progressing articular form with antigens: A25 (p < 0.001, RR = 25.2); A28 (p <
0.01, RR = 6.7); whether A10, B16, B27, B22 were not significant (p > 0.05).
Fast progressing articular-visceral form development was associated with
HLA-A28, A25, B16, B27, and significance of association was established only
for A28 (p < 0.001, RR = 7.6). The important moment in our investigation
seems to be the association of RA showed unfavorable development in
Uzbek women with antigens HLA-B16 which is a split of antigen B8 and
antigen B27, being marker of rheumatoid diseases, that correlates with
identical research in different populations.
Thus, the results of our investigation show important contribution of HLA
in predisposition to rheumatoid arthritis in Uzbek women.
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Background: Abatacept (ABT), a CTLA4-Ig fusion protein, which inhibits the
binding of CD28 and CD80 agents targeted to T-cells, is a relatively new
biological agent for RA treatment in Japan. However, there is no method for
prediction of responders, non-responders, or adverse events which can occur
during treatment. We established SNP algorithms for prediction of
responders (R) or non-responders (NR), and adverse events in ABT-treated
patients.
Materials and methods: Forty-six RA patients treated with ABT were
included in this study. Efficacy was assessed by DAS28 (CRP) at 48 weeks
after the initial treatment. Any adverse events that may have been related
to ABT administration and observed at 48 weeks of this long-term
administration and during phase II were considered to be side effects.
Genome-wide SNP genotyping was performed by Illumina Human610-
Quad chip technology. Case-controla n a l y s e sb e t w e e n5 9 8 , 8 2 1S N P sa n d
responsiveness or occurrence of adverse events were examined by Fisher’s
exact test. We selected 10 SNPs associated with ABT-responsiveness,
remission, and adverse events (p < 0.0001). We scored the relationship
between each SNP and responsiveness, the estimated total score of 10
SNPs (estimated scoring in each SNP was as follows: homo allele in the
majority in responders: +1 point, hetero allele: 0 points, and homo allele in
the majority of non-responders: -1 point), and then examined relationships
between responders and non-responders, remission and non-remission,
and occurrence of adverse events, plus or minus, and the total score.
Results: Accuracy, specificity, and sensitivity of the algorithm for
responsiveness of abatacept ranged from 90-96%. For remission,
accuracy, specificity and sensitivity of the algorithm ranged from 91-97%.
For adverse events, accuracy, specificity and sensitivity of the algorithm
ranged from 95-100%. It is therefore suggested that the SNP algorithms
can predict responders and adverse events prior to the initiation of
treatment with abatacept.
Conclusions: These highly accurate algorithms using SNP analysis may
be useful in the prediction of responsiveness and adverse events before
treatment with abatacept, and in this way can contribute to future tailor-
made treatment with biologic agents.
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Background: There is accumulating evidence that osteoclasts, the primary
cells responsible for bone resorption, are involved in bone and joint
destruction in rheumatoid arthritis. Bone resorption is highly regulated by
mature osteoclast function as well as osteoclastogenesis. The life span of
mature osteoclasts is relatively short both in vitro and in vivo,a n do n c e
differentiated, they rapidly die in the absence of supporting cell or growth
factors. Mitochondria is known as powerhouse of cell because they generate
most of the cell’s supply of adenosine triphosphate (ATP), used as a source
of chemical energy. In addition to supplying cellular energy, mitochondria
are involved in a range of other processes, such as signaling, cellular
differentiation, cell growth, and cell death. Transcription and replication of
mitochondrial DNA (mtDNA) are important steps in mitochondrial
biogenesis and mitochondrial transcription factor A (Tfam) is essential for
mtDNA transcription and replication. However, the functional significance of
mitochondria has not been established in osteoclastic bone resorption.
Materials and methods: T oa d d r e s st h i sq u e s t i o n ,w eg e n e r a t e d
osteoclast-specific Tfam conditional knock-out (cKO) mice by mating Tfam
fl/fl
mice with cathepsin K-Cre transgenic mice, in which the Cre recombinase
gene is knocked into the cathepsin K locus and specifically expressed in
mature osteoclasts. The in vivo effects of Tfam deficiency on bone
metabolism were examined by histological and histomorphometric analysis.
The survival and bone-resorbing activity of Tfam cKO osteoclasts were
determined by in vitro survival assay and pit formation assay, respectively.
Results: The expression level of Tfam, mtDNA copy number, and cellular
ATP level were markedly reduced in osteoclasts derived from Tfam cKO
mice. The body size of Tfam cKO mice was smaller than that of the
control mice, although trabecular bone volume remained unchanged by
Tfam deficiency. However, histological sections of proximal tibia and
lumbar spine of Tfam cKO mice showed significantly decreased osteoclast
number. Interestingly, Tfam cKO osteoclasts exhibited increased bone-
resorbing activity in spite of their pro-apoptotic tendency.
Conclusions: This study demonstrates that Tfam cKO osteoclasts
exhibited increased bone resorption with accelerated apoptosis,
Arthritis Research & Therapy 2012, Volume 14 Suppl 1
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survival vs bone resorption. Further investigation of mitochondria in
bone-resorbing osteoclasts will give us new insights into the molecular
mechanism regulating bone homeostasis.
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Background: TLRs 2, 4 and 9 have been implicated in murine models
and human patients of arthritis, but the other TLRs are not well-
investigated. Thus, we studied TLR expression and signaling and effect of
TLR ligand stimulation in peripheral blood (PB) and synovial fluid (SF)
monocytes (MC) of ERA patients.
Methods: Levels of TLR2, TLR4 and TLR9 were measured by flow
cytometry in ERA PBMC (n = 26), paired SFMC (n = 13) and healthy PBMC
(n = 19) Real time PCR was done for TLRs 1-9 and their adaptors IRAK1,
IRAK4, TRIF, TRAF3, TRAF6. PBMC and SFMC were stimulated with ligands
for TLR1 (pam3-cys), 2 (peptidoglycan), 3 (polyI:C), 4 (LPS), 5 (flagellin)
and 6 (zymosan). Levels of IL-6, IL-8 and MMP3 (ng/ml) were measured in
the culture supernatants.
Results: ERA PBMC had higher MFI of TLR2 [295.5(48.1-598) vs 179(68.7-
442); p < 0.05] and TLR4 [448(178-2581) vs 402(229-569); p < 0.05]
compared to controls. Intracellular TLR9 expression showed no significant
difference between both groups. In paired samples, SFMC had higher MFI
of both TLR2 [485(141-1683) vs 353(180-598); p < 0.05] and TLR4 [1016
(42.4-3159) vs 513(193-2581); p < 0.05] compared to PBMC. Difference in
TLR9 expression was not significant[ 1 ] .P a t i e n tP B M C( c o m p a r e dt o
healthy control) and SFMC (compared to corresponding PBMC) had
h i g h e rR N Ae x p r e s s i o no fT L R s 1 ,2 ,3 ,4 ,5a n d6a n dd o w n s t r e a m
adaptors. Patients PBMC produced significantly higher IL-6 (13.51 vs 6.54)
and MMP3 (61 vs 32.9) as compared to controls on stimulation by LPS.
With peptidoglycan also IL-6 (30.58 vs 10.84) and MMP-3 (102.54 vs
49.45) was higher than controls. Patient PBMCs produced more IL-6 and
IL-8 compared to healthy PBMCs on stimulation with Pam3-cys, poly I:C,
flagellin and zymosan. In paired samples, SFMCs showed a trend towards
higher IL-6 and IL-8 production compared to PBMCs (Table 1).
Conclusion: Increased TLR expression and signaling on PBMC and SFMC
from JIA-ERA patients may exacerbate disease by upregulating IL-6, IL-8
and MMP-3 in response to microbial/ endogenous ligands. TLR pathway
is a potential therapeutic target in these patients.
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Fibromyalgia (FM) is a highly populated chronic pain disease, which has
unique characteristics including generalized or widespread allodynia and
female prevalence of gender difference. Many FM patients are common
with Sjögren’s syndrome. Pilocarpine, a non-selective muscarinic
receptor agonist, is used clinically as a drug that promptes the secretion
of salvia for dry eyes and mouth. Otherwise, pilocarpine has been
shown to possess antinociceptive effect, which maybe caused by vagal
afferents activation. The experimental FM mice exposed to intermittent
cold stress (ICS) showed sustained abnormal pain, such as mechanical
allodynia and hyperalgesia to nociceptive thermal stimuli for up to 19
days, but those given constant cold stress (CCS) did not. The abnormal
pain was bilateral (generalized), female-predominant and specific for A-
delta and A-beta, but not C-fiber-stimuli. In ICS mice, intraperitoneal or
oral administration of pilocarpine showed potent anti-hyperalgesic
effects in doses without excess salivation at post-stress day5 (P5). The
anti-hyperagesic effects last for more than 1 h, but disappear at 24 h.
Daily administration of pilocarpine showed equivalent anti-hyperalgesic
effects without tolerance. These findings suggest that pilocarpine
possesses a beneficial effect for the pain treatment of FM patients with
dry eyes and mouth symptoms.
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Table 1(abstract P50) Production of IL-6 and IL-8 [median (range) ng/ml] by PBMCs and SFMCs upon TLR ligand
stimulation
Cultured with IL-6 IL-8
Normal PBMC (n = 5) ERA PBMC (n = 7) ERA SFMC (n = 3) Normal PBMC (n = 5) ERA PBMC (n = 7) ERA SFMC (n = 3)
Medium 4.4 (1.5-5.4) 7.6 (3-16.6) * 18 (9.3-24.2) 10 (4.3-12.6) 12.6 (8.1-35.7) 10 (4.3-12.6)
TNF 13.6 (9.6-14.8) 16 (12-35) 21(18-30) 30.8 (15.8-36.3) 34.4 (30.8-46.1) 31 (15.8-36.3)
Pam3cys 15.1 (13.3-19.6) 44 (26-62) ** 53 (28-71) 37.1 (11.4-41.8) 106 (42.6-147.6) ** 37.1 (11.4-42)
PolyI:C 13.1 (1.3-25.8) 28 (24-4) * 46 (45-65) 33.6 (31.1-56.3) 126(78-167) * 34(31.1-56.3)
Flagellin 14.1 (6.7-23.5) 34.9 (15-39.2) * 52.6 (40-53.8)
# 35.2 (16.1-84.2) 115 (73-162) ** 35 (16.1-84.2)
Zymosan 14.7 (8.8-36.3) 34 (28.4-39) * 48 (39.8-56.1)
# 56 (12.6-89.6) 106 (103-163) ** 56 (12.6-90)
p < 0.05** 0.01 ERA PBMC versus control PBMC p <
#0.05 ERA SFMC versus ERA PBMC.
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Page 41 of 54CD81 belomgs to a family of cell-surface protein (tetraspanin) which has four
transmembrane domains and two outer-membrane loops.Under the DNA
chip analysis, we found several genes highly expressed in rheumatoid
arthritis (RA) synoviocytes comparing with the expression in OA or normal
synoviocytes. Among these genes, tetraspanin CD81 was shown to be
involved in the progression of RA through the promotion of Synoviolin
expression.Synoviolin is already known as one of the important progressive
elements of RA in synoviocytes. We also showed Synoviolin and CD81 highly
distributed in RA tissues.
The therapeutic effect of small interfering RNA targeting CD81 (siCD81)
was examined by in vivo electroporation method. Treatment with siCD81
significantly ameliorated paw swelling of collagen-induced arthritic (CIA)
rats. In histological examination, hypertrophy of synovium, bone erosion,
and degeneration of articular cartilage were minder in rats treated with
siCD81 than in the control group and the non-specific siRNA group.
Expression of synoviolin, a rheumatoid regulator, was also suppressed by
siCD81 [1]. These results showed that siCD81 would become effective
tools for treatment of RA. In addition, siCD81 reduced the amount of
CD81 in synovial fluid indicating that quantitative analysis of CD81 opens
up the novel and highly sensitive diagnosis for RA.
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Receptor activator of NF-B ligand (RANKL; also known as TNFSF11), a TNF
family molecule, and its receptor RANK (TNFRSF11A) are key regulators of
osteoclast differentiation and function. Aberrant expression of RANKL
explains why autoimmune diseases, cancers, leukemia and periodontal
disease result in systemic and local bone loss. In particular, RANKL is the
pathogenic factor that cause bone and cartilage destruction in arthritis.
Inhibition of RANKL function by the natural decoy receptor osteoprotegerin
(OPG; also known as TNFRSF11B) or anti-RANKL antibody prevents bone loss
in postmenopausal osteoporosis, cancer metastases and arthritis. RANKL also
regulates T cell/dendritic cell communications, dendritic cell survival and
lymph node organogenesis. Intriguingly, RANKL and RANK play an essential
role in the maturation of mammary glands in pregnancy and lactation. Bone
homeostasis depends on the coordination of osteoclastic bone resorption
and osteoblastic bone formation. We reported that RANKL induces
osteoclast differentiation through activating a transcriptional programme
mediated by the master transcription factor nuclear factor of activated
T cells (NFAT) c1. Although it is well accepted that the RANKL-NFATc1
pathway is crucially important for osteoclast differentiation, little is known
about the major cellular source of RANKL in the skeletal tissue. RANKL has
been postulated to be mainly expressed by osteoblasts and bone marrow
stromal cells. However, here we show that osteocytes embedded within the
bone matrix are the critical source of RANKL in bone remodeling.
Osteocytes, the most abundant cell type in bone, are thought to orchestrate
bone homeostasis by regulating both osteoclastic bone resorption and
osteoblastic bone formation, but in vivo evidence and the molecular basis
for the regulation has not been sufficiently demonstrated. Using a newly
established method for the isolation of high-purity dentin matrix protein
1-positive osteocytes from bone, we have found that osteocytes express a
much higher amount of RANKL and have a much greater capacity to
support osteoclast formation than osteoblasts and bone marrow stromal
cells. The crucial role of RANKL expressed by osteocytes was validated by
the severe osteopetrotic phenotype observed in mice lacking RANKL
specifically in osteocytes. Thus, we provide in vivo evidence for the key role
of osteocyte-derived RANKL in bone homeostasis, establishing a molecular
basis for osteocyte regulation of bone resorption.
Figure 1(abstract P52) .
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Regulation of irreversible cell lineage commitment depends on a delicate
balance between positive and negative regulators, which comprise a
sophisticated network of transcription factors. Receptor activator of nuclear
factor-B ligand (RANKL) stimulates the differentiation of bone-resorbing
osteoclasts through the induction of nuclear factor of activated T-cells c1
(NFATc1), the essential transcription factor for osteoclastogenesis.
Osteoclast-specific robust induction of NFATc1 is achieved through an
autoamplification mechanism, in which NFATc1 is constantly activated by
calcium signaling while the negative regulators of NFATc1 are being
suppressed. However, it has been unclear how such negative regulators are
repressed during osteoclastogenesis. Here we show that B lymphocyte-
induced maturation protein-1 (Blimp1; encoded by Prdm1), which is induced
by RANKL through NFATc1 during osteoclastogenesis, functions as a
transcriptional repressor of anti-osteoclastogenic genes such as Irf8 and
Mafb. Overexpression of Blimp1 leads to an increase in osteoclast formation
and Prdm1-deficient osteoclast precursor cells do not undergo osteoclast
differentiation efficiently. The importance of Blimp1 in bone homeostasis is
underscored by the observation that mice with an osteoclast-specific
deficiency in the Prdm1 gene exhibit a high bone mass phenotype owing to
a decreased number of osteoclasts. Thus, NFATc1 choreographs the cell fate
determination of the osteoclast lineage by inducing the repression of
negative regulators as well as its effect on positive regulators.
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Multinucleation of osteoclasts during osteoclastogenesis requires dynamic
rearrangement of the plasma membrane and cytoskeleton, and this process
involves numerous previously characterized factors. However, the
mechanism underlying osteoclast fusion remains obscure. Live-imaging
analysis of osteoclastogenesis revealed that the products of PI3-kinase are
enriched at the sites of osteoclast fusion. Among the downstream molecules
whose expression was screened, the expression of Tks5, an adaptor protein
with the phox homology (PX) domain with multiple Src homology 3
domains, was induced during osteoclastogenesis. Tks5 was localized in the
podosomes and fusing membranes of osteoclasts, and reducing its
expression impaired both formation of circumferential podosomes and
osteoclast fusion without altering osteoclast differentiation. In addition, the
expression of a deletion mutant of the PX domain abrogated circumferential
p o d o s o m ef o r m a t i o na sw e l la so s t e o clast fusion, suggesting that Tks5-
dependent circumferential podosomes function as fusion machinery during
osteoclastogenesis. As Tks5 is known to promote the formation of
podosomes/invadopodia in transformed/cancer cells, we tested if these cells
also have the potential to fuse with osteoclasts. Among the cells tested,
B16F0 melanoma cells formed circumferential podosomes with Tks5
accumulation in the presence of RANKL, TGFb and TNFa.C o - c u l t u r eo f
B16F0 melanoma cells with osteoclasts in an inflammatory milieu promoted
increased formation of melanoma-osteoclast hybrid cells. Our results
revealed a previously unknown mechanism of regulation of both
circumferential podosome formation and cell-cell fusion by Tks5.
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IL-17-producing helper T (Th17) cells are a distinct T cell subset
characterized by its pathological role in autoimmune diseases. Our group
previously showed that Th17 cells function as osteoclastogenic helper
T cells in bone destruction associated with inflammation, and that
inhibition of Th17 development has the potential of a beneficial impact
on bone diseases including rheumatoid arthritis (RA) [1]. It is therefore
important to comprehend the molecular mechanism underlying Th17
development in order to develop ideal therapeutic strategies against RA.
IL-6 and TGF-b induce Th17 development, in which the orphan nuclear
receptors RORgta n dR O R a play an indispensable role. We found that
the expression of a nuclear IBf a m i l ym e m b e r ,I Bζ (encoded by the
Nfkbiz gene), was upregulated by the combination of IL-6 and TGF-b,
but independently of RORgt [2]. Not only Nfkbiz
-/- mice but also Rag2
-/-
mice transferred with Nfkbiz
-/- CD4
+ T cells were highly resistant to
experimental autoimmune encephalomyelitis, which is a mouse model
of multiple sclerosis. Nfkbiz
-/- mice were also protected from the
activation of osteoclastogenesis and bone destruction in a LPS-induced
model of inflammatory bone destruction. When activated in vitro under
Th17-polarizing conditions, IL-17 production in Nfkbiz
-/- Tc e l l sw a s
markedly reduced compared to WT cells. Notably, the expression of
RORgta n dR O R a was comparable between WT and Nfkbiz
-/- T cells.
Thus, it is unlikely that ROR nuclear receptors function downstream of
IBζ or vice versa.
In the absence of IL-6 and TGF-b, neither the ROR nuclear receptors nor
IBζ induced Th17 development efficiently. However, when IBζ was
overexpressed, either RORgto rR O R a strongly induced IL-17 production,
even in the absence of exogenous polarizing cytokines. In cooperation
with RORgt and RORa,I Bζ enhanced Il17a expression by directly binding
to the regulatory region of the Il17a gene. In addition, the expression of
Il17f, Il21 and Il23r mRNA was decreased in Nfkbiz
-/- Tc e l l s .I Bζ also
bound to the promoter or the enhancer region of these genes in Th17
cells. Our study demonstrates the essential role of IBζ in Th17
development, and points to a molecular basis for a novel therapeutic
strategy against autoimmune disease.
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Objective: Study of peculiarities of rheumatic fever (RF) in adult patients.
Materials and methods: We have studied prospectively for 5 years 200
patients (56 men and 144 women) with acute rheumatic fever (ARF in 27)
and recurrent ARF (in 173) at the age of 15-40 years (average age ± 24,5
7 years). Clinical and laboratory (ESR, antistreptolysin-O (ASL-O) and CRP)
and instrumental (ECG, ECG monitoring daily, 2-D echocardiography
color) studies conducted. The diagnosis of ARF was verified according to
the WHO diagnostic criteria in the modification of Jones’ criteria, AHA
(1999) and WHF (2008).
Results: We found that predisposing factors for the development of ARF
was the presence of tonzillopharingitis (47.5%), while carriers of group A
s t r e p t o c o c c u s( G A S )w a s3 8 . 0 %a m o n gp a t i e n t se x a m i n e d .C l i n i c a l
symptoms of carditis with echocardiographic signs of valvulitis occurred in
196 (98.0%) patients. In 54 (27.5%) of them installed valvulitis mitral valve.
Valvulitis aortic valve was detected in 24 (12.2%) patients. In 118 (60.2%)
patients observed at the same time valvulitis mitral and aortic valves, while
in 22 (39.2%) patients are men and 92 (63.8%) patients are women. In 18
(66.6%) patients with ARF was observed mitral valve prolapse (MVP), in 6
(22.2%) were in men, 12 (44.4%) in women. In 9 (4.5%) patients with ARF
proceeded pancarditis (endocarditis, myocarditis and pericarditis). Signs of
c o r o n a r i t i sw i t ht y p i c a la n g i n a lp a i nw i t hE C Gs i g n so fi s c h e m i a ,
arrhythmias, heart block were observed in 12 (6.0%) patients with RF.
Verification of diagnosis was carried out using the angiography of coronary
arteries. The symptoms of coronaritis in this patients disappeared after
anti-inflammatory therapy. Polyarthritis with ARF was observed in 40.7% of
patients, 25 (14.4%) of patients with recurrent ARF articular syndrome
manifested primarily arthralgia. In addition, 6.5% in patients with RF were
observed asymptomatic sacroiliitis stage I-II (Dale), 7 of patients are men
and 5 of them are women.
Conclusion: The reducing of clinical manifestations of ARF in adult led to
gypo-diagnostics of disease, a consequence of which was the formation
of rheumatic heart disease.
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Background: While different studies confirmed an increased risk for
smokers to develop rheumatoid arthritis (RA), the mechanisms behind this
phenomenon are not known up to now. In all probability, smoking induces
expression or post-translational modification of immune activating proteins
which then initiate an autoimmune reaction in individuals with a susceptible
genetic background. To identify these triggering molecules we screened
joints of mice that were exposed to cigarette smoke for differences of gene
expression and verified our results in synovial tissues of human smokers.
Methods: C57BL/6 mice were exposed to cigarette smoke (n = 6) or room
air (n = 8) in a whole body exposure chamber for 3 weeks. Protein and
mRNA was isolated from murine ankle joints and from synovial tissues
obtained from smoking (n = 4) and non smoking (n = 5) RA patients
undergoing joint replacement surgery. Tissues were further analysed by
Affymetrix microarrays, Real-time PCR or immunoblotting.
Results: Since data from microarray experiments had shown increased levels
of the immune receptor NKG2D ligand histocompatibility 60 (H60) after
cigarette smoke exposure, we measured H60 expression levels by Real-time
PCR in ankle joints of smoke exposed and control mice. H60 transcript levels
were 3.2 fold higher in joints of smoke-exposed mice compared to control
mice (dCT 12.5 +/-0.3 versus 14.2 +/-0.4, p = 0.03). Upregulation of H60
protein after smoke exposure was also seen in immunoblotting experiments.
Since H60 is not expressed in humans, we analysed expression of the 7
human NKG2D ligands RAET1E, RAET1G, MICA, MICB, and ULBP1-3 in
synovial tissues of RA patients. Transcripts of ULBP1-3 were not detectable in
synovial tissues and there was no difference in the expression levels of
RAET1G and RAET1E in synovial tissues of smokers compared to non
smokers. However, expression levels of MICA and MICB were 2.3 and 2.8 fold
higher in synovial tissues of smokers than in non-smokers (dCT 11.3 +/-0.2
versus 10.1 +/-0.3, p = 0.03 and dCT 10.8 +/-0.3 versus 9.3 +/-0.5, p = 0.03).
Conclusion: We found that smoking induces the expression of ligands of
the activating immune receptor NKG2D in murine as well as in human
joints. Since dysregulated expression of NKG2D ligands has been
previously implicated in induction of autoimmune responses, continuous
excess of NKG2D ligands in joints of smokers might be a trigger for the
development of RA in susceptible individuals.
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Background: MicroRNAs (miRs), a class of small non-coding RNA
molecules, act as posttranscriptional regulators and are involved in a
plethora of cellular functions. miRs have attracted a great deal of attention
as potential therapeutic targets, as the sequence-specific mode in which
they act, allows the simultaneous targeting of multiple target genes, often
members of the same biological pathway(s) [1]. Previous studies have
demonstrated that miRs are dysregulated and functionally involved in
rheumatoid arthritis (RA) [2-9]. In this study we sought to identify novel
miR associations in synovial fibroblasts (SFs), a key pathogenic cell type in
RA [10,11], by performing miR expression profiling on cells isolated from
the human TNF transgenic mouse model (TghuTNF, Tg197) [12] and
patients biopsies.
Materials and methods: miR expression in SFs from TghuTNF and WT
control mice were determined by deep sequencing and the arthritic profile
was established by pairwise comparisons. qRT-PCR analysis was utilised for
profile validation, miR and gene quantitation in patient SFs. Dysregulated
miR target genes and pathways were predicted via bioinformatic algorithms.
Results: Deep sequencing demonstrated that TghuTNF-SFs exhibit a distinct
pathogenic profile with 22 significantly upregulated and 30 significantly
downregulated miRs (fold change>1.5,p - v a l u e < 0 . 0 5 ) .q R T - P C Rv a l i d a t i o n
assays confirmed the dysregulation of miR-223, miR-146a and miR-155
previously associated with human RA pathology, as well as that of miR-221/
222 and miR-323-3p. Notably, the latter were also found significantly
upregulated in patient RASFs, suggesting their association with human RA
pathology. Bioinformatic analysis suggested Wnt/Cadherin signaling as the
most significant pathway targets of miR-221/222 and miR-323-3p and
CSNK1A1 and BTRC, the negative regulators of b-catenin, amongst predicted
gene targets. qRT-PCR assays confirmed the downregulation of these genes
in RASFs, validating our hypothesis that the newly identified miRs may
function to modulate Wnt/Cadherin signaling.
Conclusions: In this study, by performing comparative analyses between an
established mouse model of arthritis and RA patient biopsies, we identified
novel dysregulated miRs in RASFs potentially involved in pathways
important for the pathogenic phenotype of these cells and highlighting the
value of such cross-species comparative approaches [13].
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Objectives: The aim of this study is to evaluate the efficacy and safety of
methotrexate (MTX) alone and combined therapy of Etanercept (ETN) and
methotrexate (MTX), in patients with rheumatoid arthritis (RA).
Methods: Patients with RA were treated in combination with ETN (with
doses of 25 mg subcutaneously twice weekly), with oral MTX (doses up to
20 mg weekly), and alone MTX (doses up to 20 mg weekly) in period of two
years, in Rheumatology Department of Internal Clinic in Prishtina. Clinical
response was assessed using American College of Rheumatology (ACR)
criteria and the Disease Activity Score (DAS28) in 60 patients with RA.
Radiographic changes were measured in the beginning and at the end of
the study with Sharp Score.
Results: Of total number of 60 patients (10 of them were males and 50
were females) with mean age of 57.63, 10 or 16.6% of patients were treated
with combined therapy (ETN plus MTX) and 50 or 83.3% of patients with
monotherapy (MTX). The group of combined therapy (ETN+MTX) after the
treatment resulted with improvement of acute phase reactants as
erythrocyte sedimentation rate (ESR) for the first hour (41.1 vs. 10.3 mm/
hour) and C-reactive protein (CRP) (40.8 vs. 6 mg/liter) comparing to the
group treated with MTX alone there were no significant changes (ESR: 45.7
vs. 34.3 mm/hour; CRP: 48 vs. 24 mg/liter). Before treatment the severity of
the disease was high, where in group with combined therapy (ETN plus
MTX) DAS28 was 5.32, and in the group with monotherapy of MTX DAS28
was 5.90. After 2 years of treatment we had significant changes in the
results of DAS28, where in group treated with ETN plus MTX DAS28 was
2.12 ± 0.15, while in the group of patients treated with MTX DAS28 were
3.75 ± 0.39 (t = 13.03; df = 58; p < 0.0001). The group with combined
therapy showed less radiographic progression comparing to the group of
monotherapy (p < 0.05).
Conclusions: According to our results we can conclude that ETN in
combination with MTX reduced disease activity, slowed radiographic
progression and improved clinical manifestations more effectively than
MTX alone within period of 2 years. During the treatment, no serious
adverse events were noticed with combination treatment of ETN and
MTX.
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Background: The bone and cartilage destruction seen inrheumatoid
arthritis (RA) is caused by synovial pannus formation, which is characterized
by aberrant proliferation of synovial fibroblasts. Inhibition of synovial
proliferation has recently been reported to be a promising therapeutic
strategy for RA.However, the specific mechanism underlyingdysregulated
proliferation of synovial fibroblasts remains unclear.
Objective: We aimed toidentify and characterize genesthat are involved in
the aberrant proliferation of synovial fibroblasts.
Methods: Microarray analysiswas performed to identifythe genes that had
upregulated expression inmice with collagen-induced arthritis (CIA). The
effect of candidate genes on the proliferation of synovial fibroblasts was
screened using antisense oligodeoxynucleotides and small interfering RNAs
(siRNAs).
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proliferation-associated in CIA 1/serum amyloid A-like 1)that was associated
with aberrant proliferation of synovial fibroblasts. Immunohistochemical-
analysis indicated that SPACIA1/SAAL1 was strongly expressed in the foot
joints of mice with CIA and in the thickened synovial lining of the human RA
synovium. Transfection of siRNA targeting SPACIA1/SAAL1into RA synovial
fibroblastscould inhibit tumor necrosis factor (TNF)a-induced proliferation
more effectively thanit could inhibit serum-induced proliferation.In addition,
the antiproliferative effect of SPACIA1/SAAL1 siRNA was caused byinhibition of
cell cycle progression and not by induction of apoptosis.We established
transgenic (Tg) mice that overexpressed SPACIA1/SAAL1. These Tg mice did
not spontaneously develop arthritis or cancer. However,inducing CIA
causedgreatersynovial proliferation and worse diseasein Tg mice thanin wild-
type mice.
Conclusion: SPACIA1/SAAL1 plays an important role in the aberrant
proliferation of synovial fibroblasts under inflammatory conditions.
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Background: Adult-onset Still’s disease (AOSD) is an inflammatory disease of
unknown cause characterized by a high spiking fever, arthritis and
evanescent rash. The mainstay of treatment is glucocorticoids with or
without immunosuppressants. Recently, biologics such as anti-tumor necrosis
factor (TNF) antibodies have also been tried in certain refractory cases.
Results: We have had two cases of AOSD which were treated successfully
with anti-interleukin (IL-) 6-receptor antibody, tocilizumab (TOC). (Case 1)
A 36-year-old woman who was diagnosed 8 years previously, and had
been treated with various DMARDs plus etanercept (ETA) or adalimumab,
presented with a high spiky fever and elevated liver enzymes. After
excluding infection, she was treated with TOC. (Case 2) A 26-year-old
man with new-onset AOSD, which was shown to be resistant to multiple
immunosuppressants including infliximab and ETA, was treated with TOC
starting 7 months after the diagnosi s .I nb o t hc a s e s ,s e r u mI L - 1 8w a s
extremely high, and TOC promptly improved clinical symptoms and liver
function. The high level of serum ferritin also became normalized.
Interestingly, especially in case 2, the level of IL-18 remained high after
the administration of TOC, suggesting that IL-18 is located either
upstream of, or at the same level as, IL-6 in the pathogenesis of AOSD.
Next, we cultured human monocytes derived from healthy controls with
or without the presence of IL-6 and/or IL-18 in vitro. The level of ferritin
in the supernatant was significantly increased only when both IL-6 and
IL-18 were added, indicating that IL-6 and IL-18 have a synergistic effect
on the production of ferritin (Figure 1).
Conclusion: TOC can be a first-line biologic applicable against multiple-
drug-resistant AOSD. If an IL-18 blocker is developed, however, it may be
even more beneficial in that it may block the cascade of inflammation at
a point further upstream.
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Background: The GI Randomized Event and Safety Open-Label NSAID
Study (GI-REASONS) was a novel prospective, randomized, open-label,
blinded end point (PROBE) study that measured adjudicated clinical
outcomes throughout the GI tract. It was designed to assess if celecoxib
use in patients with osteoarthritis (OA) at moderate GI risk (≥55 y) is
associated with a lower incidence of clinically significant upper and lower
GI events compared to nsNSAIDs, with/without proton-pump inhibitors
(PPIs), in standard US clinical practice.
Materials and methods: 8067 OA patients were randomized 1:1 for 6-mos
with celecoxib or a nonselective (ns)NSAID, stratified by H pylori status. The
primary end point was a composite of adjudicated clinically significant
upper and lower GI events. Aspirin use was not permitted. Treatment doses
could be adjusted per US prescribing information. Patients randomized to
the nsNSAID arm could switch between nsNSAIDs; however, crossover
between treatment arms was not allowed. PPIs and histamine-2 receptor
antagonists (H2RAs) were prescribed at the providers’ discretion.
Results: 4035 celecoxib and 4032 nsNSAID patients were randomized and
included in the ITT analyses. Baseline demographics were similar. Overall,
significantly more nsNSAID users met the primary end point at 6 mos (OR,
1.82; 95% CI 1.31-2.55; p = 0.0003; Table 1). The most commonly used
nsNSAIDs were meloxicam (42%), naproxen (21%), diclofenac (20%) and
nabumetone (14%). 2596 celecoxib (64.3%) and 2611 (64.8%) nsNSAID users
completed the study. 189 patients were lost to follow-up (LTFU; 2.1%
celecoxib and 2.6% nsNSAID). Attributing the primary end point to all LTFU
patients (worst-case sensitivity analysis), celecoxib remained superior (OR
1.46; 95% CI 1.18-1.82; p = 0.0006). AEs, SAEs and discontinuations were
similar in both treatment groups. 23% of celecoxib and 24% of nsNSAID
patients used a PPI (p = NS). Moderate to severe abdominal symptoms were
experienced by 94 (2.3%) celecoxib and 138 (3.4%) nsNSAID patients (P<.01).
Conclusion: Celecoxib use had a lower risk of clinically significant upper
and lower GI events than nsNSAIDs. A major strength of this study is its
PROBE design. Simple inclusion and exclusion criteria allowed for a broad
patient population of moderate GI risk. Switching among nsNSAIDs and
allowing for dose adjustments, along with use of PPIs and H2RAs as
needed, more closely reflects daily clinical practice. GI-REASONS
demonstrates the improved GI safety profile of celecoxib throughout the
GI tract in patients treated in a “real-world” setting.
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Figure 1(abstract P62) The level of ferritin in the supernatant of
monocytes cultured with or without the presence of IL-6 and/or
IL-18 (10 ng/mL each).
Arthritis Research & Therapy 2012, Volume 14 Suppl 1
http://arthritis-research.com/supplements/14/S1
Page 46 of 54Background: Syndecan-4, a member of a syndecan family of transme-
mbrane heparansulfate proteoglycans has been recently associated with
cell-matrix-adhesion, cell-migration, differentiation and proliferation, but its
specific function in inflammatory pathologies remains unclear. We used the
human TNFalpha transgenic mouse (hTNFtg) to analyse the expression and
function of syndecan-4 in chronic-destructive-arthritis and answer the
question whether inhibition of syndecan-4 by specific antibodies may
prevent cartilagedestruction and/or improve the phenotype after onset of
the disease in this animal model of human RA.
Methods: Expression of syndecan-4 was investigated by immunohisto-
chemistry in the hind-paws of 8-weeks/12-weeks old hTNFtg mice and wild
type controls. In addition, synovial fibroblasts were isolated and analysed for
syndecan-4-expression by RT-PCR. For functional analyses, we generated
blocking-antibodies against syndecan-4. To investigate their effect on
TNFalpha mediated-destructive-arthritis, hTNFtg mice were injected with the
antibodies or with IgG-control twice weekly for 4-weeks in a preventive
manner (age-4-to-8-weeks) and for disease treatment of joint destruction
(age-8-to-12-weeks) into their hind paws. Evaluation of disease severity
included clinical parameters (weight, arthritis-score, grip-strength) as well as
histomorphometric analysis of toluidin-blue-stained paraffin sections.
Results: As seen in immunohistochemistry, there was a strong expression of
syndecan-4 in the synovial membranes of hTNFtg mice, whereas only
negligible staining for syndecan-4 was found in synovial tissues of wild type
animals. In vitro, synovial fibroblasts isolated from hTNFtg mice showed
more than 30-fold higher expression of syndecan-4 than wild type controls.
Administration of the anti-syndecan-4 antibodies but not of IgG-control in
preventive treated 4-week-old hTNFtg mice clearly ameliorated the clinical
signs of arthritis and protected the treated joints from cartilage damage. At
histomorphometric analysis, this was evident for all analysed parameters but
seen most prominently for area of distained cartilage.
Significantly reduced cartilage damage in the anti-syndecan-4 treated
hTNFtg mice was accompanied by a striking reduction in the expression
of MMP-3. The treatment with antisyndecan-4 in 8-week-old hTNFtg mice
after onset of arthritis clearly ameliorated the jointdestruction, and
improved cartilage-damage. The treatment also showed a clear reduction
of inflammation in the paws compared to the untreated animals.
Conclusions: Our findings indicate that syndecan-4 is involved
prominently in fibroblast-mediated cartilagedamage in hTNFtg mice by
regulating the exression of disease-relevant MMPs. More importantly, the
data suggest that inhibition of syndecan-4 not only prevens cartilage
damage, but also reduces the severity after onset of the disease.
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Subject of the inquiry: 35 patients with rheumatoid arthritis, 50 mature
male rats of mixed population.
Aim of the inquiry: Clinical-experimental assessment of simvastatin
efficiency and pathogenic justification of its inclusion into the complex
treatment for therapy optimization in patients with rheumatoid arthritis.
Methods of investigation: clinical-laboratory, biochemical - determination
of total cholesterol, low and high density lipoproteins, triglycerides,
calculation of atherogenic coefficient in blood serum of patients with
rheumatoid arthritis and in experimental animals.
The results achieved and their novelty: On the systemic and local levels
an approach was applied allowing consideration of nitrogen oxide
metabolism disorders as an important part of the pathogenesis of
rheumatoid arthritis. A number of new data were obtained concerning the
relationship of nitrogen oxide metabolism and C-reactive protein
formation, clinical course of rheumatoid arthritis. For the first time a
complex approach was suggested for the pathogenic justification of
simvastatin use in the scheme of conventional treatment to increase the
therapy efficiency, to achieve stable early remission in patients with
rheumatoid arthritis. It was proved that an important mechanism of
increasing the therapeutic efficiency of simvastatin was its action on the
system of endothelial function in blood and joint fluid. It was suggested
that one should include assessment of blood and joint fluid for nitrogen
oxide, nitrate diaphorase and nitrate reductase in the algorithm of
investigation and dynamic observation, choice of tactics and therapy
efficiency assessment.
Practical value: Obtained new data are necessary for increasing the
pharmacotherapy efficacy in patients with rheumatoid arthritis taking into
account the metabolic activity of NO-synthetase mechanism in blood and
synovial fluid. An algorithm was suggested for screening observation and
differentiated management of patients with rheumatoid arthritis taking
account of severity of nitrogen oxide metabolism disorders. A differentiated
approach was worked out and justified of simvastatin prescription both to
increase the efficacy of treatment taking into account the clinical activity of
the disease and to correct metabolic disorders in patients with rheumatoid
arthritis.
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Background: Increased prevalence of metabolic syndromein rheumatoid
arthritis (RA) has been reported from American and European populations
but it has not been studied in Indian patients with RA.
Objectives: The main objective of our study was to assess the prevalence
of the metabolic syndrome in Asian-Indian patients with rheumatoid
arthritis and also to studyits correlation with disease activity.
Methods: This was a prospective case control study in which 114 patients
diagnosed to have rheumatoid arthritis of more than 1 year duration and
114 healthy age (± 5 years) and sex matched controls were included. Height,
weight, body mass index, blood pressure and waist circumference of the
patients were measured at the enrolment visit. Venous samples were taken
after eight hours of overnight fasting for the estimation of serum
cholesterol, triglycerides and plasma glucose levels. Metabolic syndrome
was diagnosed according to Adult Treatment Panel III criteria [1] and the
consensus definition of the metabolic syndrome for adult Asian patients [2].
The disease activity was assessed by DAS 28.
Results: The mean age of patients with RA and control group was 44.8 and
43.2 years (p <0.36) respectively. The mean duration of RA was 6.5 years.
Though the mean BMI was similar in both the groups(25.5 and 24.2), there
was a statistically highly significant difference in mean waist circumference
(92.1 cm and 81.2 cm, p < 0.001) and diastolic blood pressure(80.5 and 75.3
Table 1(abstract P63) Clinically significant upper and lower GI events: primary analysis
Celecoxib nsNSAID
N Patients With Event n (%) N Patients With Event n (%)
All patients 4035 54 (1.3) 4032 98 (2.4)
H pylori status Positive 1401 25 (1.8) 1386 34 (2.5)
Negative 2634 29 (1.1) 2646 64 (2.4)
OR (95% CI); P value 1.82 (1.31-2.55); p = 0.0003
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Page 47 of 54mm Hg, p < 0.001) in patients with RA as compared to controls.Metabolic
syndrome was present in 36 patients and 17 controls (p < 0.05) according to
the Adult Treatment Panel III criteria and in 40 patients and 18 controls (p <
0.01) according to the consensus definition of the metabolic syndrome for
adult Asian patients. There was no significant correlation between the
metabolic syndrome and disease activity as measured by DAS-28 using both
the criteria.
Conclusions: Indian patients with RA have increased prevalence of
metabolic syndrome as compared to their age and sex matched healthy
controls, but there is no significant correlation between metabolic
syndrome and disease activity.
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Osteoprotegeirn (OPG) is an endogenous decoy receptor for RANKL, which is
a cytokine essential for osteoclast differentiation. Lipopolysaccharide (LPS) is
known to induce osteoclast formation when injected onto calvaria in mice.
Unexpectedly, we observed that mice injected with LPS up-regulate OPG
and down-regulate RANKLlevels in peripheral blood.
In the present study, we examined whether OPG is induced by microbial
infection of various kinds, and the sites and significance of OPG production
in infected mice. Wild-type mice infected withSalmonella, Staphylococcus,
Mycobacteriaor influenza virus showed increase in OPG levels in peripheral
blood. We also found that the levels of OPG in serum of human patients
infected with M. tuberculosis and M. avium were significantly increased.
Moreover, injection of mice with LPS induced OPG production specifically in
lymph nodes, especially in high endothelial venule(HEV)cells, but not in
other organs. OPG production was suppressed in c-Fos-deficient mice and
enhanced in Fra-1 transgenic mice, indicating that OPG production is
regulated by AP-1 transcription factors.Loss of OPG in mice did not affect
either their survival or Salmonella proliferation in spleen and liver after
infection with virulent strains of Salmonella. Interestingly, however, when
wild-type mice were infected with an avirulentSalmonella strain, which can
induce OPG, osteoclast development was suppressed and bone mineral
density was increased. These data reveal for the first time that lymph nodes
protect bones from infection-induced bone loss through OPG production.
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The superficial zone (SZ) of articular cartilage is critical in maintaining
tissue function and homeostasis and represents the site of the earliest
Figure 1(abstract P68) HMGB2 expression during chondrogenesis of human MSC. Immunohistochemistry shows that HMGB2 is expressed at days 1
and 3, but that expression is reduced at days 7, 14 upon induction of chondrogenesis. SO: safranin O staining.
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HMGB2 is restricted to the SZ, which contains cells expressing
mesenchymal stem cell (MSC) markers[ 1 ] .A g i n g - r e l a t e dl o s so fH M G B 2
and gene deletion are associated with reduced SZ cellularity and early
onset OA [2]. This study addressed HMGB2 expression patterns in MSC
and its role during differentiation.
HMGB2 was detected at higher levels in human MSC as compared to human
articular chondrocytes and its expression declined during chondrogenic
differentiation of MSC (Figure 1). Lentiviral HMGB2 transduction of MSC
suppressed chondrogenesis as reflected by an inhibition of Col2a1 and
Col10a1 expression. Conversely, in bone marrow MSC from Hmgb2-/- mice,
Col10a1 was more strongly expressed than in wildtype MSC. This is
consistent with in vivo results from mouse growth plates showing that
Hmgb2 is expressed in proliferating and prehypertrophic zones but not in
hypertrophic cartilage where Col10a1 is strongly expressed. Osteogenesis
w a sa l s oa c c e l e r a t e di nH m g b 2 - / -M S C. The expression of Runx2, which
plays a major role in late stage chondrocyte differentiation, was enhanced in
Hmgb2-/- MSC and HMGB2 negatively regulated the stimulatory effect of
Wnt/b-catenin signaling on the Runx2 proximal promoter.
These results demonstrate that HMGB2 expression is inversely correlated
with the differentiation status of MSC and that HMGB2 suppresses
chondrogenic differentiation. The aging-related loss of HMGB2 in articular
cartilage may represent a mechanism responsible for the decline in adult
cartilage stem cell populations.
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Materials and methods: Are surveyed 76 gout patients, middle age
equaled 56.6 ± 7.5 year. Have been distributed on 3 groups: more
younger 50, from 50 to 60 and more senior 60 years. Metabolic syndrome
was diagnosed by criteria Adult Treatment Panel III (National Institute of
Health, USA) [1]. Serum level of Uric Acid defined by colorimetric enzyme
method, glucose - by glucose oxidize method, cholesterol, triglycerides
and high density lipoproteides-cholesterol - by colorimetric method [2].
Low and very low density lipoproteides-cholesterol defined by “WT
Friedewald Equation” (1972) [3].
Results: Metabolic syndrome has been diagnosed at 46 (60.5%) patients.
Middle age patients with presence of metabolic syndrome has made 55.7
± 4.7, without - 57.9 ± 8.3 year.
Conclusions: At the same time we have not revealed age distinctions in
occurrence of metabolic syndrome at patients with primary gout,
however frequency of IHD of gout patients naturally increased with the
years - from 38% to 68%. Patients of the senior age groups the increase
in frequency of hypertension and IHD while patients of younger age have
obesity, hypertriglyceridemia and hyperglycemia is more often noted.
Acknowledgements: Research grants were received from APLAR.
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Background: To maintain the bone strength and functions, the balance
between bone resorption and bone formation has to be tightly regulated.
However, under certain pathological conditions, including osteoporosis and
rheumatoid arthritis, the equilibrium gets disrupted, resulting in a severe
bone loss. Recent studies have shown that signaling molecules involved in
the unfolded protein response (UPR) are potentially involved in the coupling
of bone resorption and bone formation [1-3]. In the present study, we
investigated the roles of UPR mediator, the IRE1a-XBP1 pathway in osteoblast
differentiation.
Materials and methods: To induce osteoblast differentiation in vitro,w e
used recombinant human BMP-2 and mouse embryonic fibroblasts (MEFs)
obtained from wild-type and Ire1
-/- embryos. Small interfering RNA-
mediated gene silencing was used to suppress the expression of the target
molecules of IRE1 (XBP1 and TRAF2) in wild-type MEFs. Osteoblast
differentiation was evaluated by analyzing the expression levels of the
transcripts for osteoblast differentiation markers (Runx2, Osterix, Osteoclacin
and type I collagen) and alkaline-phosphatase activity.
Results: We found that UPR is induced during osteoblast differentiation in
in vitro and ex vivo experiments. Most importantly, Ire
-/- MEFs and Xbp1-
Table 1(abstract P69) Frequency of revealing of signs of
metabolic syndrome at gout patients (n = 76)
Sign Frequency
CW > 102 cm 48 (63.2%)
SBP > 140 mm Hg and/or DBP > 90 mm Hg 50 (65.8%)
TG ≥ 120 mg/dl 22 (29%)
Glucose ≥ 110 mg/dl 32 (42.1%)
HDL-cholesterol < 50 mg/dl 58 (76.3%)
CW - circle waist; TG - triglycerides; SBP - systolic blood pressure; DBP -
diastolic blood pressure; HDL - high density lipoproteides.
Table 2(abstract P69) Frequency of revealing of signs metabolic syndrome at gout patients depending on age, n (%)
Sign Age groups
<50 y (n = 26) 50-60 y (n=2 6 ) >60 y (n=2 4 )
CW > 102 cm 22 (84.6%) 20 (76.9%) 6 (25%)
SBP > 140 mm Hg and/or DBP > 90 mm Hg 20 (76.9%) 14 (53.8%) 20 (83.3%)
TG ≥ 120 mg/dl 8 (30.8%) 10 (38.45%) 4 (16.7%)
Glucose ≥ 110 mg/dl 14 (53.85%) 14 (53.85%) 4 (16.7%)
HDL-cholesterol < 50 mg/dl 14 (53.85%) 24 (92.3%) 20 (83.3%)
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Page 49 of 54silenced MEFs were defective in BMP2-induced osteoblast differentiation,
indicating that the IRE1a-XBP1 pathway is essential for the maturation of
osteoblasts. Furthermore, we found that UPR induces transcription of Osterix
(a transcription factor indispensable for bone formation) via the IRE1a-XBP1
pathway, and that XBP1 directly binds to the promoter region of the Osterix
gene and functions as a transcription factor. Taken together, the present
study indicates that the UPR induced during osteoblast differentiation
stimulates Osterix transcription through the IRE1a-XBP1 pathway.
Conclusions: The present study shows that the IRE1a-XBP1 pathway is a
critical component of osteoblast differentiation. Since the IRE1a-XBP1 is
also involved in the production of a potent regulator for osteoclast
differentiation, interferon beta [1,2], the IRE1a-XBP1 pathway may be an
attractive molecular target in modulating the equilibrium between bone
formation and bone resorption under pathological conditions.
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Fibromyalgia (FM) is a common condition with generalized or widespread
allodynia that affects at least 2% of the US, European and Japanese
populations. Although the etiology of this disease remains poorly
understood, physical and psychological stressors have been assumed to play
a role in the development of FM. Previously, we have established an
experimental mouse model of FM pain, using intermittent cold stress (ICS)
exposure. This model was found to produce mechanical allodynia and
thermal hyperalgesia in a female-predominant manner, as often observed in
FM patients. In contrast, exposure to constant cold stress produced a
transient allodynia. Importantly, we found that anticonvulsant agent
gabapentin, especially when injected intracerebroventricularly, exerts
powerful anti-allodynic and anti-hyperalgesic effects in the ICS-exposed
mice. In this study, we found that ICS model mice show morphine
resistance, as often observed in FM patients. To be concrete, systemic or
intracerebroventricular, but not intrathecal or intraplantar, injection of
morphine caused no significant analgesia in the ICS-exposed mice. In
addition, we found that intracerebroventricularly administrated morphine
increases the 5-hydroxytryptamine turnover ratio in the dorsal half of the
spinal cord of control mice, but not in the ICS-exposed mice. These findings
indicate that ICS model well reflects pathological and pharmacotherapeutic
features of FM pain, and the loss of descending serotonergic activation
seems to be a crucial mechanism underlying the absence of morphine-
induced analgesia in the ICS model.
References
1. Nishiyori M, Ueda H: Prolonged gabapentin analgesia in an experimental
mouse model of fibromyalgia. Mol Pain 2008, 4:52.
2. Nishiyori M, Nagai J, Nakazawa T, Ueda H: Absence of morphine analgesia
and its underlying descending serotonergic activation in an experimental
mouse model of fibromyalgia. Neurosci Lett 2010, 472:184-187.
P72
Brain perfusion in fibromyalgia patients and its differences between
responders and poor responders to gabapentin
Chie Usui
1*, Kotaro Hatta
1, Nagafumi Doi
2, Atsushi Nakanishi
3,
Hiroyuki Nakamura
4, Kusuki Nishioka
5
1Department of Psychiatry, Juntendo University School of Medicine, 2-1-1
Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan;
2Ibaraki Prefectural Tomobe
Hospital, 654 asahi-cho, kasama-city, Ibaraki 309-1717, Japan;
3Department of
Radiology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku,
Tokyo 113-8421, Japan;
4Department of Environmental and Preventive
Medicine, Graduate School of Medical Science, Kanazawa University, kakuma-
cho, Kanazawa-city, Kanazawa 920-1192, Japan;
5Institute of Innovative
Medical Science and Education, Tokyo Medical University, 6-1-1 Shinjyuku,
Shinjyuku-ku, Tokyo 160-8402, Japan
Arthritis Research & Therapy 2012, 14(Suppl 1):P72
Purpose: The aim of the present study was to determine the brain areas
associated with fibromyalgia, and whether pretreatment regional cerebral
blood flow (rCBF) can predict response to gabapentin treatment.
Methods: A total of 29 women with fibromyalgia and 10 healthy women
without pain matched for age were finally enrolled in the study.
Technetium-99 m ethyl cysteinate dimer single photon emission
computed tomography (
99 mTc-ECD SPECT) was performed in the
fibromyalgia patients and controls. A voxel-by-voxel group analysis was
performed using SPM2. After treatment with gabapentin, 16 patients
were considered “responders”, with decrease in pain of greater than 50%
as evaluated by visual analogue scale (VAS). The remaining 13 patients
were considered “poor responders”.
Results: Compared to control subjects, we observed rCBF abnormalities in
fibromyalgia including hypoperfusion in the left culmen and
hyperperfusion in the right precentral gyrus, right posterior cingulate, right
superior occipital gyrus, right cuneus, left inferior parietal lobule, right
middle temporal gyrus, left postcentral gyrus, and left superior parietal
lobule (Table 1, Figure 1). Compared to responders, poor responders
exhibited hyperperfusion in the right middle temporal gyrus, left middle
frontal gyrus, left superior frontal gyrus, right postcentral gyrus, right
precuneus, right cingulate, left middle occipital gyrus, and left declive
Table 1(abstract P72) Regions of significant hyperperfusion and hypoperfusion in the FM group
 Z score x(mm) y(mm) z(mm) Localisation
Hyperperfusion 134 4.55 66 -10 30 R Precentral Gyrus
262 4.16 2 -62 14 R Posterior Cingulate
824 3.98 36 -82 32 R Superior Occipital Gyrus
429 3.95 18 -96 -6 R Cuneus
220 3.57 50 -38 52 L Inferior Parietal Lobule
55 3.54 52 -46 6 R Middle Temporal Gyrus
113 3.52 -30 -42 68 L Postcentral Gyrus
3.74 -14 -74 56 L Superior Parietal Lobule
709 4.66 -2 56 -22 L Superior Frontal Gyrus
Hypoperfusion 1111 4.38 -12 -32 -18 L Culmen
Results are listed by clusters.value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.
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precuneus, left middle occipital gyrus, and left declive exhibited high
positive likelihood ratios.
Conclusion: The present study revealed brain regions with significant
hyperperfusion associated with the default-mode network, in addition to
abnormalities in the sensory dimension of pain processing and affective-
attentional areas in fibromyalgia patients. Furthermore, hyperperfusion in
these areas was strongly predictive of poor response to gabapentin.
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Table 2(abstract P72) Regions of significant hyperperfusion in the poor responder group compared to the responder
group
 Z score x(mm) y(mm) z(mm) Localisation
Hyperperfusion 1260 4.08 42 -62 16 R Middle Temporal Gyrus
95 3.88 -46 6 50 L Middle Frontal Gyrus
95 3.88 -20 38 52 L Superior Frontal Gyrus
69 3.67 56 -12 56 R Postcentral Gyrus
578 3.67 14 -76 28 R Preuneus
59 3.58 4 20 36 R Cingulate
70 3.54 -20 -80 4 L Middle Occipital Lobule
77 3.51 -20 -80 -26 L Declive
Results are listed by clusters. value, Z score, Talairach coordinates of peak voxel, and anatomic localization are provided for each cluster.
Figure 1(abstract P72) Comparison of rCBF between patients with FM and age-matched healthy controls. Maximum intensity projections of SPM2
results from comparison of rCBF between patients with FM and age-matched healthy controls. a, b The FM patient group exhibited significant
hypoperfusion in the left culmen. c, d The FM patient group exhibited significant hyperperfusion in the right precentral gyrus, right posterior cingulate,
right superior occipital gyrus, right cuneus, left inferior parietal lobule, right middle temporal gyrus, left postcentral gyrus, and left superior parietal lobule.
Height threshold is < 0.001, corrected for multiple comparison.
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Background: Once considered a passive disease of ‘wear and tear’ of the
joint, osteoarthritis (OA) is now known to be driven by the expression and
activation of specific proteases that degrade the extracellular matrix of
articular cartilage. Such proteases include aggrecanases, principally
adistintegrin and metalloproteinase (Adamts) 4 and 5, and collagenases
which are members of the matrix metalloproteinase (Mmp) family. In mice,
Adamts5 and Mmp13 are considered to be the critical proteases in disease,
as mice in which these proteases have been knocked out are protected
from developing OA [1,2]. What drives these proteases in vivo is unknown,
but one possibility is that mechanical factors alone are sufficient to lead to
their expression and activation.
To test this hypothesis we investigated the effects of joint immobilisation
on protease expression and the course of disease in mice with surgically
induced OA.
Materials and methods: Destabilisation of the medial meniscus or sham
surgery was performed in 10 week old male mice. Joints were immobilised
either by prolonged anaesthesia (for a max of 4 h to examine gene
expression changes) or by sciatic neurectomy (for 4-6 h or for 12 weeks).
mRNA was extracted from whole joints at 4-6 h following induction of OA.
A microarray was performed and 47 genes validated by RT-PCR. Joints were
examined histologically after 12 weeks forcartilage damage.
Results: Many genes were regulated within 6 hours of OA surgery
(compared to sham surgery) including Adamts5, Mmp3, IL1b, Ccl2, activin
and TNF-stimulated gene 6 (Tsg6). Mmp13 was not regulated at this early
time point. Of the 47 genes studied, all gene responses were strongly
suppressed if the joint was immobilised (by prolonged anaesthesia). Joint
immobilisation by sciatic neurectomy also suppressed a number of genes
(approx. 50%) including Adamts5, and protected the joints from cartilage
degradation at 12 weeks.
Conclusion: Pathogenic protease expression occurs rapidly upon induction
of OA in mice (within 6 h) and is highly mechanosensitive. Suppression of
Adamts5 also occurs following sciatic neurectomy in which the joint is
immobilised but the mice are able to bear weight (they walk with a
‘splinted’ knee). This suggests that dynamic flexion of the destabilised knee
joint is important for induction of proteases and subsequent disease.The
pathway by which joint cells sense and respond to these mechanical signals
could represent a novel target for disease intervention.
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Background: Due to a number of factors, Helicobacter pylori (Hp)
infection is increasingly recognized as highly prevalent in many
populations and of increasing health concern. Hp infection has been
associated with digestive diseases and rheumatic diseases[1]. It remains
unclear whether all or part patients of rheumatic diseases should be
routinely screened for Hp infection. We have examined predictors of Hp
infection in rheumatic diseases so as to define who might benefit most
from screening.
Methods: 292 patients with rheumatic diseases were recruited through
outpatient rheumatology clinics between 2005-2008. The study was
approved by the Second Hospital of Shanxi Medical University Ethics
Committees, and all participating patients signed an informed consent form.
The description of this study is 3-fold: to evaluate the relationship between
Hp and rheumatic diseases, to assess the relationship between Hp and
rheumatoid arthritis (RA), to explore the relationship between Hp and
ankylosing spondylitis (AS).
Results: Patients of rheumatic diseases were significantly more likely to be
Hp infection than health control (89 vs 42%, P < 0.01). The study revealed
that 88% of RA patients and 90% AS patients suffer from Hp infection. RA
patients carried a diagnosis of Hp, a higher prevalence of the value of CRP
was associated with the DAS28(Disease Activity Scor-28) (r = 0.287,P =
0.034). AS patients carried a diagnosis of Hp, a higher prevalence of the
value of MMP-3(matrix metalloproteinase-3, MMP-3) was associated with the
BASDI(Bath AS Disease Activity Index) (r = 0.435,P = 0.009).
Conclusions: Patients of RA and AS are associated with a high
prevalence of Hp infection rate. Hp infection may be play an important
role in RA and AS.
Next steps: Further investigation with other rheumatic diseases are
planned.
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The symptoms of rheumatoid arthritis (RA) are based on the many
processes; chronic inflammation, overgrowth of synovial cells, bone and
joint destruction and fibrosis. To clarify the mechanism of outgrowth of
synovial cells, we carried out immunoscreening using anti-rheumatoid
synovial cell antibody, and cloned ‘Synoviolin’. Synoviolin, a mammalian
homolog of Hrd1p/Der3p, is endoplasmic reticulum (ER)-resident E3
ubiquitin ligases with a RING motif, and is involved in ER-associated
degradation (ERAD). Synoviolin is highly expressed in synoviocytes of
patients with RA. Overexpression of synoviolin in transgenic mice leads to
advanced arthropathy caused by reduced apoptosis of synoviocytes.
We postulate that the hyperactivation of the ERAD pathway by
overexpression of synoviolin resultsi np r e v e n t i o no fE R - s t r e s s - i n d u c e d
apoptosis leading to synovial hyperplasia. Indeed, synoviolin
+/- knockout
mice showed resistance to the development of collagen-induced arthritis
owing to enhanced apoptosis of synovial cells. In addition, Synoviolin
ubiquitinates and sequesters the tumor suppressor p53 in the cytoplasm,
thereby negatively regulating its biological functions in transcription, cell-
cycle regulation and apoptosis by targeting it for proteasomal degradation.
Therefore Synoviolin regulates, not only apoptosis in response to ER stress,
but also a p53-dependent apoptotic pathway. These studies indicate that
Synoviolin is one of the causative factors of arthropathy. Further analysis
using gene targeting approaches showed that in addition to its role in RA,
Synoviolin is essential for embryogenesis. Synoviolin deficient (syno
-/-) mice
exhibited severe anemia caused by enhancement of apoptosis in fetal liver,
and the results suggested that the liver is sensitive organ for Synoviolin.
Thus, this study aimed to explore the involvement of the Synoviolin in
fibrosis process of RA using mice model of liver fibrosis. In CCl4-induced
hepatic injury model, syno
+/- mice are resistant to onset of liver fibrosis. The
number of activated HSCs was decreased in syno
+/- mice, and some of these
cells showed apoptosis. Furthermore, collagen expression in HSCs was
upregulated by synoviolin overexpression, while synoviolin knockdown led
to reduced collagen expression. Moreover, in syno
-/- MEFs, the amounts of
intracellular and secreted mature collagen were significantly decreased, and
procollagen was abnormally accumulated in the endoplasmic reticulum. In
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Recently, it has become increasingly clear that some committed effecter and
regulatory T (Treg) cells are not stable, and the plasticity of these T-cells may
be related to the pathogenesis of autoimmunity and inflammatory diseases
[1]. However, the precise mechanisms that allow for T cell plasticity have not
yet been clearly understood. Human T-lymphotropic virus type 1 (HTLV-1) is
a retrovirus that is associated with multiorgan inflammatorydisorders such
as HTLV-1- associated myelopathy (HAM/TSP), HTLV-1- associated
arthropathy (HAAP), uveitis, Sjögren syndrome, and polymyositis [2-5]. HTLV-
1-infected T cells may contribute to development of these disorders, since
the number of HTLV-1-infected T cells circulating in the peripheral blood is
higher in patients [6]. HTLV-1 mainly infects CD4
+ T helper (Th) cells that
play central roles in adaptive immune responses. Based on their functions,
patterns of cytokine secretion, and expression of specific transcription
factors and chemokine receptors, Th cells differentiated from naïve CD4
+
T-cells are classified into 4 major lineages: Th1, Th2, Th17, and T regulatory
(Treg) cells. We recently demonstrated that CD4
+CD25
+CCR4
+ T cells, which
mainly include suppressive T-cell subsets such as Treg and Th2 under
healthy conditions, are the predominant viral reservoir of HTLV-1 in both
adult T-cell leukemia/lymphoma (ATL) and HAM/TSP [7]. Interestingly, T-cells
of this subset become Th1-like cells with overproduction of IFN-g in HAM/
TSP, suggesting that HTLV-1 may intracellularly induce Tcell plasticity from
Treg to IFN-g
+ T cells [7].In this study, using human T-cell line and HTLV-1
infected CD4
+CD25
+CCR4
+ T-cells of HAM/TSP patients, the virus-encoded
transactivating HTLV-1 Tax protein was demonstrated to induce the IFN-g
production through the expression of T-box 21(Tbx21)/T-bet, a transcription
factor that is known to direct the differentiation of naive CD4
+ cells into IFN-
g-expressing Th1 cell. HTLV-1 Tax was also demonstrated to enhance
promoter activity of Tbx21/T-bet cooperatively with transcription factor
Specificity Protein 1 (Sp1). Furthermore, transfer of HTLV-1 tax gene in
CD4
+CD25
+CCR4
+ T-cells using a lentiviral vector resulted in the loss of
regulatory function of these T cells. This is the first report to our knowledge
demonstrating the role of a specific viral product (HTLV-1 Tax) on the
expression of genes associated with T-cell differentiation resulting in
plasticity of Treg cells into Th1-like cells. These results suggest that HTLV-1
infection-induced immune dysregulation may play an important role in the
development and pathogenesis of HTLV-associated immunological
diseasesthrough its interference in the equilibrium maintained among host
immune responses.
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Background: Tofacitinib, targeting Janus kiase (JAK) has gained attention
as anorally available new disease modifying anti-rheumatic drug with
high clinical efficacy against rheumatoid arthritis (RA). While the clinical
trial has progressed and the wide usage of tofacitinib is conceivable in
the near future, the precise mechanism of action in RA patients remains
to be solved.
Materials and methods: Fifteen RA patients enrolled in tofacitinib clinical
trial were randomized to 1, 3, 5 or 10 mg BID for 12 weeks. Serumwas
collected at 0 and 12 weeks for further cytokine measurement by ELISA.To
analyze the effect at the local inflammatory site, synovium and cartilage
from a RA patient undergoing joint replacement was implanted to severe
combined immunodeficiency (SCID) mice (SCID-huRAg mouse)
andtofacitinib was administered via osmotic mini-pump and serological and
histological investigation was performed.
Results: Background of patients in clinical trial: mean age; 56.4 years, mean
disease duration; 95.1 months, methotrexate (MTX) and tofacitinib were
administered in all patients, median doses were 9.4 mg/week and 4.1 mg
BID, glucocorticoids were administered in 6 patients, median dose was 5.4
mg/day. Baseline characteristics of the disease activity; SDAI 30.0, DAS28
(ESR) 6.3, HAQ 1.1, CRP 21.0 mg/l, ESR 57.1 mm/h, MMP-3 259.3 ng/ml, RF
216.2 U/ml. After 12 weeks treatment, disease activity decreased with
statistical difference (p < 0.05) as follows; SDAI13.8, DAS28(ESR) 4.0, HAQ 0.8,
CRP 8.1 mg/l, ESR 30.9 mm/h, MMP-3 149.9 ng/ml, RF 150.8 U/ml. Among
the multiple cytokines measured, IL-6 and IL-8 tended to decrease, from
52.2 pg/ml to 28.2 pg/ml (p < 0.05) and from 41.7 pg/ml to 29.5 pg/ml (not
significant), respectively. There was a statistically significant correlation
between reduction of IL-6 and reduction of MMP-3.
In SCID-huRAg mouse, apparent invasion of RA-derived synoviuminto
cartilage was observed, whileadministration of tofacitinibmarkedly
suppressed invasion. In order to investigate the relevance with our
findings from the patients in the clinical trial, cytokines in SCID-huRAg
mouse serum was measured after administration of tofacitinib for 7 days.
Interestingly, tofacitinib significantly decreased production of human IL-6
and IL-8 as well as human MMP-3 from 29.79 pg/ml to 2.89 pg/ml, 17.89
pg/ml to 4.22 pg/ml and 65.96 pg/ml to 33.13 pg/ml respectively.
Conclusions: Tofacitinib improved disease activity and suppressed
cartilage destruction with decreased serum IL-6 and IL-8 in both, RA
patients and SCID-huRAg mouse in connection with reduced MMP-3.
These results indicate that tofacitinib reduces inflammation by
suppressing IL-6 production and consequently inhibiting cartilage
destruction in the initial several months of administration.
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Small molecule inhibitors of the Janus kinases (JAK) have been developed
as anti-inflammatory and immunosuppressive agents and are currently
subjects of clinical trials. Tofacitinib/CP-690,550 (more potent in inhibiting
JAK3 and JAK1) and Ruxolitinib/INCB-018424 (selective inhibitor of JAK1/2)
have demonstrated clinical efficacy in rheumatoid arthritis (RA), however,
the exact mechanisms that mediate the inhibitory effects of these
compounds are not known.
In this study, we examined the effects of CP-690,550 (CP) and INCB-018424
(INCB) on inflammatory responses in human macrophages (hMFs). In our
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inflammation to investigate mechanisms regulating hMF activation and
functions, and have shown that TNF can activate an IFN-JAK-STAT-
dependent autocrine loop that regulates expression of pro-inflammatory
chemokines and interferon stimulated genes (ISGs), followed by an
increase of NFATc1, that regulates osteoclastogenesis.
As expected, both inhibitors abrogated TNF-induced STAT1 activation and
expression of genes encoding inflammatory chemokines (CXCL9, 10, 11 and
CCL5) and ISGs (IFIT1 and 2, IRF7). Interestingly, both compounds attenuated
a late wave of IL-1 induction and nuclear expression of NF-B subunits.
Furthermore, ex vivo treatment with inhibitors decreased IL-1 and IL-6
expression in synovial MFs isolated from the patients with arthritis. Next, we
analyzed the effects of JAK inhibitors on TNF-induced osteoclastogenesis
and discovered that both compounds augmented nuclear levels of NFATc1
and cJun, followed by increased formation of TRAP positive multinuclear
cells. Lastly, we examined an in vivo effect of CP on innate immune
response in arthritis using K/BxN serum transfer arthritis model and found
that CP treatment significantly inhibited inflammation and joint swelling.
Taken together, our data suggest that JAK inhibitors can affect inflammatory
responses in hMFs and thus, can target both acquired and innate immunity
in RA and other chronic inflammatory diseases.
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Background: Behcet’s disease (BD) is an autoinflammatory disease with a
unique distribution characterized by uveitis, and mucosal and skin lesions,
which are characterized by the prominent infiltration of immune cells such
as lymphocytes and neutrophils. A novel helper T-cell subset Th17, IL-17-
producing helper T cells, has been appreciated [1]. IL-17 is involved in the
induction of a series of chemokines, growth factors, proteases, and
cytokines, and production of IL-17 results in induction of neutrophil
migration and chronic inflammation [2]. Based on these findings, we
hypothesized that Th17 is involved in the pathogenesis of BD.
Materials and methods: To examine a role of Th17 response in the
pathogenic process of BD, peripheral blood samples from 20 patients with
BD and 14 controls were used to evaluate phenotypic and functional
properties relevant to the Th17 response. Plasma IL-17 and CCL20 levels
were examined using ELISA. Expression levels of RORC mRNA in CD4
+
T cells were examined by RT-PCR and CD4
+ cells expressing IL-17, CCR6
was examined by flow cytometry. Evaluation of chemotaxis of CD4
+ Tc e l l s
toward CCL20 was examined by migration assay using TransWell® double
chamber system.
Results: Plasma IL-17 was higher in active BD compared with healthy
controls (P < 0.05). Expression levels of RORC mRNA in peripheral blood
mononuclear cells by RT-PCR and proportion of CD4
+ cells expressing
intracellular IL-17 were increased in patients with BD than in controls (P <
0.05 in both comparisons). Expression of chemokine receptor CCR6 was
detected in nearly all IL-17-expressing cells. The proportion of CD4
+CCR6
+
was higher in BD patients in remission compared those with active
disease (P < 0.05), suggesting that these cells are migrated to the lesions
at active disease phase. In addition, CD4
+ T cells from BD patients had
enhanced migration capacity induced by CCL20, than did those from
controls. Finally, CCL20 level was higher in BD patients than in controls
(P < 0.05).
Conclusions: These results together suggest that Th17 are involved in
the pathogenesis of BD by migrating into the lesions of BD through the
CCL20-CCR6 axis.
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Background: Racial differences were observed in clinical, serologic and
histologic presentation of lupus nephritis (LN)[1]. It has been suggested
that Th1/Th2 cytokines balance and IFNG polymorphism play important
role in the development of different pathologic pattern of lupus nephritis
(LN )[2-4]. The objective of our study is to determine the association
between autoantibodies expression, Th1/Th2 cytokines balance and IFNG
polymorphisms with pathologic class of LN in Javanese patients.
Patients and methods: We studied 60 female patients with LN (ARA
criteria,1992), and 20 healthy individual as control. Histopathologic
classification was based on WHO criteria (1995). Anti ds-DNA, anti RO,
anti nRNP and anti Sm autoantibodies were assayed by ELISA.IFNg-IL-4
balance were used to assess Th1/Th2 cytokines balance, IFNg and IL4
serum levels assayed by ELISA. Microsatelitepolymorphisms within the
first intron of the IFNG gene on chromosome 12q24.1 was performed by
DNA sequencing. The association of histopathologic phenotype of LN
with Th1/Th2 balance (IFNg/IL4),and autoantibodies expression were
analysed by Chi-square and Student T test with p < 0.05 is significant.
T h eI F N Ga l l e l ed i f f e r e n c eb e t w e e nL Nc l a s s e sw e r ea n a l y s e db yC h i -
square. The risk of LN in patients with certain IFNG allele was calculated
using Odds Ratio.
Results: Our study showed that the frequency of anti Ro, and anti nRNP
antibodies in patients with LN WHO class III, IV and V LN weresignificantly
higher compared with patients with class I and II LN. There is no
autoantibodies expression differences between class III, IV and clas V LN.
The IFNg/IL4 ratio in patients with classIII and IV LN was significantly
higher than patients with class I,II and class V LN (2.30 ± 0.89 vs 0.94 ±
0.24 and 0.69 ± 0.30, p = 0.000), but the serum level of IL4 in patient
with WHO class III and IV was significantly lower than class V (77.72 ±
40.28 pg/ml vs 145.68 ± 71.21 pg/ml. p = 0.014). The result showed that
the activity of Th1 immune response tent to be higher in patient with
WHO class III and IV LN. The frequency of IFNG 112 allele were higher in
patients with SLE compared with healthy controls (55% vs 25%, p =
0.0471) and the risk to have LN class V in patients with IFNG 112 was 6
times higher compared with patients without these allele (OR 6.1, CI 95%
3.1- 12.4, p = 0.0427).
Conclusion: The results showed different underlying mechanism of
inflammation in different pathologic class of LN.
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